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 I 
Abstract 
Non-coding RNA (ncRNA)-directed regulation of epigenetic processes has recently emerged as an 
important feature of mammalian differentiation and development. Long non-coding RNAs 
(lncRNAs) are non-protein coding transcripts longer than 200 nucleotides RNAs. Although they are 
highly expressed within the mammalian brain, their function in behaviour remains equivocal. 
Deregulation of the lncRNA regulatory systems in the brain may contribute to the development of 
neuropsychiatric disorders. 
This project aimed to identify the role of lncRNAs in association with complex mammalian 
behaviours. 
In this thesis, sequencing technologies were used to identify ncRNAs that are dynamically regulated 
in fear-related learning in mice. These technologies included nuclear enriched RNA-capture 
sequencing, whole-genome RNA sequencing (RNA-Seq) and small RNA-Seq. The use of 
complementary sequencing approaches was expected to cover the expression of all possible sizes of 
ncRNAs. RNA-capture sequencing was used to identify newly described ncRNAs transcripts within 
the brain-derived neurotrophic factor (Bdnf) locus that were modulated in association with fear 
conditioning. Whole-genome RNA-Seq analysis showed that several lncRNAs (such as Neat1, 
Malat1, Mirg, Rmst and Gomafu) were dynamically regulated in response to fear learning. This 
transcriptome profiling revealed that most of the transcribed lncRNAs were proximal to coding 
genes, which suggested in cis regulatory activity of these transcripts. Knock down of the antisense 
lncRNA to Cacng2 altered the level of Cacng2 mRNA expression, which indicated the potential 
role of lncRNAs in regulating proximal coding genes in response to neural activation and 
behaviour.  
To establish the relevance of lncRNAs in association with behaviour, this investigation focused on 
Gomafu, which has previously been linked to schizophrenia, drug addiction and brain development. 
To determine whether Gomafu affects behaviour, chimeric antisense oligonucleotides (ASOs) were 
designed to knock down this lncRNA in vivo. Infusion of ASO in the mouse mPFC did not affect 
fear-associated long-term memory but instead appeared to modulate the level of anxiety.  
The molecular mechanisms by which Gomafu exerts its function in the development of anxiety-
related behaviours were explored further. A possible in cis regulatory function of Gomafu within 
the schizophrenia locus was investigated by examining the level of expression of proximal genes 
after Gomafu knockdown. Gomafu knockdown resulted in the up-regulation of Crybb1, gene that is 
antisense to the Gomafu lncRNA. Previous investigations have suggested that lncRNAs regulate the 
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expression of coding genes in association with Polycomb group repressive complexes (PRCs). 
Immunoprecipitation assays were performed to investigate the molecular interplay between Gomafu 
and Crybb1 through PRCs. Gomafu recruited PRC1 to the Crybb1 promoter, which regulated 
Crybb1 expression levels in response to neuronal stimulation. Experimental knock down of Crybb1 
also exposed that its expression plays a role in anxiety. Gomafu knockdown increased anxiety in 
mice, whereas Crybb1 knockdown consistently attenuated this response. These results suggest that 
lncRNAs control the expression of proximal genes by recruiting the PRC, and that such epigenetic 
mechanisms may be associated with the development of fear-induced anxiety. 
Lastly, small RNA-Seq analysis of fear-conditioned mice showed the dynamic regulation of micro-
RNAs (miRNAs) and small nucleolar RNAs (snoRNAs), which are transcribed from regions 
associated with lncRNAs such as Gas5, Taf1d, Ipw, Rian, Snhgs and Mirg. The dynamic expression 
of Piwi-interacting small non-coding RNAs (piRNAs), including piRNA-30, a well-characterised 
piRNA in the mouse brain, was also detected. A copy variant of the known orphan snoRNAs, 
snord115, was also found, which suggested that snoRNAs are involved in fear learning, possibly by 
targeting coding genes and lncRNAs beyond the expected ribosomal genomic fractions.  
Overall the results of this thesis endorse the concept that lncRNAs are dynamically regulated in 
response to neuronal activation and fear learning within the mammalian brain. As proof of 
principle, this investigation demonstrated that Gomafu expression is necessary for the modulation 
of anxiety-related behaviours. This thesis also found evidence of the involvement of sncRNAs, 
transcribed from lncRNAs loci, in altering adaptive behaviours. These results support the idea that 
non-coding transcription is involved in the development of psychiatric illness. 
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CHAPTER 1 
“Nonetheless, it is clear that at some early stage in the evolution of life the direct association of 
amino acids with polynucleotides, which was later to evolve into the genetic code, must have begun. 
At this time no activating enzymes could have existed…” 
Orgel, 1968 
Parts of this chapter are included in a published review article (1). 
1. Introduction 
Molecular epigenetics, understood as the study of heritable differences in gene expression without 
changes in the core of the DNA sequence, may be relevant within the mammalian neural network. 
Neurons are the site where outside stimuli are quickly decoded by the genomic conformation of the 
brain. Yet, in a challenging environment, the output response may involve adaptive epigenetic 
mechanisms that are more readily prepared to change than the exceedingly stable DNA molecule. 
Thereafter, long non-coding RNAs (lncRNAs), as potential drivers of epigenetic regulatory 
mechanisms in the human genome, may hold information to understand the complexities of the 
brain. 
1.1 Pervasive transcription.  
The importance of non-coding RNA (ncRNA) transcription is now accepted, but its true function is 
still debated. Evidence in support of a relevant role of ncRNAs has come from studies of a variety 
of organisms, from bacteria (2-4) and yeast (5-7), to the human genome (8-11).  
The Encyclopedia of DNA Elements (ENCODE) and The Functional Annotation of the Mammalian 
Genome (FANTOM) projects have made extensive use of new sequencing technologies to expand 
our knowledge of ncRNAs. Such investigations reported that at least 40% of the human genome 
was transcribed in both directions, which suggested a potential regulatory role for natural antisense 
transcripts (12). These studies also revealed that most of the human genome is pervasively 
transcribed, whereas only ~2% of this activity corresponds to protein-coding genes (13). 
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Independent research confirmed that a proportion of these transcriptional events are antisense to 
coding genes and are predicted to influence their patterns of expression (14). These studies 
uncovered the significance of ncRNA and suggested its potential effect on the regulation of gene 
expression. The ENCODE achievements have imposed the need to redefine the concept of genes, 
which now also alludes to ncRNAs as “functional products” (15). 
Although investigations have shown that pervasive transcription may contribute to the complexity 
of eukaryotic genomic expression (16), it remains unknown to what extent these non-coding 
sequences represent independent transcripts that can be truly functional (17). 
The fact that ncRNAs, particularly lncRNAs, initially showed low conservation compared with 
coding sequences (18, 19) triggered disbelief that they have biological relevance. Nearly 25 years 
after the discovery and association of H19 as an lncRNA (20, 21), researchers still struggle with 
accepting and understanding the significance of ncRNAs. 
To decipher the question of ncRNA function in the mammalian genome and, more importantly, 
within the brain, it is necessary to considerate the origins and nature of ncRNA molecules.  
1.1.1 Origin and evolution of RNA catalytic function. 
The central dogma of molecular biology states that DNA contains all the information needed to be 
transcribed into a passive messenger RNA (mRNA), which carries the genetic code to be translated 
into functional proteins (22, 23). However, there is evidence that dynamic RNAs also contribute 
with the diversification and complexity of life forms (24).  
Francis Crick had anticipated this possibility when he envisioned that the RNA could work as “an 
adaptor”. He referred to what we now know as transfer RNA (tRNA) and suggested that this 
molecule may be able “to do the job of a protein” (23, 25). Researchers later established that DNA 
is synthesised from RNA chemical components and that ribosomes, the molecular factories of 
proteins, are conformed by RNA transcripts (26). RNA is the only molecule in nature capable of 
self-processing, through which it carries and stores genetic information and performs catalytic 
activities. Crick also hypothesized that “possibly, the first enzyme was an RNA molecule with 
replicase properties” (27).  
A primordial self-replicating RNA catalyst, able to form complex and potentially functional 
secondary structures, was then suggested as a foundation for the evolution of life on Earth (28-30). 
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The limitations of the view of RNA as a passive molecule and further support for a primordial and 
actively functional RNA world (30) became evident when the first self-splicing introns and 
ribozymes were discovered in the early 1980s. The two scientists responsible for the finding, 
Thomas Cech and Sydney Altman, received a Nobel Prize in Chemistry for their independent 
breakthrough in the catalytic properties of RNAs.  
While investigating a ciliated protozoan model system to understand RNA splicing processes, Cech 
uncovered the first catalytic self-splicing RNA (31). His group identified an intron within the 
ribosomal RNA (rRNA) gene of Tetrahymena thermophila that was spliced out before the rRNA 
was integrated into the ribosome (31). They found no obvious activity of any protein with 
enzymatic qualities but instead a self-detachment from the “intervening sequence”, which they 
called an “auto-catalytic rearrangement of RNA molecules” (31). Similarly, Altman’s team was 
working on the function of Escherichia coli RNase P complex in tRNA biosynthesis when they 
found another catalytic intron. (32). They confirmed that the RNA component of the complex was 
able to cleave tRNA independently from the protein subunit activity (32).   
Concordantly, catalytic RNAs as riboswitches were shown to be responsive to signals emitted 
within the cell by metabolites, and to modulate both the transcription and translation of mRNAs by 
selectively binding to these free metabolites (33-35). This showed the ability of RNA molecules to 
rapidly adapt and drive gene expression networks, which may have evolved to respond to external 
stimuli (36, 37).  
Since riboswitches represent a structured ncRNA domain (38), they signify another level of 
complexity implicit in functional RNAs.  
Riboswitches are the best example to explain this concept. In general, riboswitches have two 
domains, an aptamer for molecular recognition and binding, and an expression platform that allows 
interaction with the translational and transcriptional cell machinery (39). The overlapping folding of 
these two sequences re-creates the switching sequence, which determines the activated or repressed 
state of an mRNA (39). The structure within this class of catalytic RNAs is enough for them to 
carry ligand identification and for gene expression control without the need for any protein (38).  
Although these seminal discoveries support the notion of an original RNA that preceded DNA and 
proteins in evolution, they are not enough to sustain a self-replication function required to 
synthesise extensive RNA macromolecules. Because of instability and intolerance to Mg2+ ions, the 
activity of ribozymes is limited to the catalysis of RNA template extension for up to ~90 
nucleotides (40-42). In such a scenario, a primordial catalytic self-replicating RNA as the origin of 
 
 4 
life was still possible, although this idea could be questioned because of the size limitation of 
replication. Recent findings show that RNA synthetic self-replication of longer sequences is not 
only possible under freezing conditions but can also withstand selective pressure, and support the 
notion that RNAs are the building blocks of life (43, 44).  
While functional ncRNAs as riboswitches and self-splicing introns are now accepted, the argument 
about a potential RNA-based origin of life preceding a DNA–protein regulatory system will 
continue to be a matter of scientific debate.  
1.1.2 ncRNAs derived from introns. 
Identification of transcribed but untranslated “intervening sequences” in pre-mRNAs, (45-47), the 
introns of a gene (48), was a milestone discovery in molecular genetics that set the basis for 
understanding ncRNA. It is clear that intron groups I and II have self-splicing activity (49) and 
might represent the functional molecule Orgel had in mind when he developed the “RNA World 
Hypothesis”. Consequently, important information needed to interpret ncRNA may rest in the 
nuclear eukaryote introns of these classes.  
Considering that 95% of the coding genes’ sequences in the human genome are represented by 
introns, it was proposed that these transcripts may themselves have a “trans-acting” independent 
function (50). The ENCODE research has supported this early notion by indicating that exons 
account for only 3% of human genome sequences (51). This idea is consistent with research 
showing that there is a genome-wide divergence between introns and exons relative to a common 
gene transcript (52). Such results highlight the independent transcription of introns, which was 
associated by St Laurent et al. (52) with lncRNA products.  
Swinburne and colleagues have predicted that the length of an intronic sequence may affect gene 
expression and transcriptional feedback loops and might have considerable impact in eukaryote cell 
function (53).  
Early investigations uncovered “in cis acting elements” present within an intronic region of the 
murine IL-4 gene, which can regulate its harbouring gene transcription and determine its chromatin 
state (54). This is consistent with the finding of “regulatory elements” within the first intron of 
human genes and their ability to modify the expression of parent genes (55). Additionally, intron-
dependent gene looping has been shown to be a requirement for gene activation in eukaryote cells 
(56). 
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Further demonstration that introns are niches for functional ncRNA transcription, in particular 
micro-RNAs (miRNAs), small nucleolar RNAs (snoRNAs) and long intragenic ncRNAs, supported 
their role in the regulation of gene expression (57). This idea is also supported by research showing 
a tissue-specific signature of intronic transcription associated with transcriptional factors and 
disease state (58, 59). The relevance of these phenomena in the adult mouse brain was demonstrated 
by the finding of 182 intronic ncRNAs that are transcribed in specific cell compartments and brain 
regions (60).  
Processed introns can also take on particular circular structures that behave as circular long 
ncRNAs (ciRNAs), which are associated with regulation of the harbouring gene and positive 
control of RNA polymerase (RNA Pol II) transcription (61). Thereafter, introns seem to be 
functional at two levels: firstly, without the need of a transcriptional event, as in the “in-built” in cis 
regulatory elements and enhancer loops, and secondly, introns become relevant after avoiding 
splicing and degradation to become ncRNAs.  
In both scenarios, these sequences are representatives of an RNA molecule with biological authority 
to modify gene expression. Together with the original evidence establishing the catalytic function 
of intronic RNAs, these attributes suggest that understanding intronic sequences may provide proof 
of the origin and function of ncRNA. 
1.1.3 ncRNAs driving the spliceosome. 
Spliceosome activity contributes to eukaryote complexity (62), and the fact that ncRNAs can drive 
this splicing machinery provides evidence supporting the biological relevance of ncRNA. It is now 
known that ncRNAs can perform this task by different means, including sequence recognition and 
transcription factor regulation and, more importantly, catalysis of pre-mRNA substrates. The 
spliceosome is articulated by at least five small nuclear ncRNAs (snRNAs) (U1, U2, U4, U5 and 
U6) plus nearly 200 proteins (63, 64). 
Splicing of pre-mRNAs is both a processing step for transcript maturation and a co-transcriptional 
event that influences gene expression (65, 66). This dynamic process affects alternative splicing as 
much as the original transcription of a gene. For example, U1 snRNA is at the centre of the 
spliceosome target sequence recognition and can stimulate RNA Pol II to initiate transcription (67). 
This snRNA is flexible enough to also induce gene repression by interacting with PTBP1 protein 
and interrupting the spliceosome assembly to the target sequence (68). U1 snRNA has also been 
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shown to control the interaction of U6 snRNA with the splicing site of a target gene, which 
determines its cleavage position (69).   
ncRNA–ncRNA interactions can also influence the activity of the spliceosome. Although U5 
snRNA participates in spliceosome assembly and targeting of the 5" and 3" ends of substrate RNAs 
(70, 71), the snoRNA 85 can induce the 2"O-ribose methylation and pseudouridylation of U5 
snRNA, which indirectly alters the splicing event (72). 
lncRNAs have recently been indicated as drivers of alternative splicing within mammalian cells. 
This is based on evidence that both Malat1 and Gomafu lncRNAs can interact with splicing proteins 
and sequester these molecules within paraspeckle domains (73, 74).  
However, the finding that spliceosomal snRNAs can independently, that is, with no protein 
involvement, drive intron excision episodes has highlighted the significance of these molecules in 
the maturation of mRNAs and alteration of gene expression patterns. Identification of the catalytic 
activity of U6 snRNA, by means similar to those of the class II self-splicing introns, has confirmed 
the concept of functional ncRNAs and has suggested that ribonucleoprotein enzymes within the 
spliceosome could have evolved from these classes of catalytic snRNAs (75).  
This places ncRNA as a well-conserved biological mechanism involved in the regulation of gene 
expression associated with the evolution of life complexity. 
At the core of Darwinian evolution and the understanding of natural selection lays the ability of a 
molecule to transfer genetic information. Interestingly, the concept of a self-replicating molecule 
under evolutionary constraint, with the ability to store and transfer genetic information and to 
independently drive a catabolic reaction is found in ncRNAs.  
1.2 Classes of ncRNAs.  
An initial categorisation of ncRNAs is generally made according to their size; a 200 bp cut-off has 
been arbitrarily set to discern between small non-coding RNAs (sncRNAs) and lncRNAs. Within 
such division, ncRNAs are classified further according to their origin of transcription, function and 
additional size characteristics (Table 1.1). Although miRNAs are considered to be more 
scientifically relevant, lncRNAs were found first, with the discovery in 1988 of H19, which was 
understood then as a marker of early stages of muscle development (20, 21). Further research 
identified a second lncRNA, Xist, which is responsible for driving the epigenetic silencing of X 
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chromosomes in gene dosage compensation (76, 77). At the same time, sncRNAs were being 
indicated as primary transcriptional and post-translational regulators during development (78, 79). 
In 2006, Fire and Mello were awarded a Nobel Prize for their discovery of short RNA interference 
in Caenorhabditis elegans (80). This established the importance of non-coding RNAs in molecular 
biology across a range of species. Since then, multiples of new non-coding transcripts have 
continued to emerge (Table 1.1); the true functional role of most of these has not been identified.  
Table 1.1: Classes of ncRNAs based on transcripts sizes and their associated functions 
 
Class NcRNA Size Role Reference 
Small 
ncRNA 
miRNA ~22 bp 
These small RNAs represent a well-conserved mechanism of 
gene regulation. They are involved in targeted mRNA 
degradation through sequence complementarity and translational 
repression. 
(81, 82) 
snoRNA ~60 to 300 bp 
Between small and long ncRNAs classification. Associated with 
spliceosome activity, they drive chemical modifications of rRNAs 
and tRNAs for the assembly of this biological processor. A class 
of snoRNAs lacking complementarity to rRNAs and tRNAs, 
called orphans, may target coding genes. 
(83, 84) 
snRNA ~150 bp 
By interacting with several specific proteins, snRNAs form 
ribonucleoprotein complexes that have a major role in eukaryote 
mRNA splicing. 
(63, 85) 
piRNA ~26 to 32 bp 
Transcribed from highly repetitive clusters, piRNA can interact 
with a family of Piwi proteins and regulate degradation of 
transposable elements.  
(86-88) 
PASR ~26 bp to 50 bp 
Mapped within 500 nt of known TSS. Mostly overlapping with 
the 5" end of protein-coding genes. Associated with RNA Pol II, 
histone H3 and H4 acetylation and potential up-regulation of 
neighbouring genes.   
(89, 90) 
TASR ~20 bp to 200 bp 
Clustering at the 3" end. Conserved in mouse and human genomes 
with yet undescribed functions, but a potential role in gene 
expression has been suggested. 
(91) 
siRNA ~20 to 24 bp Through mechanisms  similar to those of miRNAs, siRNAs are part of RNA interference and can interrupt translational events. (92) 
Long 
ncRNAs 
eRNA ~100 bp to 91 kb 
Shows homologous chromatin modification of protein-coding 
genes and aid in enhancement of non-specific cell neighbouring 
genes expression. A subtype identified in mouse neuronal cells 
shows association with enhancers and a positive correlation with 
their mRNA synthesis. 
(93-95) 
TERRA ~100 bp to 9 kb 
Conserved in mammals and localised in the nucleoplasm in all 
mammalian chromosomes at telomeric regions of interphase and 
metaphase cells. RNA Pol II and developmental stage dependent. 
Potentially involved in eukaryotic heterochromatin conformation, 
telomere length and function in human induced pluripotent stem 
cells and regulation of telomerase activity. 
(96-100) 
LincRNA >~200 bp 
Located in intergenic regions, LincRNAs are usually in the 
antisense strand relative to a proximal coding gene and may 
regulate their expression through epigenetic mechanisms. 
(101, 102) 
ciRNA >~200 bp 
Naturally occurring circular RNAs are well conserved and have 
been suggested to regulate post-transcriptional regulation of gene 
expression.  
(61, 103) 
PALR ~200 bp to 1 kb 
Overlapping with the 5" end of protein-coding genes. Potential 
up-regulation of protein-coding genes show evolutionarily 
conserved sequences.   
(90) 
PROMPT ~200 bp to 600 bp 
Transcribed from upstream regions of annotated TSSs, they are 
polyadenylated, highly unstable and restricted mainly to the 
nucleus. Suggested to affect promoter methylation and to regulate 
transcriptional processes. 
(104, 105) 
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1.2.1 lncRNA. 
Possibly, the most versatile ncRNAs are lncRNAs, particularly those transcribed from intergenic 
regions known as long intergenic RNA (LincRNAs), which have suggested roles in the regulation 
of gene expression (101). More lncRNAs are being discovered within different organisms, yet there 
is limited consensus about their annotation and function (106). 
Most lncRNAs show common features with mRNAs, such as the active transcription signature of 
histone H3 lysine 4 trimethylation (H3K4me3) and histone H3 lysine 36 trimethylation 
(H3K36me3), polyadenylation, end-capping and RNA Pol II transcription (107, 108). The 
GENCODE v7 consortium previously identified 14,880 human lncRNAs grouped in 9277 loci (10). 
However, recent investigations have predicted that there could be as many as 95,135 lncRNA 
variants transcribed within the human genome (109). 
lncRNAs can originate by duplication of another ncRNA, via de novo transcription of precursor 
non-coding transcripts, or by loss of function of an ancestral protein-coding gene (110-112). They 
were originally thought to be the least conserved of all ncRNAs and to function primarily as 
precursors for transcription of other shorter RNAs (91). The current understanding seems to support 
a functional role for lncRNAs through their secondary structures, which allow binding of these 
molecules to epigenetic regulatory complexes (113, 114) (Fig. 1.1). Concordantly, these highly 
conserved binding motif sequences were suggested to have evolved as “promoter distal regulatory 
elements” with enhancer-like functions (115). Further investigations have indicated the significance 
of secondary structures such as niches for the transcription of sncRNAs (116) (Fig. 1.1). 
This reinforces the hypothesis that lncRNAs sustain their genomic relevance through structurally 
conserved regions, rather than by the primary transcript itself (1). 
 
Figure 1.1: Conserved structure of lncRNAs. Graphic representation of conserved secondary structures 
within lncRNA sequences, which allow the alternative generation of smaller ncRNAs and binding of 
functional proteins. 
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Although lncRNAs are present across all phyla, one-third of all lncRNAs discovered so far arose 
within the primate linage (10). More interestingly, from 49 human accelerated regions (HARs)—
sequences that appears rapidly after our divergence from our last common ancestor the 
chimpanzee—recently identified, 96% are acknowledged as non-coding segments. Among those 
sequences, HAR1 lncRNA has been associated with the development of the human neocortex and 
forebrain organization (117, 118).  
The finding of these human specific lncRNAs adds to the general view that recombination events 
leading to gene conversion are the source of mammalian evolution (119). Predictive investigations 
have shown that there is a bias towards G–C gene conversion (gBGC), where for example A–T G–
C heterozygosity generates more G–C than A–T gametes (120). The idea of base substitution 
contributes to the theory of neutral evolution because the prevalence of these alleles is not related to 
the fitness of the individual, whereas it has been shown to fix deleterious mutations in humans 
(121). Recent investigations have provided further evidence that the vast majority of HARs are not 
explained by gBGC alone (122). Conversely, these accelerated regions have been identified as 
enhancers and regulatory RNAs, which were driven by positive selection in the modern human just 
before its diversification from archaic hominids (123, 124). 
lncRNAs have both tissue- and cell compartment-specific patterns of expression. Although some, 
including H19 and Crnde can be found in the cytoplasm, it is within the eukaryotic nucleus where 
lncRNAs show highest conservation, purifying selection and conserved suggested functions (107, 
112, 125-128).  
Nuclear ncRNAs also show a high rate of turnover and their half-life depends on their physiological 
function. This supports the idea that they can provide a rapid epigenetic response to external stimuli 
(125, 129, 130). Although not much is known about their metabolism, the turnover of many 
lncRNAs is thought to be regulated through degradation by Dpc2, Dpc1, Xrn1, and particularly in 
nuclear compartments, by Xrn2 enzymatic activity (131, 132).  
lncRNAs show tissue-specific and temporal patterns of expression associated with implied 
functionality (133, 134). The possible biological relevance of these transcripts is gradually being 
revealed, particularly in the field of oncology, which has shown that aberrant expression of 
lncRNAs is involved in carcinogenesis (135-138).  
Mounting evidence is now showing that lncRNAs participate in a wide range of cellular systems 
and diseases (Table 1.2). 
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Table 1.2: Reported lncRNAs. Examples of long ncRNAs within the eukaryotic transcriptome, their 
functional diversity and molecular mechanisms driven by these transcripts. 
Identification Main function Reference 
aHIF-1-α (antisense 
hypoxia inducible factor 
alpha) 
Potential role in nuclear membrane trafficking and possibly mRNA; involved in renal 
cancer development. 
(139, 140) 
ANRIL (antisense ncRNA 
in the INK4 locus) 
Repression of the tumour suppressor gene p15INK4B through recruitment of PRC2 
complex. It is associated with atherosclerosis by interfering in cell adhesion, proliferation 
and apoptosis. 
(141, 142) 
CRNDE (colorectal 
neoplasia differentially 
expressed) 
Regulates cellular metabolic pathways in response to insulin/IGF, through which 
cancerous cells switch to aerobic glycolysis and are associated with colorectal cancer.  
(143) 
EGO (eosinophil granule 
ontogeny) 
Regulation of eosinophil granule proteins MBP and EDN, with a suggested role in 
development of bone marrow hematopoietic stem cells. 
(144) 
ERIC (E2F1-regulated 
inhibitor of cell death) 
Responsive to DNA damage, its dysregulation induces apoptosis and cell death and 
increased DNA damage. 
(145) 
FIRRE (functional 
intergenic repeating RNA 
element) 
Directs nuclear architecture across chromosomes by interacting with nuclear organisation 
factors such as hnRNPU. 
(146) 
GAS5 (growth arrest 
specific 5) 
Modulates the expression of the glucocorticoid receptor gene under starvation conditions 
and acts as a ribo-repressor and promotes growth arrest through apoptosis. Its 
dysregulation is associated with progression of various cancers. 
(147-151) 
Gdd7 (growth-arrested 
DNA damage-inducible 
gene 7) 
By interacting with TDP-43, promotes degradation of Cdk6 and regulates the cell cycle 
check point G1/S in response to UV radiation. 
(152) 
LincRNA-RoR (lincRNA 
regulator of 
reprogramming) 
Important p53 repressive function through recruitment of the heterogeneous nuclear 
ribonucleoprotein I and influence on cell cycle and apoptosis. It also stimulates cellular 
identity by promoting differentiation in pluripotent stem cells. 
(153, 154) 
HOTTIP (HOXA 
transcript at the distal tip) 
Involved in regulation of homeotic gene expression through chromosomal looping and 
binding to the adaptor protein WDR5, directing the WDR5/MLL complex to activate 
expression of HOXA. 
(155) 
HSR1 (Heat shock RNA-
1) 
By interacting with the heat shock transcription factor 1, activates heat shock proteins in 
response to heat stress. 
(156) 
HULC (highly up-
regulated in liver cancer) 
Associated with cell apoptotic pathway and cancer. Inhibits the expression of miR-372, 
which decreases the repression of its target gene Prkacb and results in increased 
phosphorylation of CREB during tumour genesis. 
(157, 158) 
Kcnq1ot1 Induces chromatin remodelling by interacting with Dnmt1 to regulate methylation of Kcnq1 through the recruitment of the histone methyltransferases Ezh2 and G9a.  
(159, 160) 
LincRNA-p21 Induced by p53, associates with hnRNP-K to allow its proper localisation and mediates repression of target genes regulated by the p53 apoptotic pathway. 
(161, 162) 
MEG3 (maternally 
expressed gene 3) 
A cAMP-responsive, maternally imprinted lncRNA that is expressed in distinct 
subpopulations of neurons and contributes to early neurogenesis. MEG3 also interacts with 
the p53 transcription factor and acts as a tumour suppressor gene and with the Jarid2 
component of PRC2, Jarid2 component in driving methylation processes in pluripotent 
stem cells. 
(163-166) 
NDM29 (neuroblastoma 
differentiation marker 29) 
Shown to promote cell differentiation and acquisition of differentiated neuron-like 
phenotype, which reduces tumour initiation cells in neuroblastomas. 
(6) 
NEAT1 (Nuclear-
enriched abundant 
transcript 1) 
Binds to paraspeckle proteins and has a role in the biology of subcellular structures, 
particularly nuclear domains. It interferes with gene transcriptional process by sequestering 
transcription factors into the paraspeckle domains.  
(167-169) 
NRON (non-coding 
repressor of NFAT) 
Represses the nuclear factor of activated T cell (NFAT) and modulates its nuclear 
trafficking and cellular localisation. 
(170) 
PANDA A (p21-
associated ncRNA DNA 
damage activated) 
Transcribed from the TrCDKN1A promoter region upon DNA damage signal. In a p53-
dependent manner, it regulates cell death by interacting with pro-apoptotic genes.  
(171) 
PAUPAR  Interacts with PAX6 transcription factor and regulates gene expression in trans to direct cell cycle and neuronal differentiation. 
(172) 
RMST 
(Rhabdomyosarcoma-2 
associated transcript) 
Interacts with nuclear and chromatin factors during neurogenesis and, in particular, the 
development of dopaminergic neurons.  
(173, 174) 
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SRA (steroid receptor 
RNA activator) 
Coactivates human sex hormone receptors. Its over–expression is associated with tumour 
progression, particularly in breast cancer. Isoforms can code for the SRA protein SRAP. It 
is also associated in pre-adipocyte cell differentiation. 
(175, 176) 
TINCR (terminal 
differentiation-induced 
ncRNA) 
By interacting with Staufen 1 protein, this lncRNA mediates stabilisation of somatic tissue 
differentiation by altering specific mRNA expression. 
(177) 
Vax2os1 (Vax2 opposite 
strand transcript) 
Its spatiotemporal deregulation, induces cell cycle modifications in photoreceptor 
progenitor cells during vertebrate development. 
(178) 
Zdbf2linc (zinc finger, 
DBF-type containing 2 
lincRNA) 
Paternally expressed and transcribed from the Gpr1 DMR. Correlates negatively with 
methylation of the maternally imprinted Gpr1 DMR locus with a suggested role in 
mammalian development. 
(179) 
 
Transcriptional and post-transcriptional regulation by lncRNAs.  
In coordination with epigenetic complexes, lncRNAs can influence transcription both locally and 
distally in an allele-specific fashion to regulate chromatin remodelling and gene expression (114).  
LincRNAs can be transcribed bi-directionally and their expression correlates with the expression of 
their proximal coding genes (93, 180). A subgroup of lncRNAs, which are called enhancer RNAs 
(eRNAs) (Table 1.1) and are transcribed from enhancer regions, prompt specific enhancer-promoter 
looping and induce gene activation (181). This class of ncRNAs displays independent transcription, 
which shows their ability to induce the in cis activation of neighbouring mRNAs (94, 182-185). 
Interestingly, this activating function occurs particularly within 500 kb of, and at a median of 100 
kb from, the transcription start site (TSS) (93-95). 
Although distal regulation is still being investigated, the initial finding that HOTAIR lncRNA can 
recruit the Polycomb group protein repressive complex 2 (PRC2) to silence developmental genes in 
a distal chromosome, established the in trans regulatory potential of lncRNAs (186). In trans 
repressive activity of Hotair was confirmed by experiments showing that deletion of this lncRNA 
leads to the de-repression of Hox genes in mice (187). 
Moreover, lncRNAs such as Paupar can undertake both pathways of regulatory functions. Paupar 
can act within the site of transcription to control Pax6 transcriptional factor expression and in trans 
through binding of regulatory elements in distal genes, or by redirecting Pax6 interactions with 
these sites (172). 
It is now known that more than 50% of all known lncRNAs interact with chromatin-modifying 
complexes such as CoRest and SMCX (108). About 20% of lncRNAs discovered in the human 
genome can bind the PRC2 complex, mostly by interacting with Ezh2, its methyltransferase subunit 
(108). By forming ribonucleoprotein complexes with these proteins, lncRNAs can operate as 
scaffolds and decoys to guide chromatin modifiers to alter the chromatin landscape and gene 
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expression kinetics (181, 188, 189).  
Chromatin remodelling by lncRNAs can also be driven by RNA–protein–DNA interactions. One 
example is that attributed to Xist in association with PRC2, PRC1 and Yy1, through which Xist 
lncRNA regulates X chromosome inactivation and gene dosage compensation in mammalian 
females (97, 114, 190).  
lncRNAs also induce chromatin modifications involved in genomic imprinting, as in the case of the 
paternally expressed lncRNA Air, which directs silencing of Igf2r, Slc22a2 and Slc22a3, through 
the recruitment of G9a histone methyltransferase (191). 
Post-transcriptional regulation by lncRNAs associated with mRNA stability has also been reported. 
An antisense ncRNA to the gene B secretase 1 (Bace1), known as Bace1-AS, can display base pair 
complementarity to Bace1, which shields this gene from RNase H enzymatic degradation (192). 
Gas5 lncRNA has been shown to tether the translation initiator factor 4E (eIF4E) protein and c-Myc 
mRNA to drive translational levels of c-Myc protein in HEK and lymphoma cell lines (193).  
Alternative splicing is a post-transcriptional event that plays a major role in the regulation and 
expression of the genome and can be affected by lncRNAs (194, 195). The highly conserved 
lncRNA Malat1 was shown to regulate nuclear transport of serine/arginine splicing factors that 
control pre-mRNA metabolism and to modulate post-transcriptional gene regulatory pathways and 
translation (73). Similarly, Gomafu lncRNA, which was initially associated with oligodendrocyte 
development and synaptic formation, has been shown to contain specific binding motif niches that 
compete with intronic mRNAs for recruitment of the splicing factor SF1 (196, 197). Gomafu also 
interacts with transcription factors such as Oct4 in the control of pluripotency (198) and has been 
detected in association with microvascular dysfunction, in which it works as a decoy for miRNAs 
linked to the affliction (199).  
The adaptability of lncRNAs in driving these complex molecular interplays may place them as 
epigenetic controllers of eukaryote gene expression.    
1.2.2 Associations between sncRNAs and lncRNAs.  
The family of sncRNAs comprises a variety of categories, as detailed in Table 1.1. Despite the 
many advances in this field, the miRNAs are the most important sncRNAs and the best understood. 
Interestingly, although lncRNAs are thought to be reservoirs for sncRNA transcription (116, 200, 
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201), new research suggests the relevance of a regulatory loop interaction between these classes of 
ncRNAs (202).  
miRNAs are a class of endogenous, sncRNAs that mediate post-transcriptional gene silencing by 
complementary binding to the 3" untranslated region of target mRNA, which is a key process for 
regulating gene expression in a tissue- and developmental stage-specific manner (203).  
miRNAs are predicted to affect up to 60% of protein-coding transcripts (204, 205) and are 
implicated in essential biological processes including stem cell division, particularly in mammalian 
development (206-208), differentiation, development (209-213), apoptosis and cancer (214-221). 
Although most miRNAs are expressed in the brain, their role in neurogenesis, synaptic plasticity 
and cognitive function is only beginning to be elucidated, and considerable work is required to 
better understand their influence within the context of psychiatric disorders (222, 223).  
Recent investigations using Dicer knockout mice have shown that miRNA dysregulation leads to 
abnormalities in brain development and neuronal stem cell differentiation (224-226), increased 
cortical neurodegeneration (227, 228) and alterations in learning and memory (229). For example, 
among an increasing number of miRNAs implicated in schizophrenia, miR-132 is a CREB-
regulated miRNA driven by NMDA receptor signalling and has been shown to be important for 
cognitive processing and is dysregulated in the brains of patients with the disorder (93, 230, 231). 
miR-219, another NMDA-receptor-regulated miRNA, has been functionally linked to the 
behavioural impairments associated with schizophrenia (232). The progression of Alzheimer’s 
disease (AD) is characterized by cognitive decline and anxiety disorder related to dementia. 
Recently, Zovoilis et al. (2011) identified miR-34c as a negative regulator of memory consolidation 
in mice and that miR-34c expression is elevated markedly in the brains of patients with AD (233). It 
has also been shown that the expression of miR-34c increases in response to acute stress, thereby 
providing a functional link between miRNA activity, cognitive function and anxiety in AD (234).  
miRNA-mediated regulation of gene function has also been implicated in the development of 
addiction. The miRNAs miR-124, Let-7d and miR-181 are up-regulated in the nucleus accumbens 
in response to cocaine, and knockdown of each of these miRNAs influences cocaine-seeking 
behaviour (235, 236). miR-324 and miR-369 regulate MEF2 and FosB, two plasticity-related genes 
required for cognitive functioning associated with cocaine-seeking behaviour (237, 238). MEF2 has 
been implicated in the suppression of excitatory synaptic density (239), and miRNA-mediated 
negative regulation of MEF2 may remove this constraint and increase synaptogenesis in response to 
cocaine-associated learning. miR-212 expression is also increased in the striatum after extended 
access to cocaine, and over-expression of this miRNA decreases cocaine-seeking behaviour (240).  
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Although miRNA biogenesis is well understood (81, 241, 242), the studies mentioned above 
showed the importance of miRNA function in the brain, yet the association between miRNA and 
lncRNA in the central nervous system (CNS) remains largely unexplored. The relevance of this 
relationship, in which ncRNAs alternatively target each other’s regulatory function, has been 
uncovered in other fields, such as cancer research. For instance, the over-expression of HOTTIP 
lncRNA is associated with decreased transcription of the Hoxa gene in hepatocellular carcinoma 
(243). These investigators also found a negative correlation between HOTTIP and the expression of 
miR-125b, which acts as a tumour suppressor gene through this mechanism (243). A similar 
function has been attributed to miR-34a, which silences UFC1 lncRNA, and failure of this pathway 
induces hepatocellular carcinoma (244). By contrast, the lncRNA Ccat1 decoys miR-218-5p from 
its target oncogenic gene Bmi1 and contributes with gallbladder cancer development (245). 
Similarly, Ptenp1, Hulc and Hotair lncRNAs also act as “sponges” by deterring miRNA activity 
involved in oncogenesis (246-248).  
Bace1-As lncRNA is an interesting example of a miRNA–lncRNA interaction in association with 
brain function. This lncRNA competes with miR-675 for an enriched binding site within exon 6 of 
Bace1 and induces Bace1 stabilization; deregulation of this mechanism has been linked to AD 
(249). 
Apart from the evidence produced in association with miRNAs, the potential link between lncRNAs 
and other sncRNA transcripts, such as endogenous siRNAs and piRNAs, which are reviewed 
elsewhere (1), has not been revealed. This may reflect the lack of understanding and research on 
these sncRNA regulatory functions. 
snoRNAs may be the most ancient ncRNA revealed to date (202). There are two types of the small 
class of ncRNAs: the C/D and the H/ACA box type of snoRNAs, which contain specific conserved 
motif sequences for base pairing of rRNAs close to the 5" and 3" end, respectively (250). Whereas 
the C/D snoRNAs drive methylation, the H/ACA snoRNAs are involved in pseudouridylation of 
target RNAs (251-253). Interestingly, the snoRNAs have also been linked to lncRNA 
transcriptional activity. A subclass of snoRNAs is transcribed from lncRNA substrates, whereas 
snoRNAs flanking non-coding regions participate in the biogenesis of lncRNAs produced from 
those sequences (254). A relationship between snoRNAs and lncRNAs has also been suggested 
(255) and is thought to have a role in neural regulation (202), although no research has proven the 
functional extent of these interactions. 
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It is expected that the discovery of the non-coding transcription function will continue to identify 
more feedback loops between sncRNAs and lncRNAs. This may contribute to the understanding of 
gene regulation through the synchronization of ncRNA layers in eukaryote systems. 
1.3 lncRNAs and their associations with cognition and 
psychiatric disorders. 
Neuropsychiatric disorders account for 7.4% of human diseases worldwide and are predicted to 
cause 12% of all deaths by 2015 (256, 257), as researchers struggle to find solutions. Investigating 
the ~98% of genomic information not currently well understood is necessary for comprehending 
one of the most complex mammalian systems—the brain.  
Reviewed opinions in the field of neuroscience suggest the importance of lncRNAs in neural 
plasticity and psychiatric afflictions (1). The ability to control epigenetic transcriptional and post-
transcriptional mechanisms makes ncRNAs good candidates for studying the molecular processes 
underlying neuropsychiatric disorders.  
Investigations of lncRNA often have technical difficulties. For lncRNAs, in vitro results may not 
reflect what is actually happening within the same system in the adult tissue (258), whereas in vivo 
validation is difficult and problematic, and thus rare. lncRNA expression levels that are specific to 
tissue-, stimuli, cell compartment and developmental stage are intrinsic to their rapidly changing 
nature, making them less likely to reproduce the basic mechanisms in more complex structures. The 
ENCODE project has confirmed the abundance of brain-specific lncRNAs and also supports the 
notion of tissue- and cell-compartmentalized non-coding expression (10).  
These characteristics have hampered the progress of more significant research on lncRNAs in 
neuroscience. The brain is such an exquisite machine programmed to promptly respond to external 
cues that tracing the changing patterns of lncRNA expression and function remains elusive and 
largely undisclosed. 
Another obstacle in post-mortem transcriptome investigations targeting lncRNAs is the fact that the 
rapid turnover of lncRNAs (in many cases ~30 min) (125) demands the very specific and 
synchronised collection of tissues. Post-mortem tissues available for investigation of psychiatric 
disorders may come from individuals whose time of death by suicide or in isolation is imprecise. 
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This would influence the expression of lncRNAs more strongly than the coding genes, which are 
normally more stable (259-261). 
Since the discovery of the expression of ~20,000 lncRNAs in the mouse brain (60), lncRNAs have 
been implicated in the development of the forebrain, hippocampus and neocortical structures within 
the vertebrate CNS (118, 262, 263). lncRNA is related to neurogenesis (165, 264, 265), synapse 
formation (196) and pluripotency of neural progenitor cells (174, 266, 267). Further, many 
lncRNAs are enriched within the mammalian brain (10, 268, 269), and are expressed in a tissue-
specific manner (11) suggesting a neural-specific function (270-272). lncRNAs transcribed in the 
CNS are preferentially located close to coding genes involved in transcriptional regulation and 
neuronal development (273) and display a co-expression response upon stimulation (274, 275). 
Additionally, deregulation of the lncRNAs loci can affect the neighbouring protein-coding genes in 
the mouse brain (268, 276).  
A recent transcriptome-wide analysis of the human cortex has identified humanoid-specific lncRNA 
expression that correlates with the age of the subject. This also shows that lncRNAs continue to 
change after the development-specific transcriptional determination in the brain (277).   
Several lncRNAs are now suspected to be contributing factors to the development of psychiatric 
and neurodegenerative disorders. For example, knockdown of the Tcl1 neuron-associated (Tuna) 
lncRNA affects pluripotency and neural differentiation of developing embryonic mouse cells. It has 
been suggested that this lncRNA plays a role in neurodegeneration associated with Huntington’s 
disease (HD) (272). Rest (repressor element-1 silencing transcription factor), a key factor in the 
development of fatal HD, has recently emerged as a central regulator of the expression of many 
ncRNAs in neural systems (278). The interaction of Rest with lncRNAs, such as Tug1 and Dgcr5, 
has further been suggested to be associated with HD and DiGeorge syndrome (279, 280). 
Concordantly, the lncRNAs Har1f and Har1r, which are cis-antisense to Har1 gene, are 
significantly downregulated in the striatum of HD patients (281). The revision of previous 
Affimetrix microarrays by Johnson (2012) also led to the finding of more lncRNAs associated with 
HD and of the differential expression of Neat1, Tug1, Meg3 and Dgcr5 in the disease (282). The 
latest research has shown that a newly described lncRNA has a neuro-protective function within the 
striatum of the brain in an HD mouse model (283). 
Investigations of schizophrenia disorder using post-mortem cortical tissue have found dysregulation 
of Gomafu lncRNA and have suggested its involvement in splicing regulation of genes associated 
with this condition (74). It has been suggested that the lncRNA disrupted in schizophrenia 2 
(Disc2), which is transcribed in the antisense direction to the protein-coding transcript Disc1, 
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regulates Disc1 expression and splice variant levels in schizophrenic patients (284-286). This 
lncRNA has also been implicated in bipolar depression and autism spectrum disorders (287, 288). 
Concordantly, the expression of lncRNAs is thought to participate in mitochondrial dysfunction 
associated with the early onset of schizophrenia (289). 
In AD, the highly conserved lncRNA Bace1-AS, is significantly up-regulated. By competing for its 
binding motif, Bace1-AS, prevents miR-485-5p-induced expression of the Bace1 gene, a key factor 
in proper cognitive function (249, 290). Another study of AD reported that Bace1-AS induces 
Bace1 stability through base-pairing association with this gene (192). A recent investigation 
reported that lncRNA 51A, which is transcribed antisense to sortilin-related receptor 1 (Sorl1), is 
downregulated in AD patients. Increased expression of 51A has been found in vitro and ex vivo AD 
post mortem samples. This upregulation leads to alternative splicing of Sorl1, and its consequent 
depletion induces significant amyloid beta (Aβ) overproduction, which may prompt 
neurodegeneration, (291). Finally, other ncRNAs have been named as biomarkers of AD including 
the lncRNA Bc200, which is upregulated in cortical regions of AD patients; the newly described 
lncRNA 17A, which by modulation of Gpr51 splicing results in a significant impairment in GABA 
receptor signalling in AD (292); and the overlapping transcript to the Sox2 gene, Sox2ot, which 
regulates CNS vertebrate development and neurogenesis (265). Similarly, models of chronic 
epilepsy and AD have exposed co-expression patterns of lncRNAs with adjacent genes involved in 
the development of these diseases (293, 294).  
lncRNAs have also been implicated in an inherited neurodegenerative disorder known as 
spinocerebellar ataxia type 7 (SCA7), which is caused by the presence of a repetitive sequence 
within the Ataxin-7 gene. This coding gene is flanked by two well-conserved CTCF binding sites. 
The transcription of an antisense Ataxin-7 lncRNA, known as Sccant1, is dependent on the presence 
of these motif sequences and its expression correlates inversely with Ataxin-7 expression in SCA7 
patients (295). Lastly, manipulation of lncRNAs has been proposed as a therapeutic intervention for 
the treatment of cognitive deficits associated with Angelman syndrome (296). 
The relevance of lncRNAs to addiction has also been shown and may open the doors to new studies 
of the molecular aetiology of this behavioural disorder. A microarray transcriptome approach has 
revealed 603 differentially expressed lncRNAs in the nucleus accumbens brain region of cocaine-
conditioned mice (297). The up-regulation of Meg3, Gomafu, Neat1 and Malat1 is also associated 
with heroin abuse (298, 299).  
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Studies in other behavioural conditions have also reported on the irregular expression of lncRNAs. 
Investigations of the post-mortem brain of people who have died by violent suicide have reported 
on the significant expression of an lncRNA antisense to the MARCKS gene marker. The researchers 
also found that the level of MARCKS antisense lncRNA expression is independent of MARCKS 
transcription, suggesting a role for the lncRNA in mental illness leading to suicide (300). 
Synaptic plasticity is a major part of the molecular wiring of information within the brain. 
Interestingly, no investigation has studied the true extent of the potential involvement of lncRNAs 
in these processes. A recent study reported that Gomafu lncRNA may be involved in the alternative 
splicing of ERBB4, a gene associated with long-term potentiation (LTP) within the hippocampus, 
and this finding suggests that Gomafu may play a role in synaptic plasticity (301). 
The BDNF locus is an attractive target of investigation to determine whether ncRNAs are drivers of 
its function within the brain (302). The human antisense transcript Bdnfos (or Bdnf-AS) has been 
shown to interact with its sense mRNA in double-stranded RNA (dsRNA) duplex (303). Recent 
investigations have shown the existence of the mouse homologue, Bdnf-AS, which inhibits Bdnf 
mRNA transcription by the recruitment of Ezh2, a member of the PRC2 complex. Moreover, 
knockdown of Bdnf-AS correlates with the reversible up-regulation of Bdnf mRNA and protein 
expression, both in vitro and in vivo, and with an increase in neurite outgrowth and neuronal 
maturation (304). The reciprocal expression of BDNF and its antisense non-coding transcripts has 
been shown within the context of epilepsy (275).  
These investigations are recent, and although non-coding transcription is a relevant phenomenon 
that occurs in the mammalian brain, its true function in determining behaviour has not been proven. 
Whether this is because of the highly specific nature of lncRNAs, which are difficult to detect in 
behavioural experiments, or whether this is potential proof of their lack of significance in complex 
responses remains to be studied.   
Since the discovery of DNA, various genomic findings have undoubtedly contributed to the 
understanding of how the human brain works at the molecular level. However, there seems to be a 
stratum of information associated with lncRNAs, which may be responsible for patterns of gene 
expression in a highly adaptive nature that is yet to be defined.  
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1.4 Epigenetics in brief. 
The term “epigenetics” was first ascribed by Conrad Waddington to define any molecular 
mechanism that induces a change in the phenotypic expression from a particular genotype (depicted 
in Fig. 1.2) (305, 306). This concept was later revisited as “heritable changes in the gene function 
that cannot be explained by changes in the DNA sequence”, which adds a complex layer of 
inheritance to this phenomenon (307). One of the mechanisms originally believed to be responsible 
for modulations in the expression of fixed genotypes is DNA methylation. Researchers proposed 
this idea in 1968 by suggesting that methylation processes are the likely basis for long-term 
memory in the brain (308). Soon after, the milestone investigations that confirmed the “switching 
on and off genes” through DNA methylation were reported in the context of developmental biology 
and X chromosome inactivation (309, 310).  
   
Figure 1.2: Epigenetic Landscape. Reproduced image of the Conrad Waddington epigenetic landscape 
represents the cell as blueprint of gene expression (the ball), which can take different trajectories that alter 
the final cell fate (311). 
Since then, other molecular pathways that can affect DNA, such as acetylation, phosphorylation, 
ubiquitination and sumolyation, and the core molecules of chromatin conformation, the histone 
proteins, have been included as epigenetics drivers of gene modulation (312).  
Interestingly, many of these processes are driven by lncRNA activity (313, 314). For example, the 
lncRNA Tarid controls Gadd45A, a master molecule in the regulation of DNA demethylation, to 
activate the expression of the Tcf21 tumour suppressor factor in cancerous cells (315). More 
investigations have established that lncRNAs can bind the PRCs group of proteins. Panda, Malat1, 
Meg3, H19, Anril and Hotair lncRNAs all interact with different members of the PRC2 family, 
such as Ezh2 and Jarid2 proteins, to affect the expression of genes associated with essential life 
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processes such as cell senescence, cell differentiation, tumorigenesis and development (142, 166, 
316-319). 
The epigenetics notion, which focuses on the perception of a genomically stable genotype, is now 
challenged by the unravelling nature of the RNA molecule. With the discovery of RNA-specific 
methylation patterns, a new field of “RNA epigenetics”, which implies that RNA is independent of 
its DNA, is foreseen (320-323).  
1.5 Fear conditioning in memory and pathological behaviours. 
Understanding the neurobiology of learning and memory implies decoding of “experience-
dependent plasticity” as a source for information processing (324). Fear is a generalised emotion 
common to the animal kingdom, and decision-making triggered by fear is a basic example of a 
complex synaptic plasticity response (325). Fear learning powered the evolutionary advantage of 
self-preservation and survival, but the same mechanisms are now known to sustain pathological 
behaviours related to the persistent memory of adverse events (326). Dysregulation of this adaptive 
response is considered a source of the psychopathologies associated with anxiety and post-traumatic 
stress disorder (PTSD) (327-330). 
Pavlovian fear conditioning has been used extensively to study behaviour and is a proven technique 
to elucidate the cellular and molecular mechanisms supporting memory and cognition in rodent 
models (331). In particular, cued fear conditioning has been suggested as an experimental model of 
fear-associated afflictions and phobias (332). Pavlovian fear conditioning is both a proven tool for 
studying associative learning and a model for investigating the “pathogenesis of anxiety disorders” 
in rodents (333-335).  
In this paradigm a neutral stimulus (NS) is paired with a noxious unconditioned stimulus (US) and 
presented to the animal so that the NS that represents the prediction of an imminent US becomes a 
conditioned stimulus (CS) (336). Through a series of CS–US pairings, the CS evokes fear behaviour 
in the animals (conditioned response or CR), which can be measured as a level of freezing and is 
considered to be representative of learning acquisition (324).  
Two of the most common models used in rodent-based fear-cognitive experiments include delay 
fear conditioning (-CS is co-terminated with US) and trace fear conditioning (CS–US stimuli are not 
co-terminated but separated by a “trace interval”). Each model has traditionally been associated with 
different regions of neuronal activation in the brain. Recent research has shown that shock only-
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conditioned and delay fear-conditioned mice do not respond to distractors as trace conditioned mice 
do, indicating the relevance of trace fear in attention-related investigations (337).   
Early investigations of the behaviour of monkeys have elucidated that damage to the amygdala 
neurons is responsible for fear reduction and the associated emotional response in these animals 
(338). This has persuaded scientists to hypothesize that the amygdala is the centre of the control of 
the primitive emotional response to fear. The amygdala is a complex section of the brain that 
involves the integration of several nuclei, some of which are specifically involved in the fear 
response, particularly those associated with a cue (324). Studies to understand the acquisition of fear 
memories have focused mainly on the hippocampus and amygdala neural circuitries (339). 
However, to articulate and project a fear response, the amygdala interconnects and receives sensory 
inputs from both the hippocampus and the cortex (340, 341).  
Although the hippocampus is crucial for the processing of contextual and trace fear learning (342-
346), its role in delayed fear appears questionable (347-349). Experimental research has shown that 
the involvement of the hippocampus in delayed fear conditioning may be related to the US nature, 
where dorsal hippocampus engagement depends on the strength of the US (350). 
Recent investigations have shown that the pre-frontal cortex (PFC) is a vital participant in fear 
processing, although the true scope of the medial PFC (mPFC) involvement in the acquisition and 
storage of fear memories is being revealed and remains a matter of argument (351). Consistent with 
these views, general depression of neural connectivity within the PFC as a result of fear conditioning 
has been reported and shows the relevance of this site in the expression of learned fear (352). The 
activation of the pre-limbic cortical region (PL) is involved in the expression of learned fear but not 
in the expression of innate fear (353). Previous research has proven the PFC to be equally necessary 
for trace and contextual fear memory acquisition (354, 355), although its participation in delayed 
fear also remains controversial (337, 353, 354).   
The PFC region is a major site involved in stress-associated disorders, and it is likely to elicit an 
anxiety response to the fear-conditioning paradigm (356-358). Fear conditioning induces greater 
anxiety-like behaviours in “high fear learning mouse lines”, which have been studied to identify a 
direct genetic link between fear conditioning and anxiety (359). The PFC is also vulnerable to 
dendritic spines loss caused by stress, which is a preliminary stage in the development of 
schizophrenia (360). Consequently, the PFC is thought to be a likely neurological site for stress and 
anxiety conditions (357, 358, 361).  
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Interestingly, lncRNAs are particularly present in the PFC. Research has detected the transcription 
of human accelerated non-coding sequences in the PFC and suggested that is consistent with the 
diversification of hominids from primates (118).  
Investigations have also established the relevance of the mouse strain in behavioural changes 
elicited by fear conditioning experiments (362-368). Delay and trace fear conditioning effects have 
been shown to be strain specific (364, 366). Comparisons between strains have shown that C57/BL6 
animals are prone to show stressful and anxious responses (367, 369, 370). Fear conditioning 
models can be adapted for investigating associative learning and stress-related and post-traumatic 
disorders in mice (371). Therefore, the relevance of the behavioural training depends on the training 
intensity, the brain region investigated and the strain used.  
Overall, there is now consensus about the relevance of non-coding transcription in the human 
genome. lncRNAs are enriched in the brain transcriptional landscape, where they show a high level 
of specificity. Evidence of their involvement in adaptive responses is anticipated.  
1.6 Research hypothesis. 
ncRNAs are highly expressed in the mammalian brain, yet little is known about their biological 
function in the nervous system. The objective of this thesis was to elucidate the functional relevance 
of lncRNAs and their molecular mechanisms of action in driving the regulation of the expression of 
genes associated with mammalian behaviour.  
While there is insufficient research to support the idea that lncRNAs can influence behavioural 
phenotypes, the evidence reviewed suggests that lncRNAs may play a role in driving behavioural 
responses. Non-coding transcription may have biological and functional roles yet to be explained in 
relation to neural plasticity, cognition and neuropsychiatric disorders. The hypotheses tested in this 
thesis were that ncRNA transcription plays a role in mammalian behaviour and that lncRNAs 
contribute to complex behaviour by regulating the expression of proximal coding genes.  
Deep sequencing technologies, such as RNA capture sequencing and whole-genome RNA 
sequencing (RNA-Seq), were used to detect important coding genes associated with neural 
plasticity and psychiatric disorders. This was followed by identification of neighbouring lncRNAs 
with possible regulatory roles, as described in chapter 3. In vitro assays and qPCR validation with 
the objective of confirming tissue-specific patterns of expression and in cis regulatory function 
upon neural induction of lncRNAs are described in chapter 4. An important objective of this 
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investigation was to demonstrate the potential in vivo function of lncRNAs associated with 
mammalian behavioural training because no research has yet achieved this. Concordantly, the role 
of Gomafu lncRNA as a factor in the development of mice anxiety, which was investigated using in 
vivo knockdown assays, is described in chapter 5. The findings of chromatin immunoprecipitation 
(ChIP) experiments are consistent with a potential in cis regulatory role of Gomafu and are 
described in chapter 6. A small RNA-sequencing approach provided further support for the idea that 
ncRNAs may act in the synchronised interaction between sncRNAs and lncRNAs and is described 
in chapter 7.  
The findings of this thesis contribute to the understanding of ncRNAs by identifying the ncRNAs 
that are dynamically activated upon stimulation of the mouse brain. More importantly, it provides 
suggestive evidence indicating that lncRNAs may be regulators of mammalian behaviour through 
epigenetic mechanisms.  
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INTRODUCTION
From whence we came, whither we go: the rise of the RNA world.
When Woese, Orgel, and Crick each wrote about the origin and
evolution of the genetic code they laid the foundation for “The
RNA world hypothesis,” which was later developed by Gilbert
(Woese, 1967; Crick, 1968; Orgel, 1968; Gilbert, 1986). This
hypothesis stemmed from the fact that ancient RNA had the abil-
ity to transmit heritable information as well as, in the case of
ribozymes, being endowed with enzymatic capacity (Cech et al.,
1981; Kruger et al., 1982; Guerrier-Takada et al., 1983; Joyce, 2002;
Cech, 2011). With the advent of next-generation sequencing tech-
nology, coordinated efforts such as the ENCODE and FANTOM
3 projects have revealed that more than 90% of the genome is
actively transcribed, whereas only ∼2% codes for functional pro-
tein. These landmark observations brought into question the true
value of RNA as a regulatory molecule and have since motivated
scientists to embark on a deeper exploration of the biological
function of so-called“junkDNA”or“genomic darkmatter”(John-
son et al., 2005; Derrien et al., 2011). Many non-coding RNAs
(ncRNAs) are highly conserved and correlate with the degree of
eukaryotic complexity, further strengthening the argument that
they are more than simple artifacts of evolution (Griffiths-Jones
et al., 2005; Taft et al., 2007; Heimberg et al., 2008; Mattick, 2011).
In fact, their ability to drive transcription, direct epigenetic pro-
cesses, and silence gene expression make ncRNAs ideal candidates
for insight into molecular evolution and a better understanding of
themolecular pathways of neuropsychiatric disease. In this review,
weprovide anoverviewof the current state of knowledge regarding
the involvement of various classes of ncRNAs in neural plasticity
as well as their potential role in a variety of neuropsychiatric disor-
ders, particularly those characterized by impairments in cognitive
function.
NON-CODING RNA: A KEY DRIVER OF GENE REGULATION
The broad potential of ncRNAs to critically regulate transcrip-
tion and translation has been appreciated for some time with the
discovery and characterization of various ncRNA families, the
majority of which have been shown to be capable of directing
epigenetic processes (Mattick and Makunin, 2006). A simplistic
division of the different classes of ncRNAs can be made based on
their size: small ncRNAs, between 20 and 200nt, and long ncRNAs,
arbitrarily identified as any ncRNA over 200 nt. Small ncRNAs
amazed the scientificworldwhen theywere identified as inCaenor-
habditis elegans as being involved in the post-transcriptional
regulation of genes during development (Lee et al., 1993; Wight-
man et al., 1993). Moreover, Fire and Mello were awarded a Nobel
prize in 2006 for their discovery of RNA interference in C. ele-
gans (Fire et al., 1998). Long ncRNAs have also recently entered
the spotlight. For example, Rinn et al. (2007) recently discovered
a long ncRNA called HOTAIR, which regulates epigenetic con-
trol over the HOXD locus, thereby providing novel evidence for a
functionally relevant role for this enigmatic family of non-coding
transcripts.
SMALL ncRNAs: miRNAs
MicroRNAs (miRNAs) are a class of endogenous, small ncRNAs
that mediate post-transcriptional gene silencing by complemen-
tary binding to the 3′-untranslated region (3′ UTR) of their target
mRNA, a key process for regulating gene expression in a tissue-
and developmental stage-specificmanner (Liu andKohane, 2009).
As illustrated in Figure 1A, the biogenesis of miRNAs begins in
the nucleus through a canonical pathway as a large primary-RNA
(pri-RNA) molecule, which folds into a stem loop transcribed
by both RNA polymerase II (RNA Pol II) and RNA polymerase
III (RNA Pol III; Kim, 2005; Borchert et al., 2006). This hairpin
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FIGURE 1 | (A) miRNA biogenesis begins in the nucleus where Drosha and
DGCR8 cleave the primary RNA resulting in a miRNA precursor that is
exported to the cytoplasm by Exportin5 and Ran-GTP61 where it is then
processed by Dicer andTRBP. Next, the mature miRNA duplex is incorporated
to the RISC where it is cleaved Dicer, associates with AGO2, and
subsequently binds to the 3′ UTR of a target RNA leading to either mRNA
degradation or translational repression. (B) Similarly, siRNA biogenesis
depends on Dicer activity and incorporation into the RISC, however siRNAs
avoid cleavage by Drosha as they are derived from exogenous viral or
endogenous double-stranded RNA molecules mostly within the cytoplasm.
Given the specificity of base pairing, the final outcome of the siRNA
interference is the cleavage and degradation of their target mRNAs.
structure is then processed by an enzyme known as Drosha, which
works with the RNA-binding protein DGCR8 (DiGeorge critical
region 8, called Phasa in invertebrates; Kim, 2009) to produce
a ∼70 nt (precursor) pre-miRNA that is then shuttled to the
cytoplasm via Exportin5 and Ran-GTP61. The pre-miRNA is
cleaved in the cytoplasm by an enzyme called Dicer, together with
double-stranded RNA binding proteins (dsRBPs) including TRBP
(Yi et al., 2003). At this stage, a double-stranded mature miRNA
can be detected; however, its inhibitory capacity depends onDicer-
mediated incorporation of one of its strands, together with the
Argonaute (Ago) protein, into the RNA-induced silencing com-
plex (RISC; Chendrimada et al., 2005). The RISC then directs
the miRNA toward a complementary “seed” sequence within the
3′ UTR of its target mRNA (Wightman et al., 1993; Reinhart et al.,
2000; Pillai et al., 2005). The level of complementarity between the
miRNA and its target mRNA determines whether the mRNA is
degraded or translation is disrupted (Sakurai et al., 2011). Recent
findings suggest that these canonical processes have many vari-
ations (Volk and Shomron, 2011). For example, insertion at 5′
UTR and coding sequences has been shown to result in simi-
lar miRNA activity, and substrates for the formation of miRNA
can found be within intronic regions (mirtrons), directly spliced
by RNA Pol II, thereby eluding the activity of Drosha (Lee et al.,
2004; Ruby et al., 2007). Furthermore, they may also be derived
from small nucleolar RNAs, transfer RNAs or by tRNase Z activity
(Yang and Lai, 2011).
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MicroRNAs are predicted to affect up to 60% of protein-
coding transcripts (Lewis et al., 2005; Friedman et al., 2009), and
have been implicated in essential biological processes includ-
ing stem cell division particularly in mammalian development
(Hatfield et al., 2005; Shcherbata et al., 2006; Qi et al., 2009), dif-
ferentiation and development (Reinhart et al., 2000; Foshay and
Gallicano, 2009; Xu et al., 2009; Liu et al., 2012; Zhang et al.,
2012b), as well as apoptosis and cancer (Wang et al., 2008b, 2009;
Kim, 2009; Corthals et al., 2011; Rissland et al., 2011; Sreekumar
et al., 2011; Nie et al., 2012; Yi et al., 2012). Recent investiga-
tions using Dicer knockout mice have also shown that miRNA
dysregulation leads to abnormalities in brain development and
neuronal stem cell differentiation (De Pietri Tonelli et al., 2008;
Huang et al., 2010; Kawase-Koga et al., 2010), increased cortical
neurodegeneration (Davis et al., 2008; Hebert et al., 2010), and
altered learning and memory (Konopka et al., 2010). Although
most miRNAs are expressed in the brain, their role in neurogen-
esis, synaptic plasticity, and cognitive function is only beginning
to be elucidated, and considerable work is required in order to
better understand their influence within the context of neuropsy-
chiatric disorders (Bredy et al., 2011; O’Connor et al., 2011). For
example, among an increasing number of miRNAs implicated in
schizophrenia, miR-132 is a CREB-regulated miRNA driven by
NMDA receptor signaling, which has been shown to be impor-
tant for cognitive processing and is dysregulated in the brains
of patients with the disorder (Kim et al., 2010; Moreau et al.,
2011; Miller et al., 2012). Furthermore,miR-219, anotherNMDA-
receptor-regulated miRNA, has been functionally linked to the
behavioral impairments associated with schizophrenia (Kocerha
et al., 2009). The progression of Alzheimer’s disease is character-
ized by cognitive decline and anxiety disorder related to dementia.
Recently, Zovoilis et al. (2011) identified miR-34c as a negative
regulator of memory consolidation in mice, with miR-34c also
markedly increased in the brains of patients with Alzheimer’s dis-
ease. Interestingly, around the same time, it was demonstrated that
the expression of miR-34c increases dramatically in response to
acute stress, thereby providing a potential link between miRNA
activity, cognitive function and anxiety in Alzheimer’s disease
(Haramati et al., 2011).
More recently, we reported a role for miRNAs in regulating
cognitive processes associated with fear-related anxiety disorder.
Fear-extinction learning in C57/Bl6J mice led to increased expres-
sion of the brain-specific miRNA, miR-128b, which disrupted
stability of several plasticity-related target genes and regulated for-
mation of fear-extinction memory. We proposed that increased
miR-128b activity might facilitate the transition from retrieval of
the original fear memory toward the formation of a new fear-
extinctionmemory, the disruptionof whichwould have important
implications for the development of fear-related anxiety disorder
(Lin et al., 2011).
MicroRNA-mediated regulation of gene function has also
been implicated in the development of addiction. The miRNAs
miR-124, Let-7d, and miR-181 are up-regulated in the nucleus
accumbens in response to cocaine, andknockdownof eachof these
miRNAs influences cocaine-seeking behavior (Chandrasekar and
Dreyer, 2009, 2011). Using an elegant dopamine cell type-specific
knockout approach, Schaefer et al. (2010) demonstrated thatAgo2,
a subunit of Argonaute, is critical for mediating the motiva-
tional aspects of cocaine self-administration. Importantly, there
are specific Ago2-dependent miRNAs that are cocaine-inducible,
including miR-181a,miR-324, and miR-369, which may therefore
be involved in this effect. Indeed, miR-324 and miR-369 reg-
ulate MEF2 and FosB, two plasticity-related genes required for
cognitive functioning associated with cocaine-seeking behavior
(Pulipparacharuvil et al., 2008; Renthal et al., 2009). AsMEF2 has
been implicated in the suppression of excitatory synaptic density
(Flavell et al., 2006), a miRNA-mediated negative regulation of
MEF2 may remove this constraint and increase synaptogenesis in
response to cocaine-associated learning. Furthermore, miR-212
expression is increased in the striatum after extended access to
cocaine, and over-expression of this miRNA decreases cocaine-
seeking behavior (Hollander et al., 2010). Recently, it has been
demonstrated that the methyl CpG-binding protein 2 (MECP2)
mediates the escalation of reward-seeking behavior in rats through
a homeostatic interaction with miR-212 and subsequent regula-
tion of brain-derived neurotrophic factor (BDNF) in the striatum
(Im et al., 2010). This is a particularly interesting finding as it pro-
vides some of the first evidence to suggest that ncRNA-directed
regulation of the epigenome occurs in an activity-dependent
manner in vivo.
SHORT INTERFERING RNAs
Very little is known about the role of short interfering RNAs
(siRNAs) in the context of neurodegenerative disease or neu-
ropsychiatric disorders; however, we include these small ncRNAs
because of their demonstrated ability for targeting gene silenc-
ing in a variety of contexts. Similar to miRNAs, siRNAs are
∼22 nt non-coding transcripts that are derived from natural anti-
sense transcripts, pseudogenes, and repetitive sequences within
endogenous dsRNA, as well as by an exogenous viral replication
mechanism that is able to initiate degradation of homologous
mRNAs (Sharp, 2001; Tam et al., 2008; Cech, 2011; Zhang et al.,
2012c). The biogenesis of siRNAs is similar to that of miRNA;
however, unlike the nuclear origin of miRNAs, they may originate
in both the cytoplasm and nucleus (Figure 1B; reviewed in Verdel
et al., 2009). This class of ncRNAs is associated with theAgo family
as well as the RISC complex, which transports the guide strand
to a target mRNA. Importantly, siRNAs show significantly more
specific base pairing relative to miRNAs, and use Slicer activity
to cleave and degrade their target mRNAs (Valencia-Sanchez et al.,
2006). The specific base complement of exogenous siRNAs to viral
mRNAs, particularly in Drosophila and C. elegans, represents an
efficient antiviral immune response (Wilkins et al., 2005; Umbach
and Cullen, 2009), whereas endogenous siRNAs are impor-
tant for controlling somatic transposable elements in Drosophila
(Chung et al., 2008) as well as in plants (Ito, 2011).
Perhaps the most striking quality of siRNAs is their synthetic
reproducibility, which makes them attractive tools to be used in
gene therapy for a variety of diseases. Thefirst successful attempt to
treat a human disease through RNAi-mediated gene silencing was
demonstrated with the use of siRNA against hepatitis C in mice
(Song et al., 2003). SiRNA has since emerged as the next “new class
of drugs” (Peer and Lieberman, 2011); however, several hurdles
must be overcome before siRNA-mediated gene therapy will make
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its way to the clinic. The primary issue is to effectively deliver
siRNAs without degradation by phagocytosis or the production of
off-target effects. A second concern is the design of membrane-
permeable siRNAs that readily cross the blood–brain barrier
(Dominska and Dykxhoorn, 2010). Advances in siRNA delivery
have begun to address these challenges through the development
of labeled magnetic nanoparticles, PEGylated LPD (liposome-
polycation-DNA), and cationic liposomes (Li et al., 2011). siRNA
has been successfully used to treat viral infections including polio,
human papilloma virus, echoviruses, and adenoviruses (Morris-
sey et al., 2005; Saulnier et al., 2006; Tan et al., 2007; Eckstein
et al., 2010). Furthermore, siRNAs have also been demonstrated
to be efficacious in the treatment of human pancreatic can-
cer (Zhong et al., 2012), lung carcinoma (Podesta et al., 2009),
and fibrodysplasia ossificans progressiva (Kaplan et al., 2011;
Takahashi et al., 2011).
Reports on the putative function of both endogenous and
exogenous siRNAs in the brain and their regulation of behavior are
emerging. Within the context of Parkinson’s disease, a neurode-
generative disease characterized by cognitive decline, Hommel
et al. (2003) found that siRNA-mediated knockdown of Th, which
is a gene responsible for the production of tyrosine hydroxylase
and a key enzyme within the dopaminergic pathway, attenu-
ated locomotor abnormalities in a mouse model of Parkinson’s
disease. Neuronal dysfunction due to mutations in the human
α-synuclein gene affect dopaminergic levels and have been asso-
ciated with idiopathic Parkinson’s disease as well as dementia
with Lewy bodies. Delivery of lentiviral-mediated siRNA has been
shown to effectively diminish endogenous expression of this gene
both in vitro and in vivo (Sapru et al., 2006). SiRNA designed
to target human Htt, a gene involved in Huntington’s disease,
which is also a neurodegenerative disorder characterized by cog-
nitive impairment, attenuates striatal neuropathology, and motor
deficits in a mouse model of Huntington’s disease (Difiglia et al.,
2007). Moreover, these studies have been extended in both mice
and non-human primates, in which administration of siRNAs
selective for Huntingtin are effective in delaying neurodegener-
ation, and may also have some efficacy in preventing the cognitive
decline observed in Huntington’s disease (Lombardi et al., 2009;
Pfister et al., 2009; Zhang et al., 2009; McBride et al., 2011;
Stiles et al., 2012).
It has been widely demonstrated that exogenous siRNA is also
a useful approach for inducing loss of function in studies inves-
tigating genes involved in synaptic plasticity, and learning and
memory. Early research found that siRNAs could be used to
silence endogenous and heterologous genes within the rat hip-
pocampus (Krichevsky and Kosik, 2002). The important role of
GluR1 in the acquisition and consolidation of spatial memory
has recently been demonstrated using siRNA (Das et al., 2012).
Interestingly, knockdown of CREB by siRNA has elucidated the
important role of O-GlcNAc-mediated glycolysation of CREB in
regulating dendritic outgrowth, a process critical for the forma-
tion of long-term memory (Rexach et al., 2012). Concordantly,
siRNA-mediated knockdown of the alpha 2 subunit of theGABAA
receptor within the amygdala decreases binge drinking, thereby
suggesting a potential role for endogenous siRNA in the regu-
lation of addiction-like behavior (Liu et al., 2011). Furthermore,
Panossian et al. (2012) employed an RNAi approach to demon-
strate the essential role of the stress hormone neuropeptide Y
(NPY ) in regulating the stress response.
Remarkably, the stability and turnover of both miRNA and
siRNA depend on the methylation status of their 3′ UTR,
which potentially protects these small RNAs from urydination
and exonucleolytic degradation (Ji and Chen, 2012; Zhao et al.,
2012).This observation supports the prospective role of endoge-
nous siRNAs, which is to control gene expression in mammalian
oocytes (Tam et al., 2008; Watanabe et al., 2008; Nejepinska et al.,
2012). These regulatory properties are also consistent with the
findings of Song et al. (2011) who identified endogenous siRNAs
in humans and mice, which are involved in developmental pro-
gramming of male germ cells. Even more exciting is the fact that
endogenous siRNAs may also direct transcriptional gene silencing
in the metazoan genome through the regulation of chromatin
modification. For example, in C. elegans, Schizosaccharomyces
pombe, and Drosophila they direct H3K9 methylation to estab-
lish the formation of heterochromatin (Fagegaltier et al., 2009;
Burkhart et al., 2011).
Experience-dependent expression of endogenous siRNAs has
only recently been uncovered in the mammalian genome. For
instance, siRNA associated with genes involved in synaptic plas-
ticity are up-regulated in the hippocampus of mice subjected to
an olfactory discrimination paradigm (Smalheiser et al., 2010). As
mentioned, endogenous siRNAs aremostly derived from repetitive
elements in germinal tissues, thus supporting the hypothesis that
siRNAs might have evolved to sustain genomic stability during
early development. However, considering the remarkable find-
ings of Smalheiser et al. (2011), who identified an endogenous
siRNA complementary to SynGAP1, and that dysregulation of
SynGAP1 correlates with mental retardation as well as autism
(Hamdan et al., 2009), these observations suggest a potentially
important role for endogenous siRNA in cognitive disorders.
Together, these early findings lay the foundation for the use
of siRNA-mediated gene knockdown as a therapeutic interven-
tion in a variety of disorders; however, it is not yet known
whether manipulation of siRNAs will be applicable to the clinical
treatment of cognitive deficits associated with neuropsychiatric
disease.
PIWI-INTERACTING RNAs
P-element induced wimpy testis (PIWI)-interacting RNAs (PiR-
NAs) are the most distinct but least investigated of all the small
ncRNAs, and appear to function by repressing target gene expres-
sion within the nucleus instead of the cytoplasm (Saito et al.,
2006). They are associated with a subfamily of Ago proteins
containing an N-terminus called PAZ (from PIWI homologous
Argonaute and Zwillie) and a C-terminus PIWI domain (Parker
et al., 2005). PIWI proteins are highly abundant in the germline,
and play an essential role in normal gonadal development in
mice, with mutations resulting in male infertility (Cox et al.,
1998; Girard et al., 2006; Klattenhoff and Theurkauf, 2008; Beyret
and Lin, 2011). In 2001, Aravin et al. discovered a novel small
ncRNA involved in the silencing of the testis-expressed Stel-
late gene in Drosophila but they did not realize that they were
looking at PIWI protein interacting RNAs (Aravin et al., 2001;
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Siomi et al., 2011). Later,Watanabe et al. (2006) revealed the exis-
tence of mouse germline small RNAs between ∼26 and ∼30 nt
long, which they named gsRNAs. Although these investigators
verified an expression pattern that correlated with MIWI and
MILI, two members of the PIWI protein family, they did not
uncover the extent of the association and the true nature of the
piRNAs. This connection was later made in mice where it was
discovered that MILI and MIWI murine PIWI proteins bind,
respectively, to 26 and 30 nt RNAs, which subsequently became
known as piRNAs (Aravin et al., 2006; Girard et al., 2006; Grivna
et al., 2006). Soon after, piRNAs were found in rat testes (Lau
et al., 2006) as well as in Drosophila where they induced silencing
of the Suppressor of Stellate locus found on the Y chromosome
(Vagin et al., 2006).
Although it was initially suggested that piRNAs are only
expressed in germinal cells (Carmell et al., 2007; Grimson et al.,
2008; Beyret and Lin, 2011), they are also found in somatic tissue
(Malone et al., 2009; Lee et al., 2011; Yan et al., 2011; Rajasethupa-
thy et al., 2012). PiRNAs elude cleavage by Dicer and Drosha and
are mostly derived from repetitive elements called piRNA clusters
(Aravin et al., 2006; Girard et al., 2006; Grivna et al., 2006; Saito
et al., 2006; Brennecke et al., 2007; Malone et al., 2009; Malone and
Hannon, 2009). Although these clusters retain interspecies conser-
vation, piRNA sequences themselves show no evolutionary con-
servation (Aravin et al., 2006; Girard et al., 2006; Lau et al., 2006).
This interesting characteristic suggests a locus-specific function of
piRNAs whereby they inhibit only those transcripts derived from
the genomic region in which they originate (Lau et al., 2006).
PiRNAs can also be derived from the 3′ UTR of protein-coding
genes and euchromatic transposable elements (Muerdter et al.,
2012), as well as from non-repetitive genomic DNA (Kim et al.,
2008). In addition, through the insertion and transcription of an
exogenous sequencewithin an endogenous piRNAcluster locus,de
novo piRNAs can be produced fromnon-repetitive protein-coding
sequences (Kawaoka et al., 2012). This revelation paves the way for
the exploration of the role of piRNAs in the regulation of protein-
coding genes through sequence-specific recognition and a Dicer-
independent siRNA pathway, perhaps by using PIWI nuclease
activity.
PiRNAs are transcribed through two well-described mecha-
nisms (Figure 2). The so called “ping pong” pathway is mainly
observed in the cytoplasm of germ cells where pre-piRNAs derived
from transposons are cleaved by unknown nucleases and form a
complex with MILI proteins to direct MILI slicer activity against
target mRNAs. This step results in a new secondary piRNA. The
secondary piRNA is then coupled to a MIWI2 protein, which in
turn exhibits endonuclease activity on theopposite strand andpro-
duces a new pre-piRNA, which again forms a complex with MILI
in an amplification loop (Brennecke et al., 2007; Kim et al., 2009;
Siomi et al., 2011; Pillai andChuma,2012). TheMIWI2 interacting
piRNA is also transported back to the nucleus where it represses
transposable elements through the regulation of DNAmethylation
(Aravin and Bourc’his, 2008; Aravin et al., 2008; Kuramochi-
Miyagawa et al., 2008; Watanabe et al., 2011). A modification
may occur where pre-piRNAs are associated with MIWI proteins
instead of MILI and generate a secondary piRNA that appears to
remain in the cytoplasm and drives the “primary pathway,” which
is present in somatic cells (Kim et al., 2009; Siomi et al., 2011;
Pillai and Chuma, 2012).
Remarkably, piRNAs exploit DNA methylation and chromatin
remodeling to serve their regulatory function in mammals. Muta-
tions induced in murine MILI result in a loss of DNAmethylation
and a consequent up-regulation of long interspersed element-1
(LINE-1) and IAP (intracisternal A particle) elements (Aravin
et al.,2007). Similarly,MIWI2mutants also show increased expres-
sion of LINE-1 and IAP repetitive sequences, which correlate
with higher DNA demethylation levels in the testes (Carmell
et al., 2007). Initially, co-immunoprecipitation studies of MIWI2
failed to demonstrate a direct interaction with DNMT3a and
DNMT3b, suggesting that PiRNAs do not directly regulate the
activity of these enzymes (Aravin et al., 2008). However, additional
investigations have shown impaired de novo DNA methylation
and decreased piRNA levels in germline cells derived from MILI
knockout mice, thus verifying a role for MILI-bound piRNAs
in timing the methylation of transposons (Kuramochi-Miyagawa
et al., 2008). Interestingly, Watanabe et al. (2011) proposed that
piRNAs may interact with other small ncRNAs transcribed from
differentially methylated genomic regions in order to drive de
novo methylation of the locus corresponding to the associated
ncRNA. PiRNAs seem to also participate in chromatin remod-
eling processes by recruiting major chromatin modifiers. These
piRNAs, identified as piALU RNAs, have been shown to regu-
late chromatin organization within and around centromeres as
well as by directing mechanisms of DNA repair and transcription
(Blackwell et al., 2012).
Although the main role of piRNAs appears to be in the
maintenance of genomic integrity and DNA stability through
epigenetic silencing of transposable elements during early devel-
opment (Vagin et al., 2006; Aravin et al., 2007; Brennecke et al.,
2007; O’Donnell and Boeke, 2007; Dharap et al., 2011), the identi-
fication of ischemia-responsive piRNAs in the cortex of the adult
rat (Dharap et al., 2011) suggests an important role for piRNAs
across the lifespan. The recent demonstration that intergenic
piRNAs are expressed in the mouse hippocampus, particularly
within the dendritic compartment, indicates that piRNAs are
functionally active in the adult central nervous system (CNS).
Knockdown of piRNA QD541777 in hippocampal neurons leads
to a decreased number of dendritic spines potentially via the reg-
ulation of mRNA derived from Cdk5rap1 andMark 1/2, two genes
with active roles in CNS development (Lee et al., 2011). More-
over, a cluster of four piRNAs was also found to be associated
with other genes involved in dendrite formation and neuronal
migration (Lee et al., 2011). Consistent with these findings, Kandel
and colleagues recently discovered neuronally expressed piRNAs
that promote DNA methylation of the CREB2 promoter thereby
facilitating synaptic plasticity in Aplysia (Rajasethupathy et al.,
2012). These findings suggest a potential role for piRNAs in tran-
scriptional gene silencing and in the epigenetic facilitation of
long-term memory.
Interestingly, the TUDORprotein interacts with PIWI proteins,
and consequently with piRNAs, in coordinating the regulation of
LINE-1 retrotransposon activity (Chen et al., 2009; Reuter et al.,
2009; Siomi et al., 2010; Yabuta et al., 2011). Together with the fact
that LINE-1 influences experience-dependent neuronal plasticity
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FIGURE 2 | Primary single-stranded intergenic piRNAs are transcribed
within the nucleus from well-conserved clusters of repetitive elements.
Once in the cytoplasm they either interact with MIWI proteins and initiate the
“primary pathway,” or directly with MILI proteins to trigger the “ping-pong
cycle.” PiRNAs associated with MILI direct its slicer activity against target
mRNAs, thereby producing a secondary piRNA, which is then coupled to
MIWI2. MIWI2 piRNA can return to the nucleus where it targets repetitive
elements, or remains within the cytoplasm where it exerts endonuclease
activity on the opposite strand to reproduce a new pre-piRNA that interacts
with MILI in a self-amplification loop.
and somatic mosaicism within the hippocampus (Coufal et al.,
2009;Muotri et al.,2009;Muotri et al.,2010), one can envisionhow
the activity of piRNAs might be integral to these processes. It is
remarkable that the current focus on the role of piRNAs is limited
to the silencing of transposable elements in early development
when in fact they may be potent regulators of neural plasticity and
cognitive function.
LONG ncRNAs
Long ncRNAs are transcripts over 200 nt long that can be found
in both the cytoplasm and the nucleus where they exhibit tightly
regulated spatiotemporal patterns of expression (Kapranov et al.,
2007; Guttman et al., 2009; Khalil et al., 2009). Initially, long
ncRNAs were believed to be the least conserved of all ncRNAs
and to mainly serve as precursors for small RNAs (Kapranov et al.,
2007). Their low level of expression also fueled the debate that
they might merely be the result of transcriptional noise or arti-
facts of high-throughput sequencing (Struhl,2007;VanBakel et al.,
2010). However, it has been shown that some long intergenicRNAs
are under purifying selection in mammals (Ponjavic et al., 2007;
Guttmanet al.,2009) and exhibit cross-species conservation aswell
as function-specific stability (Marques and Ponting, 2009; Ulitsky
et al., 2011; Clark et al., 2012). Interestingly, nuclear long ncRNAs
undergo a high rate of turnover and are relatively unstable, which
is concordant with the notion that they provide a mechanism for
rapid response to external stimuli (Mercer et al., 2009; Clark et al.,
2012). Due to these characteristics, long ncRNAs appear to be in
a state of constant and rapid evolutionary development. However,
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short sequences nested within long ncRNAs, particularly those
close to the promoter region, are highly conserved (Ponjavic et al.,
2007; Guttman et al., 2010; Ulitsky et al., 2011),which suggests that
theymight represent coremotifs forRNAbinding proteins respon-
sible for the extensive chromatin remodeling functions attributed
to a variety of long ncRNAs. This would support the idea that it is
the function of long ncRNAs in relation to protein-coding genes,
and not their primary sequence, that is critical for their influence
on gene expression and positions long ncRNAs as flexiblemodular
scaffolds (Guttman and Rinn, 2012).
Although, the precise biogenic pathway of long ncRNAs is not
yet fully understood, it involvesRNAPol II-mediated transcription,
polyadenylation, and end-capping (Guttman et al., 2009). Long
ncRNAs are derived from sense and antisense strands, intergenic
and intronic regions, and overlapping regions of protein-coding
genes. Furthermore, novel subsets of long ncRNAs called macro-
RNAs are believed to serve as precursors for other small and long
non-coding transcripts (Furuno et al., 2006). These might origi-
nate via de novo transcription of precursor non-coding transcripts,
by duplication of another ncRNA or by loss of function of an
ancestral protein-coding gene (Ulitsky et al., 2011). An interesting
example of a long ncRNA derived from a former protein-coding
sequence isXist, whichhas arisen from themutatedprotein-coding
gene, Lnx3 (Duret et al., 2006). Moreover, Tsx is a long ncRNA
derived from the loss of protein-coding function within the same
locus (Anguera et al., 2011). It has also been proposed that long
ncRNAs originate from genomic sequences from exonic regions,
from chromosome rearrangement, or by duplication of the non-
coding gene through retrotransposition activity and insertion of
transposable elements (Ponting et al., 2009).
Long ncRNAs may function as enhancers as well as repres-
sors through coordinated regulation of epigenetic processes, both
in cis and in trans, as illustrated in Figure 2 (Khalil et al., 2009;
Orom et al., 2010a,b; Guttman et al., 2011). Considering that
they account for the majority of the non-coding transcriptome
(Mattick and Makunin, 2006; Jia et al., 2010), that 20% of long
ncRNAs found in the human genome are bound to the poly-
comb group protein repressive complex (PRC), and that more
than 50% of all known long ncRNAs interact with other chro-
matin modifying complexes such as CoREST and SMCX (Khalil
et al., 2009), they are likely to be heavily involved in the epigenetic
regulation of neural plasticity. Prototypical examples of epigenetic
regulation directed by long ncRNAs include chromatin remodel-
ing by Xist, acting in cis, to drive X chromosome inactivation
(Duret et al., 2006), andHOTAIR, operating in trans, to silence the
HOXD locus by recruitment of PRC2 (Rinn et al., 2007). Their
role in imprinting is also evident in the activity of the pater-
nally expressed lncRNA, Air, which directs silencing of IGF2R,
Slc22a2, and Slc22a3, through the recruitment of G9a histone
methyltransferase and methylation of H3K9 domains (Nagano
et al., 2008). Another example of a long ncRNA that induces chro-
matin remodeling involves Kcnq1ot1, which interacts with Dnmt1
to regulatemethylation of theKcnq1 gene through the recruitment
of thehistonemethyltransferasesEzh2 andG9a (Mohammadet al.,
2010, 2008; Pandey et al., 2008). Each of the examples further
emphasizes the important role of long ncRNAs in directing epi-
genetic processes. Given the emerging appreciation for epigenetic
mechanisms in learning and memory (Day and Sweatt, 2010), an
understanding of how long ncRNAs direct the epigenome within
the context of neural plasticity, cognition, and neuropsychiatric
disorders is on the horizon.
Long ncRNAs have already been associated with several neu-
rodegenerative disorders characterized by impaired cognitive
function. For instance, along ncRNA isoform of the overlapping
SOX2 gene transcript called SOX2OT regulates CNS vertebrate
development, as well as neurogenesis in adult mice (Amaral et al.,
2009), and thus represents a candidate biomarker for Alzheimer’s
disease (Arisi et al., 2011). Furthermore, the novel long ncRNA17A
directs the splicing of GPR51, thereby producing an alterna-
tive GABAB receptor isoform, which results in a significant
impairment in GABAB receptor signaling in Alzheimer’s disease
(Massone et al., 2011). An additional example of the versatility
of long ncRNAs in driving gene expression within the human
brain is the BACE1 antisense transcript, which preventsmiR-485-
5p induced expression of BCAE1 gene by competing for the same
binding site on its mRNA. Indeed, dysregulation of this long
ncRNA has also been reported in Alzheimer’s disease (Faghihi
et al., 2010). Disruption of key long ncRNAs may also play a role
in the development of psychiatric disorders. For example, the
long ncRNA disrupted in schizophrenia 2 (DISC2), is antisense to,
and overlaps with, its protein-coding transcript DISC1. This long
ncRNA has been implicated in schizophrenia, bipolar depression,
and autism spectrum disorder (Millar et al., 2000; Chubb et al.,
2008; Williams et al., 2009).
It is becoming clear that long ncRNAs have a direct role in
the regulation of genes involved in neural plasticity and cogni-
tive function. For example, BDNF supports neuronal survival and
synaptic plasticity and is critically involved in learning and mem-
ory (Hall et al., 2000; Rattiner et al., 2004a,b; Bredy et al., 2007).
A human antisense transcript called BDNFOS or antiBDNF was
previously shown to interact with its sensemRNA,BDNF (Pruun-
sild et al., 2007). Interestingly, very recently a conserved antisense
transcript to BDNF has been discovered in mice, which inhibits
BDNF transcription by recruitment of EZH2, a key component
of the epigenetic silencing complex, PRC2. Additionally, admin-
istration of a sequence-specific inhibitor called an antagoNAT
or siRNA-mediated knockdown of BDNF-AS both lead toup-
regulation of BDNF mRNA and protein expression in vitro and
in vivo, resulting in increased neurite outgrowth and maturation
(Modarresi et al., 2012).
The potential importance of long ncRNA activity related to
higher order cognitive processing is also highlighted by the discov-
ery of human accelerated region 1 (HAR1F), which is expressed
in Cajal–Retzius neurons and was one of the first long ncRNAs
shown to be involved in human neocortical development (Pollard
et al., 2006). Recently it was found that repression of HAR1F by
REST leads to its decreased expression in the striatum of Hunting-
ton’s disease (Johnson et al., 2010), and that REST also interacts
with DGCR5 and TUG1 lncRNAs leading to DiGeorge syndrome
and Huntington’s disease (Johnson et al., 2009; Johnson, 2011).
Johnson (2012) extended these investigations and confirmed that
both TUG1 andNEAT1 are significantly up-regulated in Hunting-
ton’s disease brains, whereasMEG3 andDGCR5 showed decreased
expression.
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Among other functions, the organization of the nuclear archi-
tecture also seems to require the transcription of the polyadeny-
lated long ncRNA NEAT1, which is associated with nuclear
paraspeckles (Clemson et al., 2009; Souquere et al., 2010), and
NEAT2 (also known asMALAT1 –metastasis-associated lung ade-
nocarcinoma transcript 1), which regulates synapse formation
(Bernard et al., 2010). Furthermore, the long ncRNA Cycling D1
(CCND1) interacting with a protein called translocated in liposar-
coma (TLS; as indicated in Figure 3), acts as a transcriptional
co-repressor and as a sensor of DNA damage by binding and
repressing both CREB and p300 acetyltransferase leading to the
silencing of their target gene (Wang et al., 2008a). Given the impor-
tant role of CREB and p300 in regulating neural plasticity and
cognitive function, it would be interesting to determine whether a
disruption of the long ncRNA CCND1 can cause impairments in
cognitive function similar to those observed when either CREB or
p300 is inhibited.
The ability of long ncRNAs to interact with transcription fac-
tors also endows them with a remarkable capacity to orchestrate
mammalian neurogenesis, which will undoubtedly have an influ-
ence on cognition. For example, the long non-coding transcript
Evf2, derived from the Dlx5/6 gene locus, binds to the home-
odomain ofDlx-2 forming an enhancer-like complex that activates
Dlx5/6 expression (as described in Figure 3; Feng et al., 2006).
The relevance of this long ncRNA in the hippocampus and cogni-
tion is exemplified through studies on Evf2 knockout mice, which
exhibit impaired synaptic plasticity and spatial memory as a result
of aberrant interneuron development (Bond et al., 2009). Extend-
ing these discoveries, Ng et al. (2012) have demonstrated that long
ncRNAs interact with transcription factor SOX2 as well as PRC2,
with the authors suggesting that they are required for pluripo-
tency of neural progenitor cells. Additionally, long ncRNAs have
been shown to direct that activity of other ncRNAs within the
CNS. Indeed, the cytoplasmic long ncRNA, lncRNA_N2, harbor-
ing miRNA miR-125B, regulates the transcription of this small
RNA and indirectly promotes neurogenesis.
More excitingly, long ncRNAs have also been associated with
drug addiction and, potentially, fear-related anxiety disorder.
For instance, the long ncRNAs MIAT, MEG3, and NEAT1/2 are
up-regulated within the nucleus accumbens of heroin abusers
(Michelhaugh et al., 2011). Accordingly, a previous genome-wide
association study has implicatedMEG3 with potential predisposi-
tion to heroin addiction (Nielsen et al., 2008). Interestingly,MIAT
is associated with the nuclear matrix and is involved in oligo-
dendrocyte development (Mercer et al., 2010), whereas MEG3
is a cAMP-responsive, maternally imprinted, long ncRNA that
is expressed in distinct subpopulations of neurons (Zhao et al.,
2006; Michelhaugh et al., 2011) and contributes to early neuro-
genesis (Mercer et al., 2010). More recently, the lncRNA RMST,
also known as dorsomedial telencephalon gene 2 (DMT2), was
revealed to interact with nuclear and chromatin factors dur-
ing the development of dopaminergic neurons (Ng et al., 2012).
Additionally, the long ncRNA BC1 has been shown to direct the
activity of the dopamine 2 receptor (Drd2) as well as metabotropic
FIGURE 3 | (A) Upon receiving a signal for DNA damage, the long ncRNA
CCND1 binds to theTLS protein to direct a protein complex to the CCND1
target gene where allosteric modification of CREB and the histone
acetyltranserases (HATs) CBP and p300 are produced, which results in
gene silencing. (B) Long ncRNA Evf2 is transcribed from an ultra conserved
intergenic region within the Dlx-5/6 locus. Binding of this long ncRNA to the
Dlx-2 protein triggers transcriptional activation of the Dlx-5/6 enhancer region
in a homeodomain-specific manner.
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glutamate receptors (mGluR), which are required for balancing
neuronal excitability at the synapse (Zhong et al., 2009), and that
BC1−/−mice develop increased anxiety (Centonze et al., 2007).
Considering the important role of Drd2 andmGluRs in regulating
the extinction of conditioned fear, it is possible that a dysregula-
tion of the long ncRNA BC1 contributes to the development of
fear related anxiety disorders.
Through their interaction with various epigenetic regulatory
proteins, long ncRNAs might serve as molecular brakes on tran-
scriptional activity, as originally proposed by McQuown and
Wood (2011) within the context of HDAC activity and memory
formation, which in our opinion would also contribute greatly
to rapid, experience-dependent, variations in genomic function.
Consequently, it is anticipated that long ncRNAs will have pro-
found effects on neural plasticity and cognition associated with
neuropsychiatric disorders. In summary, cell type-specific pat-
terns of long ncRNA expression may serve to coordinate the
fidelity of synaptic plasticity and neural connectivity by dynam-
ically monitoring and integrating multiple transcriptional and
post-transcriptional events (Mercer et al., 2008; Qureshi and
Mehler, 2011).
Finally, as described inTable 1, there are alsomany other classes
of ncRNAs not discussed in this review, the understanding of
which is only starting to emerge.
Table 1 | Identification and known characteristics of other ncRNAs.
NcRNA Size Characteristics Reference
eRNAs ∼100 bp to 91 kb Show homologous chromatin modifications to protein coding genes, aid in
enhancement of non-specific cell neighboring genes expression. A subtype
identified in mouse neuronal cells shows association with enhancers and
positive correlation with their levels of mRNA synthesis
Kim et al. (2010),
Orom et al. (2010a,b)
TERRAs 100 bp to 9 kb Conserved in mammals localized in the nucleoplasm in all mammalian
chromosomes at telomeric regions of interphase and metaphase cells.
RNA Pol II and developmental stage Dependant. Potentially involved in
eukaryotic heterochromatin conformation, telomere length and function in
human iPS cells and regulation of telomerase activity
Azzalin et al. (2007),
Schoeftner and Blasco (2008),
Deng et al. (2009),
Luke and Lingner (2009),
Redon et al. (2010),
Yehezkel et al. (2011)
tel-sRNAs ∼24 bp Evolutionary conserved, potential involvement in telomere structure and function,
suggested to be regulated by epigenetic mechanisms
Cao et al. (2009)
TASRs 20–200 bp Clustering at the 3′ end. Conserved in mouse and human genomes with yet
undescribed functions but potential role in gene expression suggested
Kapranov et al. (2007),
Carninci et al. (2008),
Zhang et al. (2012a)
aTASRs Unspecified 5′ poly U short RNAs antisense to 3′ ends of annotated regions undetermined
functionality.
Kapranov et al. (2010)
PASRs 26–50 bp Mapped within 500 nt of knownTSS. Mostly overlapping with 5′ end of protein
coding genes. Association with RNA Pol II, Histone H3 and H4 acetylation and
potential up regulation of neighboring genes
Kapranov et al. (2007), Carninci
et al. (2008), ENCODE
Transcriptome Project (2009)
PALRs 200 bp to 1 kb Overlapping with 5′ end of protein coding genes. Potential up regulation of protein
coding genes showing evolutionary conserved sequences
Kapranov et al. (2007)
PROMPTs ∼200–600 bp Transcribed from upstream regions of annotatedTSSs, they are polyadenylated,
highly unstable and mostly restricted to the nucleus. Suggested to affect
promoter methylation and regulate transcriptional processes
Preker et al. (2008, 2011)
TiRNAs ∼15 to 30 bp Enriched in the nucleus, transcribed from downstream ofTSS sequences are linked
to CpG rich promoters, transcription factor binding, and widespread transcription
initiation inducing up regulation of protein coding genes
Taft et al. (2009, 2010)
Stress-tiRNAs Unspecified 5′ and 3′ end small-derived RNAs from tRNAs are induced to inhibit translation as a
stress response pathway
Emara et al. (2010)
spliRNAs ∼18 bp Developmental stage and region specific expression, Dicer and Drosha
independent pathways.Weakly expressed, associated with highly expressed loci
(Taft et al., 2010)
moRNAs ∼20 bp Processed by nuclear Drosha, 5′ derived transcripts from of miRNAs precursors,
weakly expressed and with unknown functions
Langenberger et al. (2009),
Taft et al. (2010)
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Although the biogenesis of most of these non-coding tran-
scripts remains unclear, their tissue-specificity and developmental
stage-dependent expression provides strong evidence for their
biological relevance justifying the need for further research into
the complex regulatory potential hidden within the eukaryotic
transcriptome.
OUTLOOK AND CONCLUSION
The huge repertoire of ncRNAs, that we are only beginning to
recognize, suggests a sophisticated RNA-mediated layer of control
over genomic function that has evolved to coordinate tissue- and
developmental stage-specific regulation of gene expression. The
redundancy in consensus sequences typical of most ncRNAs allows
for a highly efficient transcriptional regulation of protein-coding
genes, whereas the potential stability provided by the methyla-
tion status of most small ncRNAs supports their well established
role in regulating gene expression. In the case of some long ncR-
NAs, their low level of conservation may contribute directly to
their function by enabling the cell to respond to external stim-
uli with greater flexibility, thereby conferring a rapidly adaptive
plasticity that is distinct from, and more complex than, the much
slower acting protein-coding genes (Mattick, 2011). Consequently
and given that ncRNAs are highly expressed in the brain, it is
anticipated that they will play a significant role in driving neu-
ral connectivity within learning and behavioral adaptation of
higher eukaryotes. This firmly positions ncRNAs at the fore-
front of cell-to-cell communicationwithin the context of cognitive
function and potentially in the development of neuropsychi-
atric disorders. Given that a significant proportion of known
long ncRNAs interact with repressive complexes, future investi-
gations will expand on these observations through the application
of innovative techniques including high-throughput sequencing
together with UV-crosslinking and immunoprecipitation (HITS-
CLIP; Zhang and Darnell, 2011), chromatin isolation by RNA
purification (ChIRP; Chu et al., 2011), capture hybridization anal-
ysis of RNA combined with RNA sequencing (CHART; Simon
et al., 2011), and RNA-capture-Seq (Mercer et al., 2011). Such
studies will aid in the determination of novel ncRNAs and their
genome-wide binding sites, which will be important to elucidate
the essential role of RNA-directed epigenetic regulation of gene
function. Most studies on ncRNAs have been based on stem cell
and embryonic development, with the function of miRNAs in the
adult brain only recently becoming appreciated. Moreover, in vitro
studies examining long ncRNAs and piRNAs, and their influence
on neural plasticity, are emerging. It will be exciting to see how
these in vitro findings translate in vivo and to elucidate whether
the biological significance of these ncRNAs will extend to mem-
ory and cognition. Furthermore, RNAi will be a useful tool to
facilitate the knockdown of ncRNAs that are associated to neu-
ropsychiatric disorders, such as TUG1 and NEAT1. Consequently,
if lncRNAs truly representmodular scaffolds, then it will be imper-
ative to determine the stability of the epigenetic processes directed
by all classes of ncRNAs, particularly those resulting from rapidly
changing behavioral responses. Given the fact that endogenous
siRNAs are mostly represented in oocytes, whereas piRNAs are
strongly expressed in the male germ line, each capable of exerting
their owngenomic function, alsomakes themattractive candidates
to investigate their potential influence on genomic imprinting
and transgenerational epigenetic inheritance. Finally, since many
ncRNAs remain transcriptionally quiescent until a specific devel-
opmental stage is met or an appropriate environmental signal is
received (Kretz et al., 2012), it will be important to decipher the
mechanisms coordinating such precise and rapid genomic respon-
siveness. The central dogma of protein-coding genes controlling
the eukaryotic genome represents an archaic constraint on our
journey to truly expand the understanding of gene–epigenome–
environmental interactions. It is undeniable that this layer of gene
regulation has many fundamental biological and functional roles
yet to be explained and it might be within neural plasticity, cog-
nition, and neuropsychiatric disorders where the lasting signature
of ncRNAs could be at their most significant.
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CHAPTER 2 
“We have to remember that what we observe is not nature herself, but nature exposed to our 
method of questioning” 
Werner Heisenberg, 1958 
2. Methodology  
High-throughoutput RNA-Seq has transformed transcriptome and gene expression research. This 
technology has been used to investigate the transcription of ncRNAs across all phyla and has 
expanded our understanding of the human genome. By moving away from probe hybridization and 
fluorescence dye pre-established methods such as microarrays, and other tag-built approaches such 
as serial analysis of gene expression or cap analysis of gene expression, RNA-Seq avoids the high 
risk of background interference and tag-targeted region limitations (1). It also eludes the need for 
bacterial constructs for complementary DNA (cDNA) conversion, which can influence sequence 
representation outputs (2). The advantages include the ability to identify isoform variants, newly 
discovered transcripts and highly accurate quantitative results; however, a potential transcriptional 
bias based on CG content, transcript length and dinucleotide frequencies might need to be 
accounted for in the bioinformatics data analysis (3).  
Recent advances in RNA-capture sequencing (4) have allowed the detection of RNA molecules 
with low expression level, which are otherwise concealed by conventional RNA-Seq assays, and 
have helped to uncover new transcripts. Construction of SeqCap EZ libraries (Roche NimbleGen, 
Pleasonton, CA, USA) involves hybridization of predesigned biotinylated long oligonucleotide 
probes against selected genomic regions. This provides the “capture of sequences” of a total of 50 
Mb of targeted transcripts in the genome, which are then subjected to RNA-Seq to magnify the 
coverage within the objective regions. The inclusion of hybridization enhancing oligos suppresses 
secondary capture and greatly increases the efficiency of mapped unique reads and, thus, the chance 
to discover rare transcripts and splice variants. Sequencing technologies have been selected to 
identify non-coding transcripts expression and their potential regulatory pathways in association 
with complex adaptive behaviour in mammals.  
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2.1 Animals for sequencing and expression validation trials. 
All protocols related to live animals were approved by the Institutional Animal Ethics Committee of 
the University of Queensland, and all techniques were performed according to the University’s 
safety procedures. 
Naïve 9-week-old C57BL/6 male mice were housed individually in sections of divided cages and 
given free access to food and water under a 12 h light/dark cycle in a humidity- and temperature-
controlled vivarium. Behavioural tests were conducted during the light cycle, and all procedures 
were performed with approval from the Animal Ethics Committee of The University of Queensland. 
2.2 Fear conditioning behavioural training. 
2.2.1 Fear conditioning training for transcriptome and capture sequencing 
analyses. 
Mice were subjected to delay fear conditioning, and their tissues were collected and used for 
sequencing library preparation. Three groups of mice were used (n = 8 per group). 1) The naïve 
group was age-matched home cage animals. 2) The fear conditioned (FC) group received six 
pairings of 2 min 80 dB white noise as the CS, which was co-terminated with a 1 s foot-shock at 0.7 
mA as the US. An inter-trial interval (ITI) of 2 min was given between each CS–US pair. 3) The 
context (Ctx) group was exposed to the same amount and duration of CS only (Fig. 2.1). Training 
was performed during the light phase in red light-illuminated testing rooms. Only mice that showed 
a minimum 70% score of freezing during the CS interim were included in the experimental 
analysis. Mice were sacrificed after 90 min, the mPFC and hippocampus were dissected, and 
nuclear-enriched RNA was extracted.  
  
Figure 2.1: Delay Fear Conditioning. After a 2 min period of adaptation to the chamber, cued fear 
conditioning was induced in mice with six pairings of CS–US, including an interval of 2 min between each 
pair. The treatment was compared with the context-exposed and home caged animals (naïve).  
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2.2.2 Fear conditioning and recall test to investigate ncRNA functionality. 
Fear conditioning acquisition and the test to determine the in vivo function of Gomafu lncRNA 
included a knockdown and a control group. Knockdown animals were infused with 600 nM of 
Gomafu chimeric ASOs (IDT Technologies) in the mPFC, and the control group received saline 
infusion. Three hours after infusion, the mice were trained for fear acquisition (three CS–US 
pairings with foot shocks of 0.4 mA) followed by a two-CS test for memory recall in the same 
context 24 h later. The animals were sacrificed after 90 min, the mPFC was dissected, and nuclear-
enriched RNA was extracted. 
2.2.3 Mild fear conditioning and shock-only control. 
Mice were subjected to fear conditioning acquisition and the shock-only test to investigate the 
possible involvement of the pain response associated with the candidate genes expression in vivo. 
Four groups were compared: 1) home caged (naïve); 2) fear conditioned (FC) (three CS–US 
pairings with foot shocks at 0.4 mA); 3) Ctx group exposed to the same amount and duration of CS 
only; and 4) shock-only mice that were given three consecutive foot shocks of 0.4 mA for 1 s with 
an interval of 2 s. The mice were sacrificed after 90 min, the mPFC was dissected, and nuclear-
enriched RNA was extracted. 
2.3 Mild stress and anxiety tests.  
The knockdown and control groups were subjected to anxiety tests 3 h after ASO infusion (for 
Gomafu knockdown assay), and 2 weeks after lentivirus infusion (for Crybb1 knockdown 
experiment). This tests involved the repetition of mild stressors to induce anxiety (5), including a 10 
min exposure to a 27 × 27 × 20.3 cm open field chamber with 200 lux of light intensity, which was 
followed by an interval of 30 min rest period. Mice were then introduced for 10 min into an 
elevated plus maze (under bright light at 900 lux in the open arms and 200 lux in the closed arms), 
and the time spent in the open arms was recorded (Fig. 2.2). Following a second interval of 30 min 
mice were again placed in the open field for 10 min, when the time in the centre was measured 
automatically in seconds, and ambulatory time, distance travelled and self-grooming time were 
calculated as a ratio between zone results. Crybb1 gene function in relation to anxiety-related 
behaviour was also examined using this experimental approach. The ASO was substituted by the 
infusion of a short hairpin RNA (shRNA) by surgical cannula placement directed to knockdown 
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Crybb1 mRNA. The mice were trained to experience mild anxiety 10 days after the initial shRNA 
lentivirus administration.  
 
Figure 2.2: Anxiety test. Behavioural test including the repetition of a mild stressor to elicit an anxious 
response in mice infused with ASOs for Gomafu lncRNA and shRNA for Crybb1 knockdown compared 
with control mice. 
2.4 Stereotaxic surgery and cannula implantation. 
Before surgery, mice were anaesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg). 
Surgery was performed under stereotaxic guidance, and cannulas were implanted bilaterally within 
the pre-limbic region of the PFC (PrLPFC) at +1.8 mm anteroposterior (AP) and –2 mm 
dorsoventral (DV) to the Bregma coordinates. Mice were allowed to recover for a minimum of 7 
days before behavioural experiments were attempted. Animals were transcardially perfused after 
training with cold phosphate-buffered saline (PBS) (Lonza, cat. No. 17-515, Walkersville, MD, 
USA) and fixed with 4% paraformaldehyde (PFA) (Sigma Aldrich, cat. no. P6148, St. Louis, MO, 
USA) in PBS (Lonza, cat. no. 17-515, Walkersville, MD, USA). Brains were dissected and 
sectioned, and localization of ASOs and shRNAs in the brain determined by fluorescence 
microscopy. mPFC infusions for both knockdown assays were performed in vivo using a Harvard 
Apparatus (Harvard Bioscience Company, cat. 883015, Holliston, MA, USA) and constant pressure 
syringe pumps inducing 1.5 µl per hemisphere for 5 min with a rest period of 3 min before 
removing the syringe. 
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2.5 Tissue dissection and nuclear-enriched RNA extraction. 
Mice were sacrificed by cervical dislocation 90 min after each behavioural assay, and the mPFC 
and hippocampi regions were dissected on ice and snap frozen in dry ice. The tissues were 
homogenized in nuclear buffer comprising .32 M sucrose, 10 mM Tris-HCl pH 8, 5 mM CaCl2, 3 
mM Mg(Ac)2, .1 mM EDTA, 1 mM DTT, .1% Triton-X-100, 1× protease inhibitor (Roche, cat. no. 
04693116001, Pleasonton, CA, USA) and double-distilled H2O to a final volume of 10 ml. Samples 
were gently homogenized on ice in a glass Dounce tissue grinder using pestle sizes A and B 
consecutively. The lysate was then passed through a 50 mm strainer and centrifuged for 9 min at 
3000 rpm and 4°C. The supernatant containing the cytosolic fraction was removed, and the nuclear 
pellet was dissolved in 500 µl of RNA lysis buffer (RLT Qiagen, cat. no. 74104, Valencia, CA, 
USA) with 50 µl of β-mercaptoethanol (Sigma-Aldrich, cat. no. M6250, St. Louis, MO, USA) 
followed by addition of an equal volume of ethanol, and subjected to RNA extraction using an 
RNase Mini Kit (Qiagen, cat. no. 74104, Valencia, CA, USA); unless the use of TRIzol was 
specified (Ambion, cat. no. 15596018, Carlsbad, CA, USA). Reverse transcription and cDNA 
synthesis were performed using the Quantitech Reverse Transcription kit protocol (Qiagen, cat. no 
205313, Valencia, CA, USA). Hippocampal nuclear RNA was isolated using an MiRvana RNA kit 
(Life Technologies, cat. no. AM1560, Waltham, MA, USA) following the instructions for small 
RNA-enriched elution. The final RNA concentration was measured using QUBIT RNA HS Assay 
(Life Technologies, cat. no. Q32852, Waltham, MA, USA), and quality was assessed on RNA 600 
Nano chips (Agilent Technologies, G2938-90034 Rev. B, Sta. Clara, CA, USA) run on the Agilent 
2100 Bioanalyzer (Agilent Technologies, Sta. Clara, CA, USA). Only samples with an RNA 
Integrity Number (RIN) ≥8 were included in the sequencing experiments. A total 500 ng of RNA 
was immediately reverse transcribed using a Qiagen QuantiTect Kit (Qiagen, cat. no 205313, 
Valencia, CA, USA), with the exception of RNA eluted from RNA immunoprecipitation (RIP) 
assays, which was reverse transcribed using Super Script III First Strand Synthesis (Invitrogen, cat. 
18080-051, Carlsbad, CA, USA). The remaining RNA was kept at –80°C. Complementary DNA 
was stored at –20°C 
Validation of the nuclear enrichment protocol. To verify the efficiency of the protocol for 
enrichment of the cytosolic fractionation, cytoplasmic and nuclear RNA expression levels were 
measured in cortical neurons culture following potassium chloride (KCl) treatment (Fig. 2.3, A). 
The early response gene Egr1 is rapidly induced and transported to the cytoplasm, where it is 
translated into the active protein under stimulation of both neurons and cancer cells (6, 7). 
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Therefore, the levels of Egr1 were compared against the endogenous nuclear RNA, small nucleolar 
U6 RNA. As expected, Egr1 mRNA was significantly up-regulated in the cytosol 1 h post 
stimulation, and U6 expression was enriched in the nuclear fraction (Fig. 2.3, B-C). 
 
 
Figure 2.3: Validation of the protocol for in vitro nuclear enrichment. (A) Illustration of neuronal culture 
preparation for cell fractioning and RNA extraction. (B) KCl treatment of cortical neurons revealed a 
significant up-regulation of Egr1 mRNA expression (two-way ANOVA, ***p < .001, F (2, 12) = 16.66), 
with significant enrichment in the cytosol at 1 h (t test, **p < .01, t = 8.132 df = 4) and 3 h (t test, *p < .05, t 
= 3.096 df = 4). (C) Although KCl-induced depolarization did not alter the expression of the nucleolar RNA 
U6 in the cytoplasm, there was significant nuclear enrichment at 1 h post stimulation (t test, *p < .05, t = 
3.486 df = 4). 
To confirm that nuclear enrichment was effective for the RNA sequencing protocol, the number of 
reads captured by a highly expressed neuronal mRNA, Bdnf, were compared with the nuclear-
specific lncRNA, Gomafu (8). There was a greater capture of nuclear sequencing reads for the 
lncRNA Gomafu (~800,000 aligned reads) compared with Bdnf mRNA (~60,000 aligned reads) 
(Fig. 2.4, A-B). 
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Figure 2.4: Validation of the protocol of in vivo nuclear enrichment . (A, B) Gomafu lncRNA was 
significantly down-regulated following fear conditioning (FC) (ANOVA, F (2, 21) = 3.992, *p <.05) despite 
the higher number of aligned reads compared with Bdnf mRNA, which was significantly up-regulated in 
context-exposed animals (Ctx) (ANOVA, F (2, 21) = 33.69, ****p < .0001).  
2.6 Primers design, PCR and gel electrophoresis. 
All genomic primers (Appendix, Table A.1) were designed using Primer3 software based on the 
2011 (GRCm38/mm10) assembly sequences from the University of California Santa Cruz (UCSC) 
genome browser. Each primer set was then subjected to a BLAST search using The US National 
Centre for Biotechnology Information (NCBI) browser to verify specific match of the targeted 
transcript. cDNA samples were then subjected to PCR to confirm the presence and size of the 
fragment products corresponding to each primer, as follows: .15 mM forward and reverse primers, 
.15 mM dNTPs, 1× PCR buffer, .16 mM Taq, 100 ng DNA, and dH2O to a final volume of 10 µl. 
The PCR protocol was as follow: 35 cycles of denaturation at 95°C for 30 s, annealing at 59°C 
(variable according the primer-specific temperature) for 30 s and extension at 72°C for 45 s 
followed by a final extension at 72°C for 2 min. PCR products were subjected to gel electrophoresis 
on a 2% agarose gel containing .5 µg/ml of SYBR Safe DNA gel stain (Life Technologies, cat. no. 
S33102, Waltham, MA, USA) for 30 min at 95 V. A DNA ladder of 100 bp fragments was also 
loaded in each gel to provide for fragment size identification and validation.   
2.7 Target gene validation and gene expression by quantitative 
real-time PCR. 
Validation of target genes extracted from RNA-Seq results, and exploratory data for gene 
expression was performed using SYBR Green (Sigma Aldrich, cat. no. S9194, St. Louis, MO, 
USA) and qPCR detection method (9, 10). Assays were run on the Corbett RotorGene 3000 with 
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optimized protocol as follows: 1× Q SYBR Green Supermix (Sigma-Aldrich, cat. no. S9194, St. 
Louis, MO, USA); .15 µM reverse and forward primers; 80 ng of cDNA and dH2O to a final 
volume of 10 µl. The following cycling parameters were used: preheating at 95°C for 10 min, and 
35 cycles of denaturation at 95°C for 15 s, annealing at 59°C (variable according to the primer-
specific temperature) for 30 s and extension at 72°C for 30 s. Non-specific products and fragment 
size identification for each gene were verified by loading PCR products on a 2% agarose gel. The 
2ΔΔCt method (11-13) was used to estimate the different levels of gene expression and for further 
statistical calculations. Ppia (peptidylprolyl isomerase A (cyclophilin A) was the reference gene to 
establish the delta cycle threshold values (ΔCt) required by this methodology. 
2.8 RNA-Seq and cDNA library preparation. 
Sequencing technologies were used to identify ncRNAs that are dynamically regulated in the mouse 
mPFC in response to fear-related learning (Illustrated, Fig. 2.5). These included nuclear-enriched 
RNA-Capture, whole-genome RNA-Seq and small RNA-Seq (Fig. 2.6).  
 
Figure 2.5: Transcriptome screening method. Overview representation of a cDNA library preparation 
with nuclear-enriched RNA extracted from fear-conditioned mice to obtain a real-time gene expression 
profile.  
Because lncRNAs are known to modulate gene expression in cis, a capture sequencing approach 
was taken to target regions of interest with the addition of reads coverage flanking the loci to 
identify the potential in cis regulatory activity of lncRNAs. Given that sequencing libraries are 
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produced according to an RNA size selection, a third approach was inferred to detect the expression 
of small non-coding transcripts.  
The use of complementary sequencing approaches was expected to cover the expression of all the 
possible sizes and levels of expression of ncRNAs (Fig. 2.6) with RNA-seq and RNA-capture 
intended to detect lncRNAs and coding genes, and Small-RNA-seq directed to identify sncRNAs. 
             
Figure 2.6: RNA Sequencing coverage. The level of coverage provided by the three different RNA 
sequencing assays used in this research. 
2.8.1 Nuclear RNA-Capture sequencing (SeqCap EZ Library).  
RNA-Capture sequencing allows for the enrichment of selective regions from fragmented total 
RNA samples, which improves the read coverage of these specific targets. Within transcriptome 
sequencing assays, the “capture” of such sequences allows for an in-depth screening, which 
increases the ability of this methodology to detect transcripts expressed at low levels. Roche 
NimbleGen Inc. has developed this technology in close adherence with the work by Mercer et al. 
(4). Although the original experimental design was based on array platforms, here these were 
replaced using a solution-based strategy applying SeqCap EZ probes. These predesigned 
oligonucleotide probes enabled the hybridization of cDNA to the regions of interest and the 
assembling of paired-end libraries. The aim of this approach was to allow for the identification of 
proximal lncRNAs to predetermined genes of interest (Table 2.1) and the detection of rare 
transcripts within the target loci. 
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Table 2.1: RNA-Capture targets. List of genes included in the RNA-Capture sequencing assay showing 
chromosomal location extending 1 Mb in the flanking regions. Each region was assigned five times (Bdnf) or 
two times the number of reads available for the loci to increase in-depth coverage. 
Chromosome Start position Stop position Replicates required (total bp) Total 
Target gene within 
sequence 
2 108,674,700 110,727,043 5(2,052,343) 10,261,715 Bdnf 
5 111,213,230 113,228,935 2(2,015,705) 4,031,410 Gomafu (lncRNA) 
19 4,795,690 6,845,478 2(2,049,788) 4,099,576 
Malat1 (neat2) + 
Neat1 (lncRNA) 
x 102,414,467 104,424,583 2(2,010,116) 4,020,232 Tsx (lncRNA) 
6 66,035,096 68,037,407 2(2,002,311) 4,004,622 Gadd45a 
18 35,930,285 38,187,657 2(2,257,372) 4,514,744 Pcdha 
5 76,265,494 78,283,697 2(2,018,203) 4,036,406 Rest 
16 32,969,073 35,514,027 2(2,544,954) 5,089,908 Kalrn 
10 91,081,746 93,165,178 2(2,083,432) 4,067,492 Rmst (lncRNA) 
11 2,639,794 4, 648,808 2(2,009,014) 4,018,028 Tug1 (lncRNA) 
7 141,242,006 141,345,001 2(102,995) 205,990 Drd4 
11 76,948,597 77,082,343 2(133,746) 267,492 SLC6a4 
3 102,419,928 102,571,013 2(151,085) 302,170 Ngf (nerve growth 
factor) 
16 18,356,882 18,476,716 2(119,834) 239,668 Comt 
x 16,569,698 16,737,812 2(168,114) 336,228 Mao-A 
Potential discoveries were expected to include a class of ncRNAs with likely regulatory function of 
proximal coding genes and which is transcribed within 700 bp downstream and upstream of these 
genes (14). Concordantly, lncRNAs transcribed within a window of 500 kb of TSSs, as well as 
those associated with enhancer regions, were shown to activate neighbouring genes (15-17). Such 
influence on gene expression by lncRNAs was predicted to occur as far as 2.5 Mb from a coding 
sequence (18). In support of the view that lncRNAs can have an in cis regulatory function, a recent 
investigation has found that linage-specific antisense lncRNA transcription correlates with greater 
expression of adjacent coding genes (19). These kinds of lncRNAs were likely to be captured by the 
capture sequencing technology, and this observation justified the sequencing design implemented 
here. The captured loci included the gene sequence plus 1 Mb downstream and upstream of the 
transcript region. The genes selected for this trial are detailed in Table 2, with a total capture target 
size of 49,495,681 bp. 
 
 53 
Given these observations, the RNA-Capture experiment represents a targeted approach to identify 
possible in cis regulation of proximal lncRNAs on genes involved in fear-conditioned behaviour, 
including Bdnf, Rest, Kalrn and Pcdha (Table 2).  
This experiment also included the main lncRNAs likely to be involved in mammalian neuronal 
plasticity such as Gomafu, Neat1, Malat1 and Tug1 (Table 2). These long non-coding transcripts 
are not in proximity to any significant protein-coding gene, and their activity in relation to potential 
coding gene targets is unknown.  
Nuclear RNA-Capture library generation. To prepare a cDNA-indexed library, 1.5 µg of 
nuclear-enriched RNA from the mPFC was used accordingly to Illumina TruSeq RNA Sample 
Preparation v2 protocol (Illumina Inc., San Diego, CA,USA). The RNA-Capture-Seq involved eight 
biological replicates for each group: naïve, fear conditioned and context only. Each library sample 
was amplified using LM-PCR using a Phusion High-Fidelity PCR kit (NEB, E0553S, USA) 
followed by purification using the Qiagen QIAquick PCR Purification kit (Qiagen, cat. no. 28104, 
Valencia, CA, USA). The quality of the library end product was verified on a DNA 1000 chip 
(Agilent Technologies, G2938-90014 Rev. B, Sta. Clara, CA, USA) run on the Agilent 2100 
Bioanalyzer (Agilent Technologies, Sta. Clara, CA, USA) with an expected fragment amplification 
of 260 bp. This was followed first by hybridization of pools of four barcoded samples at 250 ng 
input each to six SeqCap EZ probes and next using a wash and recovery step using Streptavidin 
Dynabeads (Life Technologies, cat. no. 11205D, Waltham, MA, USA). Captured cDNA was 
amplified again using LM-PCR with the Phusion High-Fidelity PCR kit (NEB, E0553S, Ipswich, 
MA, USA) and purified Qiagen QIAquick PCR Purification kit (Qiagen, cat. no. 28104, Valencia, 
CA, USA). The quality of the final library of captured cDNA was verified on an Agilent DNA 1000 
chip (Agilent Technologies, G2938-90014 Rev. B, Sta. Clara, CA, USA) and run on the 
Bioanalyzer with expected fragment amplification between 260 bp and 400 bp. Finally, the libraries 
were quantitated using quantitative PCR (qPCR) according to the KAPA kit instructions (KAPA 
Biosystems, KK4824, Cape Town, South Africa). A total of six pools resulting from the 
combination of four samples each were loaded on the c-Bot for cluster generation at a final 
concentration of 9 pM, with an optimum target of cluster density between 750 and 850 k/mm2. 
Clusters were then paired-end sequenced at 100 bp on the Illumina HiSeq v3 platform.  
2.8.2 Nuclear RNA-Sequencing.  
A subset of 1 µg mPFC nuclear-enriched RNA from six samples per treatment was used to build a 
nuclear-enriched RNA library with a different indexing barcode from that in the previous Capture 
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experiment. Samples with a low read alignment were excluded, which resulted in five animals for 
the naïve and context groups and four for the fear-conditioning group. 
This library was intended, firstly, to provide a transcriptome analysis and gene expression landscape 
of the treated animals and, secondly to validate the Capture sequencing results as previously 
reported (4). The present approach was not used to provide identification of rare transcripts because 
of its low coverage when compared with the RNA-Capture trial (4). However, it was thought that 
the experience-dependent expression of moderately expressed lncRNAs and protein-coding genes 
across the genome could be screened by total RNA sequencing.  
RNA-Seq library generation. This library was constructed following the instructions in the 
Illumina TruSeq RNA Sample Preparation v2 protocol (Illumina Inc., San Diego, CA, USA) and 
combined into two pools of 10 nM final concentration. A total 9 pM per pool was c-Bot amplified 
and run on the Illumina HiSeq v3 platform under the same specification as the CapSeq EZ library. 
In all sequencing experiments, libraries were distributed so that an equal number of samples from 
each treatment group was combined in each lane to avoid potential bias in the flow cell efficiency.  
2.8.3 Small RNA-Seq. 
Because of the required step of RNA fragmentation for size selection while compiling the two 
previously mentioned libraries, small RNA transcripts can be excluded from these assays (Fig. 7). 
Thereafter, a third specific library was constructed to target such transcripts. The small RNA-
Sequencing library was prepared using eight biological replicates for each group: naïve, fear 
conditioned and context. One microgram of nuclear-enriched RNA was used to build a small RNA 
library using the Illumina TruSeq RNA Sample Preparation v2 protocol (Illumina Inc., San Diego, 
CA, USA). The quality of the DNA library was verified on an Agilent DNA 1000 chip (Agilent 
Technologies, G2938-90014 Rev. B, Sta. Clara, CA, USA) and run on a Bioanalyzer, with 
quantification determined by qPCR, after which the samples were multiplexed in pools of four, c-
Bot amplified, and paired-end sequenced at 50 bp to be run on the Illumina HiSeq v3 platform 
(Illumina Inc., San Diego, CA, USA). 
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2.9 Bioinformatics. 
2.9.1 RNA-Capture and RNA-Seq. 
A general consensus for RNA-Seq analysis and pipeline determination normally includes: 1) pre-
processing of reads by adapter removal and exclusion of low quality sequences; 2) assembling and 
matching to a genome of reference; 3) estimation of transcript-identified gene expression; 4) data 
normalization; and 5) identification of differences in gene expression between treatment groups 
(20).  
A combination of TopHat and Cufflinks2 algorithms was used for the analysis of the sequencing 
assays (21, 22). A clear advantage of this approach is that the success of transcript assembly 
applying Cufflinks does not depend on the existence of open reading frames (ORFs), which was 
appropriate for this investigation because most ncRNAs either do not contain ORFs or are 
significantly shorter than the characteristic protein-coding RNAs.  
Thereafter, the initial step in the bioinformatics data analysis was the removal of index sequences in 
the library using Illumina’s Consensus Assessment of Sequence and Variation (CASAVA) software 
version 1.8.2, which produced files in FASTAQ format ready to be processed. The resulting 
FASTAq files were provided for the mapping of reads to the mouse genome using the Bowtie2 and 
TopHat 2.0.6 programs. The advantage of TopHat is that it can align RNA sequencing reads by 
considering the splice junction transcript region between exons without the need to rely on previous 
gene annotation (21, 23). 
Cufflinks 2.0.2 (BETA) algorithms, which include Cuffcompare, Cuffmerge and Cuffdiff, were 
then implemented for assembly of RNA-Seq reads into transcripts. Cuffcompare allows for the 
comparison of the identified transcripts with the genome of reference and an estimation of their 
abundance (24). Subsequently, Cuffmerge was used to unify samples from each treatment to allow 
the application of Cuffdiff for the analysis of differential levels of transcripts expression between 
treatment groups (22, 25, 26).  
It was necessary to consider that there seemed to be an intrinsic limitation given by the level of 
expression to determine the lower threshold established by most packages currently available. This 
automatically excluded transcripts expressed as extreme low levels that the software associates with 
background noise when, in reality, there may represent rare novel ncRNAs. 
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2.9.2 Small RNA-Seq.  
To analyse the small RNA sequencing library, the adaptor sequences at the 3" end of the 50 nt 
single-end reads were trimmed using cutadapt (v1.2) (27) with options ‘-e 0.1 –m15’. Reads were 
then mapped to the mouse reference genome (mm10) using bowtie2 (v2.0.2) (28) and applying the 
‘sensitive-local’ option or default parameters. The annotation file was further constructed using 
miRBase (v20) (29), fRNAdb (v3.4) (30), and Ensembl BioMart. Predicted transcripts overlapping 
known sncRNAs were categorized into miRNAs, Piwi-interacting RNAs (piRNAs), snoRNAs, 
snRNAs, and other miscellaneous RNAs. Putative sncRNA primary transcripts (e.g., miRNA 
precursors) were predicted and annotated using NorahDesk software (31). 
2.10 Cell culture and electroporation. 
Primary mouse cortical neurons cell culture. In vitro assays using mouse primary cortical and 
hippocampal neurons were used to confirm the trends in gene expression of candidate transcripts. 
The cultures were used to confirm the activity-dependent stimulation of genes through membrane 
depolarization with KCl treatment. Membrane depolarization by KCl is a widely recognised assay 
used to induce neuronal activation by triggering calcium-dependent pathways that subsequently 
stimulate activity-dependent gene expression (32). KCl was applied at a concentration of 50 mM. 
Primary neuronal cultures were also used to investigate RNA stability, which was verified by the 
addition of actinomycin D (Life Technologies, cat. no. 11805-017, Waltham, MA, USA) at a final 
concentration of 5 µg/ml to day 7 cultured neurons. Lastly, neuronal cultures were implemented to 
interrogate the gene knockdown assays. 
Cortical and hippocampal neuronal cells were dissociated from C57BL/6 mouse embryos at day 
E16 and plated onto poly-L-ornithine hydrochloride-coated plates. Cultures were grown in 
Neurobasal medium (Gibco Life Technologies, cat. 21103-049, USA) containing foetal bovine 
serum (FBS) (Sigma-Aldrich, cat. no. 12003C, St. Louis, MO, USA); 5% for cortical neurons or 
1% (for hippocampi neurons), 1% penicillin–streptomycin, 1% of GlutaMAX (Life Technologies, 
cat. no. 10567014, Waltham, MA, USA), 2% B27 supplement (Life Technologies, cat. no. 
1504044, Waltham, MA, USA), and were maintained at 37°C with 5% CO2. Electroporation of 
ASOs was performed using a nucleofector system (Lonza, cat. no. VPI-1003, Walkersville, MD, 
USA) according to the manufacturer’s instructions.  
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2.11 Gene knockdown by chimeric ASOs.  
Given the focus of this project on nuclear ncRNAs, the use of ASOs was the preferred method for 
gene silencing. Other systems, such as the use of RNA interference (RNAi) or shRNA may not be 
as effective because of the predominant localization of the RNAi machinery in the cytoplasm of 
mammalian cells. Gene knockdown with ASOs has also been demonstrated to be successful both in 
vitro and in vivo and is becoming a promising pharmaceutical tool for psychiatric disorders (33-36). 
The knockdown of RNA molecules located specifically within the nuclear compartment represents 
a technical challenge for conventional methodologies biased on the nature of the protein-coding 
mRNA sequence. Alternatively, if in vivo efficiency is not achieved, other techniques such as 
pooling of endoribonuclease-prepared siRNAs (esiRNAs) (37) and “translation arrest” methodology 
could be trialled (38).  
ASOs are 18 to 20 oligonucleotides that bind target sequences and recruit RNase-H, an enzyme that 
degrades RNA–RNA and RNA–DNA hybrids. ASOs can also hinder translation by binding to 
specific sequence motifs and interrupting the normal splicing regulatory sites. The chemistry 
modifications of these oligos, generated by IDT (Integrated DNA Technologies Inc., Coralville, 
Iowa, USA), include a phosphorothioate backbone, which greatly facilitates their uptake through 
the cell membrane, and 2"-O-methyl addition at both the 5" and 3" ends, which avoids exonuclease 
attack and increases nuclear stability (39). Another advantage of ASOs is that they do not require 
lipid or viral carriers, which decreases the risk of immune reactions in the treated animal.  
ASOs design. ASOs were designed using IDT software. According to the literature (39-42), the 
sequences chosen targeted the splicing regulatory regions known as the exonic splicing enhancer 
(ESE), which has higher G and C content and lower potential for RNA secondary structure 
formation. The software used included the ESE Finder 3.0 and RESUE ESE web server and the 
RNA Structure web server from the University of Rochester Medical Center 
(http://rna.urmc.rochester.edu). The selection of the Gomafu target region of 20 oligomers is shown 
in Fig. 2.7.  
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Figure 2.7: ASO target sequence. Reproduction from the target sequence close to ESE regions for ASO 
design. The probability scores indicated correlate with the risk of secondary structure. 
2.12 Knockdown by shRNA. 
ShRNAs constructs were obtained from GeneCopoeia (GeneCopoeia Inc., Rockville, MD, USA). 
The plasmids were first tested in vitro using a Lipofectamine assay. Consequently, 3 µg of DNA 
plasmid was mixed with 100 µl of Optimen medium (Life technologies, cat. no. 51985091, USA) 
and left to rest for 15 min. Next, 4 µl of Lipofectamine (Life Technologies, cat. no. 11668-019, 
Waltham, MA, USA) was added to 96 µl of Optimen (Life Technologies, cat. no. 51985091, 
Waltham, MA, USA), rested for 5 min, and then mixed with the DNA solution and rested again for 
20 min before infusion into cell cultures. The medium was replaced after 4 h of incubation. RNA 
was extracted and the levels of gene expression were measured 5 days later. The lentivirus 
packaging was performed to allow for the in vivo infusion of the virus. Briefly, human embryonic 
kidney 293 (HEK) cells were cultured up to passage 10 and transfected in Optimen medium with 
the lentivector expression construct (PMDG-VSV-G), a third-generation packaging plasmid for 
producing viral particles (pRSV-Rev) and a third-generation envelop plasmid (pMOLg/pRRE). 
After transfection, cells were incubated for 48 h at 4°C in the dark. Virus was harvested by 
centrifuging the supernatant for 15 min at 4°C and resuspending the pellet in 150 µl of 1× PBS 
(Lonza, cat. No. 17-515, Walkersville, MD, USA). The virus was aliquoted and storage at –80°C 
for further infusion.  
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2.13 RNA immunoprecipitation (RIP).  
Briefly, 7 million E16 cells were grown for 10 days, washed with cold 1× PBS (Lonza, cat. no. 17-
515, Walkersville, MD, USA), treated with trypsin (Gibco Life Technologies, ref. 25300-054, 
Waltham, MA, USA) for 1 min, pelleted, washed again and re-suspended in PBS. Cells were then 
fixed in 1% PFA (Sigma Aldrich, cat. no. P6148, Louis, MO, USA) for 10 min at room 
temperature. Cross-linking was stopped by adding glycine to a final concentration of .125 M at 
room temperature for 10 min. After pellet collection and repeated washes, the cells were 
resuspended in RIPPA buffer comprising 50 mM Tris ph7.4, 150 mM NaCl, 1% NP-40, .5% 
sodium deoxycholate, .1% SDS with RNase out (Life Technologies, cat. no. 10777-019, Waltham, 
MA, USA) and protease inhibitors (Roche, cat. no. 04693116001, Pleasonton, CA, USA). Cells 
were then rested on ice and then subjected to sonication. Cell debris was eliminated by 
centrifugation, and samples were pre-cleared with protein G magnetic beads (Life Technologies, 
cat. no. 10004D, Waltham, MA, USA). Antibodies of interest were pre-bound to the magnetic 
beads and later bound to the lysate. Reverse cross-linking at 65°C and Proteinase K (Sigma-
Aldrich, cat. no. p2308, Louis, MO, USA) treatment at 55°C for 45 min were performed before 
elution and RNA extraction with TRIzol (Ambion, cat. no. 15596018, USA). Samples were treated 
with TURBO DNase enzyme (Life Technologies, cat. no. AM-2239, Waltham, MA, USA) for 
genomic decontamination before cDNA reverse transcription using a Super Script III kit 
(Invitrogen, cat no. 18080-051 Carlsbad, CA).  
2.14 Chromatin immunoprecipitation (ChIP). 
Dissociated cortical neurons were subjected to electroporation with 200 nM ASO for Gomafu 
knockdown, followed by protein-specific pull-downs 3 h post transfection. For in vivo studies, 
tissues were dissected and homogenized 90 min after training. During the stimulation assays, cells 
were subjected to 50 mM KCl treatment, and 90 min post stimulation, the cells were fixed in 1% 
PFA, quenched with glycine and pelleted in the same conditions as for the RIP assay. Cells were 
resuspended in 1% SDS ChIP cell lysis buffer with protease inhibitors (Roche, cat. no. 
04693116001, Pleasonton, CA, USA) and rested on ice for 10 min before being subjected to 
chromatin shearing by sonication. Cell debris was eliminated by centrifugation, and samples were 
pre-cleared with protein G magnetic beads (Life Technologies, cat. no. 10004D, Waltham, MA, 
USA). The antibodies of interest were pre-bound to the magnetic beads and later bound to the lysate. 
Four micrograms of ChIP-grade antibodies was used; the antibodies were specific to BMI1 (1T21, 
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Abcam, Cambridge, England), SUZ12 (ab12073, Abcam, Cambridge, England), RING1B (D22F2, 
Cell Signaling, Danvers, MA, USA), H2AK119 (D2764, Cell Signaling Danvers, MA, USA), mouse 
IgG (103533, Active Motif, Carlsbad, CA, USA) and rabbit IgG (2295402, Millipore, Billerica, MA, 
USA). Reverse cross-linkage at 65°C and Proteinase K (Sigma Aldrich, cat. no. p2308, St. Louis, 
MO, USA) treatment at 55°C for 45 min were followed by phenol DNA isolation. DNA–protein 
interactions were analysed by RTqPCR using primers specific to the binding motifs of the proteins 
being investigated.  
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CHAPTER 3 
“The modern observations deprive all former writer of any authority, since if they had seen what 
we see, they would have judged as we judge” 
Galileo Galilei, 1612 
Parts of this chapter are included in the paper published in Biological Psychiatry (1).  
Spadaro PA, Flavell C, Widagdo J, Ratnu V, Trup M, Ragan C, Mattick JS and Bredy TW (2015). “Long 
non-coding RNA-directed epigenetic regulation of gene expression is associated with anxiety-like behavior 
in mice”. Biological Psychiatry. doi:10.1016/j.biopsych.2015.02.004 
3. RNA-Sequencing for Non-coding and Coding 
Transcriptome Associations in Mammalian Behaviour 
Introduction 
Mendel’s observation, which lead to the concept of genetic inheritance, together with the first X-ray 
crystallography of the DNA molecule by Rosalind Franklin, which contributed to the discovery of 
the DNA helix, are milestones of molecular genetics. Since then, new technologies that allow a 
deeper appreciation of the eukaryote genomic architecture have continued to be developed. 
In 2008, the first scientific papers exploiting RNA-Seq platforms (2-4), including the very first 
mammalian transcriptome screening (5), started to rewrite the characterization of the RNA 
molecule and changed the concept of genes as previously understood (6, 7). Researchers now have 
a broader view of the underlying differences in gene expression among organisms and as a cause of 
disease (8, 9), as well as an insight into a new layer of transcription, the non-coding RNA stratum 
(10). The use of these technologies now allows investigators to pose biological questions at the 
single-cell level (11-13) and clinicians to consider personalised medical treatment based on 
transcriptome studies (14, 15). RNA-Seq has also influenced the field of neuroscience, in particular 
the detection of specific genes that may be predictive biomarkers of a range of mental conditions 
(16-19).  
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Comparisons between newly available gene expression data and chromatin marks have also 
revealed information about epigenetic mechanisms (20). RNA-Seq is not enough to uncover the 
dynamic processes associated with rapid adaptive responses, and this deficiency has given rise to 
research on networks involving molecular interplay (21-24). For example, the results of 
transcriptome analyses, such as RNA-Seq and ChIP-Sequencing, allows for the identification of 
whole-genome expression associated with chromatin occupancy of regulatory molecules and can 
help determine the relevance of epigenetics mechanisms in the nervous system (1, 20, 25, 26). 
One of the latest developments, which have relevance to the study of ncRNAs, is RNA Capture 
Sequencing (RNA-Capture-Seq) (27). This technology can help identify rare transcripts, which are 
the signatures of new isoforms and ncRNAs normally expressed at low levels that would otherwise 
be undetected by conventional sequencing approaches. These advances in uncovering the nature of 
the RNA molecule challenge the concept of epigenetics, which was traditionally defined as 
“heritable changes in the gene function that cannot be explained by changes in the DNA sequence” 
(28). With the discovery of RNA-specific methylation patterns and the likely effect on gene 
expression, a new field of “RNA epigenetics” is anticipated (29-32).  
The accurate decoding of environmental stimuli may represent an adaptive advantage, which could 
rely on the modulation of RNA molecules with the ability to address DNA epigenetic 
modifications. It is possible that understanding the neural networks underlying adaptive behaviour 
could provide insights into gene expression associated-epigenetic responses in the mammalian brain 
(33-35).  
This chapter focuses on two different sequencing techniques, RNA-Seq and RNA-Capture-Seq to 
describe the nuclear transcriptome landscape of fear conditioning in mice and its predictive 
relevance in stress-linked afflictions. The present investigation also uncovered newly described, 
coding and non-coding transcripts within a major gene associated with synaptic plasticity, the brain-
derived neurotrophic factor (Bdnf). 
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3. Results 
3.1 RNA-Seq transcriptome of Fear conditioning in mice.  
Using a paired fear conditioning paradigm, the animals included within the transcriptome profiling 
in this investigation showed a minimum 70% score of freezing after six pairs of CS and US during 
the behavioural training (Fig. 3.1, A). Both sequencing approaches achieved over 90% average of 
reads mapping to the mouse genome and even alignment percentages per sample (1). Low 
expression of the vast majority of lncRNAs hinders the correct validation through commonly used 
gene expression assays. lncRNAs with a p value > .03 would not have been properly validated, as 
for example in the case of Malat1 tests (1). Therefore, establishing a p < .03 value as a cut off to 
consider genes detected by the RNA-Seq approach, ∼ 400 loci comprising coding and non-coding 
genes were included for further analysis (Fig. 3.1, B). 
  
Figure 3.1: Fear conditioning RNA-Sequencing. (A) Freezing profile of mice subjected to cued fear 
conditioning (FC) showing significant freezing up to an 80% average. Low freezing scores were exhibited by 
the control group exposed to context (Ctx) and cue alone. (B) BioVenn graphic of loci detected by nuclear-
enriched RNA-Seq with a p-value (p) <.03 corresponding to each pairwise comparison for naïve, Ctx and 
(FC) group. 
The coding fraction was analysed separately from the non-coding genes to identify potential 
candidates for further in vivo and in vitro experiments. 
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3.1.1 RNA-Seq profile of protein-coding loci. 
RNA-Seq analysis revealed significant modulation of protein-coding genes, some of which are 
implicated in behavioural regulation, stress and neuropsychiatric disorders (Tables 3.1 and 3.2). 
Table 3.1: RNA-Seq. Identification of genes associated with psychiatric disorders detected by RNA-Seq 
analyses 
Gene p value Identified trend Association Reference 
Apoe 
.01419; 
 .01882 
 
Up-regulated in FC 
relative to Naïve 
and Ctx 
Polymorphisms indicated as markers for AD and 
impaired memory retention.  (36-38) 
Ccnd1 .00263  
Down-regulated in 
Ctx exposure Altered cell cycle dynamics in schizophrenia. (39) 
Dtnbp1 .01891; .00043 
Up-regulated in FC 
relative to Naïve 
and Ctx 
Molecular marker for AD. Modulates synaptic 
plasticity in schizophrenia (40-42) 
Fkbp5 
.0007; 
1.54E-05 
 
Up-regulated in FC 
and Ctx relative to 
Naïve 
Polymorphisms associated with schizophrenia, 
bipolar disorders, suicidal behaviour, stress-related 
disorders and AD. 
(43-47) 
Htr2a .0219451  
Up-regulated in Ctx 
relative to Naïve  Involved in cell stress response and a marker for AD. (48, 49) 
Nptx1 .00934 
Down-regulated in 
Ctx relative to 
Naïve 
Synaptic plasticity. Down-regulated in HD. (50, 51) 
Nr4a2 .00313  
Down-regulated in 
Ctx exposure 
Long-term memory in contextual fear. Indicated as a 
schizophrenia marker. (52-54) 
Nr4a3 .00362 Down-regulated in Ctx exposure Associated with schizophrenia and bipolar disorder. (55) 
Ptgds 5.66E-06;  .00172 
Up-regulated in FC 
relative to Naïve 
and Ctx 
Up-regulation serves as a diagnostic tool for 
schizophrenia.  (56) 
Qk .00560  
Up-regulated in FC 
relative to Naïve 
Involved in splicing activity associated with 
schizophrenia. (57) 
Sgk1 
.00028; 
.00534 
 
Up-regulated in FC 
and Ctx relative to 
Naïve 
Induces decreased neuronal differentiation associated 
with stress and depression. (58, 59) 
Next the Database for Annotation, Visualization and Integrated Discovery (DAVID) suit v6.7 (60, 
61) was used to predict the functional annotation clustering and potential role of the detected coding 
loci. Although many genes associated with synaptic plasticity were identified by the RNA-Seq 
screening (Table 3.1), gene ontology analyses did not reveal enrichment of pathways implicated in 
learning and memory as a result of the fear conditioning protocol. Instead, this approach indicated 
the enriched association of genes detected with neural migration and stress. The functions were 
grouped in 135 clusters, among which the first significant cluster was related to cell neural 
migration processes (Table 3.2). Cell migration has been shown to be an essential pathway required 
to aggregate neurons with similar function within the mammalian cerebral cortex and the 
hippocampus, dysregulation of which has been linked to psychiatric illnesses (62-66).  
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Within the second cluster, an enhancement for a stress response linked to chaperon heat shock 
proteins (HSPs) was also detected, particularly the Hsp70 heat shock superfamily (Table 3.3), 
which is a chief regulator of cellular apoptotic pathways upon stress stimuli (67, 68) with relevance 
to neurological disorders (69-74). 
Table 3.2: Table 3.2: Predictive association of loci detected by RNA-Seq. Functional enrichment terms of 
differentially regulated loci predicted by GO analysis (DAVID bioinformatics tool). 
Clusters Function p-value Benjamini score 
1st 
Enrichment 
score= 3 
Cell migration 3.1 E–4 4.1 E–1 
Neuron migration 4.6 E–4 3.2 E–1 
Cell motility 1.6 E–3 3.7 E–1 
Cell localization  1.6 E–3 3.7 E–1 
Cell motion 2.7 E–3 4.4 E–1 
2nd 
Enrichment 
score= 2.74 
 Hsp70 9.4 E–4 1.4 E–1 
Stress response 1.4 E–3 9.0 E–2 
Hsp70, conserved site 1.6 E–3 1.2 E–1 
PIRSF002581: chaperone Hsp70 9.7 E–3 4.5 E–1 
 
Previous investigations support the notion that generalized sensitization or non-associative 
responses correlate with repetition of fear cues and training intensity (75-77). The experiments 
described here included a strong fear conditioning protocol (six CS–US pairings of a 0.7 mA foot 
shock), which may lead to an increase in stress reactivity and anxiety. Consistent with this view, the 
fear-conditioned mice in this investigation showed high levels of freezing, during both the CS onset 
and the inter-trial interval (Fig. 3.2, A); whereas there were no significant differences in the level of 
freezing before and after each stimulus (Fig. 3.2, B).  
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Figure 3.2: Freezing behaviour profile in mice during fear conditioning showing generalized 
sensitization and anxiety-associated responses. Fear-conditioned mice showed high levels of freezing in 
response to the CS, during the inter-trial interval (A) and in proximity to each stimulus (B), indicating a 
generalized fear response. 
To confirm the RNA-Seq findings, candidates linked to relevant brain-associated function were 
selected for downstream analysis. The expression of two protein-coding genes, Bdnf exon IV and 
Homer1, which are involved in neural plasticity and memory (Table 3.3, Fig. 3.3, A-B), was 
examined further.  
Bdnf is considered to be an important regulator of the neuronal circuitries driving learning and 
synaptic plasticity (78). This gene has a complex structure that allows its differential epigenetic 
response to stimuli (79, 80); and Bdnf exon IV has been shown to participate in memory processes 
within the mammalian PFC (81). Homer1 is located at the post-synaptic membrane and is 
associated with the regulation of synaptic plasticity, glutamate receptor trafficking and neural 
function (82-85). Additionally, the Homer family of proteins has been implicated in the 
development of neuropsychiatric disorders and neurological diseases (86-93). Homer1-knockout 
mouse models have shown its relevance within hippocampus signaling to motivation-based learning 
activities (94). The Homer1 signaling-associated pathway is linked to cognitive function (84, 95) 
and stress modulation (96). Its interaction with glutamate receptors has also been shown to direct 
stress-induced deficits in learning and memory of fear conditioning and spatial formation (97, 98). 
The experiments in this thesis showed a significant increase in the expression of Bdnf exon IV and 
Homer1 mRNA in Ctx mice (Fig. 3.3, A, B), which confirmed the findings of previous studies 
demonstrating the activity-dependent nature of these genes in models of experience-dependent 
plasticity.  
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Considering the predicted enrichment for a functional stress response associated with the fear 
conditioning training and to explore the predicted involvement of the HSP70 heat shock family of 
proteins (Table 3.2), genes associated with a stress response, such as Hsp901b, which is also a 
member of the HSP70 group (43, 99), and Npas4 (100) were investigated. Up-regulation of Npas4 
is associated with fear learning, whereas its down-regulation correlates with stress and impairment 
of fear memory (100-103). The experiments in this thesis confirmed a significant decrease in the 
expression of the activity-dependent gene Npas4 (Fig. 3.3, C). This might have been induced by an 
underlying stressful response because stressors can also lead to fear incubation or enhanced fear-
potentiated startle, which may be more related to anxiety than to learning (75, 76, 104). 
Concordantly, an increase in the expression of the stress-related gene, Hsp901b, was also observed 
following fear conditioning (Fig. 3.3, D). Consistent with a potential stress response, conditioned 
animals in this experiment showed high levels of freezing as predicted for the US event and at 60 
seconds before the expected CS (Fig. 3.2). Such behaviour may expose a maladaptive anticipatory 
response possibly driven by fear sensitization inductive of an anxiety state.  
 
Figure 3.3: qPCR validation of plasticity-related genes. (A–D) Analysis of protein-coding genes 
confirmed up-regulation of Bdnf exon IV mRNA (naïve vs Ctx ***p < .001, Kruskal–Wallis test statistics = 
16.58), up-regulation of Homer1 (naïve vs Ctx, *p < .05, ANOVA, F(2,20) = 5.119), down-regulation of 
Npas4 (naïve vs FC, *p < .05, ANOVA, F(2, 20) = 5.5), and up-regulation of Hsp901b (naïve vs FC, **p < 
.01, Kruskal–Wallis test statistics = 9.459).  
Further selection of significantly regulated protein-coding genes detected in the transcriptome 
screening approach, which are relevant to brain function and neurological disorders, were 
confirmed by qPCR, indicating changes of expression level in the Ctx and fear-conditioned groups 
(Table 3.3).  
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Table 3.3: Validation and reported function of protein-coding genes detected by RNA-Seq   
Gene p-value Validated Trend Function Reference 
Dusp1 .0001 Down-regulated in FC vs Naïve 
Interaction with p53, directs cellular oxidative stress 
response. Association with fear learning in the hippocampus 
and amygdala. Biomarker for mood disorders. 
(105-107)  
Cdkn1a .0001 Up-regulated in Ctx vs Naïve 
Regulator of cell cycle progression, involved in central 
nervous system inflammatory and oxidative stress response. 
Associated with stress and anxiety. 
(108-110) 
Bdnf .0003 Up-regulated in Ctx vs Naïve 
Over-expression associated with working memory deficit, 
anxiety and stress. Related to neural plasticity and fear 
extinction memory. 
(81, 111-113) 
Htra1 .0012 Up-regulated in FC vs Naïve 
Associated with programmed cell apoptosis. Involved in the 
metabolism of β-amyloid and linked to AD. Control of 
neuronal maturation. 
(114-116) 
Hspa1A .0015 Up-regulated in FC vs Naïve 
Increased expression associated with drug abuse and cellular 
stress. Down-regulated in association with AD. (117-119)  
Crybb1 .0018 Up-regulated in FC vs Naïve 
Up-regulation related to neurodevelopmental disorders such 
as schizophrenia and autism. Locus association with anxiety 
and schizophrenia. 
(120-122) 
Cacng2 .006 Up-regulated in Ctx vs Naïve 
Associated with cerebral ataxia and epilepsy. Related to 
schizophrenia, bipolar and depressive disorders. Involved in 
synaptic plasticity and learning. 
(123-125) 
Hsp90b1 .0088 Up-regulated in Ctx vs Naïve 
Linked to oxidative stress, bipolar disorders, and stress 
vulnerability associated with alcohol abuse. (126-129)  
Thereafter, the results from the screening of coding genes involved in mice fear conditioning 
showed the participation of major genes linked to brain function. These observations further 
predicted a response other than fear learning per se that might be associated more with stress 
disorders. 
3.1.2 RNA-Seq profile of ncRNA loci. 
Because of the complications inherent in confirming the overlapping exon transcripts, this analysis 
focused only on lncRNAs transcribed within intergenic and non-exon overlapping regions. A total 
of 53 ncRNAs loci were identified as being markedly modulated in either Ctx-exposed or fear-
conditioned mice (Fig. 3.4, A–C). These included the known lncRNAs Neat1, Malat1, Rmst, Mirg 
and Gomafu (1). These versatile lncRNAs have been shown to influence a wide range of systems 
and disease states.  
For instance, Neat1, participates in determining the cell architecture of paraspeckle compartments 
(131) and has been linked to heroine abuse (132), determination of myeloid differentiation of acute 
promyelocytic leukaemia-associated cells (133), and regulation of splicing events of genes involved 
in adipogenesis (134). Malat1 is involved in the prognosis and development of cancer (135-139) 
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and is the only known lncRNA capable of recruiting splicing factors to the transcriptional site of 
genes linked to synapse formation and maintenance (140).   
The brain-enriched lncRNA Rmst is thought to be an epigenetic driver of pluripotency and neuronal 
differentiation through an alternative interaction with PRC2 and Rest proteins (141). Investigations 
have confirmed that Rest represses Rmst in neuronal stem cells. At the onset of neurogenesis, Rest 
releases the repressive mark from Rmst, which in turn acts as decoy molecule to sequester Sox2 and 
relieve neurogenic transcription factors from Sox2 repressive activity (142).   
A modulation of the imprinted miRNA containing lncRNA, Mirg, was detected in the RNA-Seq 
assay. The small RNA-Seq experiment, described in chapter 7, identified a cluster of miRNAs 
transcribed from Mirg within the hippocampus region of fear-conditioned mice. Mirg, Rian, Gtl2, 
and Meg3 lncRNAs originate from a conserved chromosomal region in mammals that is maternally 
imprinted and they are known substrates for sncRNA generation (143-146). During mouse 
embryogenesis, Mirg expression is enriched within the central nervous system (147), and the 
sncRNAs transcribed from this lncRNA are considered to be a “schizophrenia-associated miRNA 
signature” (148). Gomafu is highly enriched within the mammalian brain and is a well-understood 
lncRNA that is associated with neural activity (57, 149-151). Further information about Gomafu 
lncRNA is provided in chapters 5 and 6. 
Most of these non-coding transcripts were found within 100 kb of the nearest protein-coding gene, a 
finding that is consistent with the potential cis-regulatory function relative to these neighbouring 
mRNAs (152-154) (Fig. 3.4, D). 
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Figure 3.4: Intergenic lncRNA in fear conditioning. (A–C) Volcano plot showing log2 fold changes in 
lncRNAs with p-values <0.03 in each pairwise analysis. Up-regulation of genes in context (B,C) and in naïve 
(D) animals is shown to the right side of the 0 in each figure. (D) Distribution analysis of lncRNA loci 
showing the close proximity to coding genes. 
With the aim of uncovering potential novel biological association activity of lncRNAs, and 
considering that lncRNAs have been shown to regulate proximal coding genes in cis (155-160), two 
intergenic lncRNAs of unknown function were validated, together with Gomafu lncRNA. Both 
transcripts exhibited a significant, but non-specific, decrease in expression following behavioural 
training (Fig. 3.5, A-B). The first of these non-coding transcripts, Gm21781, is upstream of a gene 
that encodes a DNA-binding protein known as zinc finger and BTB domain containing 2 (Zbtb2). 
This coding gene has recently been shown to be a transcriptional repressor and a modulator of the 
cell cycle arrest pathway through regulation of p53 and p21 (161). Zbtb2 has also been reported to 
induce cell proliferation through interactive reprogramming of the cell metabolic pathway (162). 
More interestingly, Zbtb2 has been detected in screening investigations of neurite outgrowth and 
regeneration (163) and has been shown to be a potent epigenetic regulator associated with DNA 
hypomethylation events (164). The second lncRNA, Gm11762, is antisense to neuronal pentraxin 1 
(Nptx1), a well-conserved gene that is enriched within the nervous system in humans (165). Nptx1 
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has been shown to be induced upon neural stimulation and to contribute to neural linage 
specification in pluripotent steam cells (166) and is associated with addictive behaviour and autism 
(167, 168). This gene was previously reported to enhance synaptogenesis and glutamate signalling 
through clustering of AMPA receptors (50). 
Finally, significant down-regulation of the neuropsychiatric disease-related lncRNA Gomafu, was 
detected following fear conditioning but not after context exposure (Fig. 3.5, C). Importantly, the 
down-regulation of Gomafu in fear-conditioned animals was also observed in the targeted RNA-
Capture experiment, thereby confirming the previously reported activity-dependent nature of the 
expression of this lncRNA (57). Taken together, these data suggest that experience-induced 
regulation of lncRNAs may play a role in regulating cognitive processes in the adult brain. 
 
Figure 3.5: qPCR validation of lncRNAs. (A-B) Analysis of lncRNAs demonstrates a non-significant 
slight up-regulation of Malat1 and down-regulation of Gm21781 lincRNA and Gm11762 lncRNA following 
fear conditioning relative to naïve mice (ANOVA, **p < .01, F(2, 20) = 7.308 and ANOVA, **p <.01, F(2, 
20) = 5.892, respectively). (C) Specific down-regulation of Gomafu lncRNA in fear-conditioned mice 
(ANOVA, **p < .01, F(2, 20) = 5.953 naïve vs FC and Ctx vs FC). 
The RNA-Seq data suggested that experience-induced regulation of lncRNAs might play a role in 
regulating fear and stress-associated processes in the adult brain, with potential relevance in the 
modulation of proximal coding genes. 
3.2 RNA-Capture-Seq. 
RNA-Capture-Seq allows for the discovery of transcripts expressed at a low level and for the 
identification of rare isoforms differentially expressed within a given gene, which may not be 
detected by RNA-Seq (27). Through this approach, newly described isoforms and non-coding 
variants were identified within the loci stated in Table 2.1 in chapter 2. As previously indicated in 
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the description of the RNA-Seq assay, Bdnf mRNA exon IV (Fig 3.3, A) was up-regulated and 
Gomafu lncRNA was down-regulated in Ctx animals (Fig. 3.5, C). These trends were confirmed in 
the RNA-Capture Seq experiment (1); thereafter both genes were chosen for further research. To 
provide evidence of the power of this technology and its relevance in the field of lncRNA 
investigations, the Bdnf locus is analysed in this chapter, and the results for Gomafu lncRNA are 
described in chapters 5 and 6. 
3.2.1 RNA-Capture of the Bdnf locus.  
Evidence showing that Bdnf is a regulator of neuronal circuitries driving learning and synaptic 
plasticity has been reviewed (169). This gene has a complex structure that allows its differential 
epigenetic response to stimuli and has been shown to participate in memory processes within the 
mammalian PFC (81, 112, 170).  
Bioinformatic analysis of RNA-Capture-Seq outputs associated with the chromosomal position 
relative to the Bdnf-coding gene detected new coding and non-coding isoforms (Fig. 3.6). This 
approach identified different variants of an lncRNA previously reported antisense to Bdnf (171). 
Interestingly, a newly described overlapping lncRNA was also discovered on the sense direction of 
Bdnf  (here referred to as “Isoform 15”) (Fig. 3.6).  
Neither the antisense nor the novel sense isoform was detected by the RNA-Seq trial, which 
suggested that the capture technique was essential for the discovery of these low-abundance 
transcripts. 
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Figure 3.6: Novel Bdnf locus-associated sequences. Transcriptional structure representation of the Bdnf 
locus outputs from RNA-Capture-Seq, showing novel antisense isoforms for Bdnf-AS ncRNAs. Individual 
diagrams kindly produced by Dr. Qiongyi Zhao. 
Pruunsild et al. (172) and Modarresi et al. (171) reported non-coding transcription of sequences 
associated with the Bdnf chromosomal region. Both groups worked over a similar ncRNA locus that 
was antisense to Bdnf, which largely overlapped its cognate coding gene (Fig. 3.7, A,B). After 
observing a co-expression pattern between both genes, Pruunsild et al. proposed a Bdnf-AS 
potential regulation of Bdnf mRNA. The second team of researchers showed the ability of Bdnf-AS 
to bind Ezh2, a member of the PRC2, and to redirect its repressive activity over Bdnf (171). These 
investigators demonstrated that level of Bdnf mRNA could be affected in HEK293 cells by the 
knockdown of its antisense non-coding transcript, yet no neural-specific assay was performed in 
these studies to indicate the relevance of the findings in the brain.  
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Figure 3.7: Bdnf-As ncRNA precedents. Reproduced from (172) (A) and from (171) (B). Previous 
discoveries depicting an lncRNA antisense to Bdnf, which largely overlapped with this coding gene, as 
opposed to the transcript variants detected by RNA-Capture-Seq within this investigation (Seen in Fig. 3.6).  
Next, the existence of the novel non-coding isoforms was confirmed by qPCR analysis. Using 
primers specific to the distal non-coding Isoform 15 (Fig. 3.7), this transcript was detected in all 
experimental groups; however, no differential levels were found (not shown).  
Levels of Bdnf exon IV within the mPFC and hippocampus tissue of fear-conditioned mice (Fig. 
3.8, A and C) were compared against the pattern of expression of its antisense lncRNA (Fig. 3.8, B 
and D). A context exposure up-regulation of Bdnf IV was confirmed within both regions (Fig. 3.8, 
A and C). The use of non-overlapping exon primers designed to amplify specifically the antisense 
transcript confirmed the down-regulation of Bdnf-AS ncRNA in the mPFC of Ctx and fear-
conditioning groups relative to the naïve animals (Fig. 3.8, B). Conversely, the antisense transcript 
showed a fear-specific up-regulation trend (Fig. 3.8, D) within the hippocampus of the same 
animals.  
A
B
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Figure 3.8: Tissue-specific expression patterns of Bdnf-AS ncRNA. Confirmation of BDNF mRNA exon 
IV showed up-regulation of this transcript upon context exposure stimulation in both the mPFC (naïve vs Ctx 
***p < .001, Kruskal–Wallis test statistics = 16.58) (A) and the hippocampus brain regions (ANOVA, naïve 
vs Ctx *p < .05, F(2, 21) = 3.947) (C). By contrast, the novel non-coding variant showed a fear-specific 
response, which showed the opposite trend between the mPFC and hippocampus (ANOVA, naïve vs Ctx and 
naïve vs Ctx **p < .01, F (2, 20) = 6.075; and naïve vs FC and Ctx vs FC **p < .01, Kruskal–Wallis test 
statistics = 10.56, respectively)  (B-D).  
These results showed a tissue-specific pattern of expression that occurs only at the lncRNA gene 
level. Given the overlapping nature of these genes, these outcomes also support the idea of 
independent transcription for both transcripts and the possible involvement of different molecular 
mechanisms in the regulation of the coding and non-coding fractions.  
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Chapter Conclusion and Perspectives 
In this chapter, coding and non-coding genes with acknowledged relevance in brain function and 
behaviour were examined and confirmed through the use of RNA-Seq technologies. The mPFC 
nuclear-enriched transcriptome screening of fear-conditioned mice showed a considerable presence 
of genes related to cognitive processes and neuropsychiatric conditions. It also highlighted the 
presence of lncRNAs that were responsive to the behavioural training and were derived from 
chromosomal regions in close proximity to coding genes. 
The highly developed prefrontal cortex in humans may be the brain region that differentiates us, 
from the rest of the animal kingdom (173). It has evolved as the centre of command for higher 
cognitive functions that allow extraction and interpretation of meaning from experiences (174). The 
vast majority of the most recently evolved sequences, which are found in this brain region, are 
identified as ncRNAs (175). This raises the question as to why such a preeminent transcription of 
ncRNAs has taken place in a brain area related to sophisticated molecular mechanisms and complex 
behavioural responses, and whether non-coding gene dysregulation in the prefrontal cortex can lead 
to modifications in behaviour of mammals. 
There is no publicly available bioinformatics software to predict the functional commitment of sets 
of lncRNAs. Consequently, this question was transferred to the coding genes detected through the 
transcriptome profiling, where gene ontology analysis predicted a functional stress response. 
Because of its engagement in emotional decoding of external cues, the prefrontal cortex is 
considered to be a key site of the response to stress (176). Reaction to fear is a basic ancestral 
mechanism involved in survival and adaptation. Anxiety is intrinsically related to the exposure to a 
fearful event and is required to elicit a coping mechanism; however, persistent anxiety may become 
pathological and may interfere with the adaptive response (177). Predictive analysis and the cited 
literature have suggested a possible involvement of stress-associated neural circuitries that differ 
from those involved in learning and memory. 
Although the RNA-Seq profiling uncovered important lncRNAs, the use of a Capture sequencing 
approach was nonetheless critical to detecting the expression of rare and novel transcripts. The 
RNA-Capture-Seq assay allowed us to confirm the expression patterns of candidate genes and to 
identify a new set of coding and ncRNAs relative to the Bdnf locus.  
Bdnf-AS variants had been suggested (171, 172), but the lncRNA reported by these investigators 
runs antisense and overlaps with the Bdnf mRNA. The antisense lncRNA detected here is 
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transcribed from an upstream region with a minor overlapping sequence and is therefore a different, 
and newly described lncRNA (171, 172).  
The in vivo confirmation of the Bdnf-AS lncRNA, which is expressed at a low level, was shown to 
respond to training in a tissue-specific fashion, and this pattern of expression contrasted with its 
associated mRNA modulation. Although the previous investigations suggested the molecular 
mechanisms to explain the regulatory interplay between Bdnf and its ncRNA counterpart, their cell 
line model was not specific for predicting neural function.  
Overall, the different sequencing approaches of fear-conditioned mice exposed the participation of 
lncRNAs in a predictive functional stress response and a possible role in the regulation of 
neighbouring genes.  
These results may show the potential relevance of non-coding molecules, long believed to be by-
products of transcription, in complex mammalian behaviour. 
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CHAPTER 4      
“What we call the mind, is not something that the individual is born with, as he is born with his 
brain, or something that the brain produces, but something his genetic equipment helps him 
acquire…” 
Friedrich von Hayek, 1988 
4. Characterization of Stargazin Antisense lncRNA in cis 
Regulatory Functions  
Introduction 
The distinctive circuitry in our brains, formed by more than 100 billion neurons, determines the 
human ability to interpret the environment, making us an intellectual species. This adaptive 
decoding of external cues occurs because of the neuron-to-neuron communication at the synapse, 
and its success is largely dependent on the strength and duration of such interactions, which is 
known as synaptic plasticity. The discovery of how experience can alter synaptic plasticity to result 
in complex and specific behavioural responses is one of the major quests in neuroscience (1). 
The normal regulation of excitatory glutamate alpha-amino-3-hydroxy-5methyl-4-
isoxazolepropinoic acid receptors (AMPARs) is essential to neural synaptic transmission associated 
with cognitive processes (2). Effectively, AMPARs are the guides for excitatory neurotransmission 
in the mammalian CNS by initiating the postsynaptic depolarization that triggers neuronal firing 
(3). AMPARs are formed by tetramers of glutamate receptor subunits (GluR1 to GluR4), which 
drive the functional ionic channels that contribute to the modulation of synaptic strength (4, 5). 
Long-term potentiation (LTP) is a crucial step in the plasticity of the brain and is required for 
learning and memory events (6). There is growing evidence that AMPAR trafficking into and out 
the postsynaptic density of a synapse (PDS) plays a major role in LTP and in activity-dependent 
lasting changes in the synaptic strength (7-12). AMPAR trafficking has been also shown to 
participate in learning and memory events (13-16). Although many AMPAR-interacting proteins 
contribute to these neural activities, the precise regulatory pathway of AMPARs in LTP is still 
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being unravelled (17). Most such molecules can interact with the C-terminal tail of GluR subunits 
in a brain region-specific fashion and induce phosphorylation of the receptors to activate their 
trafficking (17, 18). 
One of these proteins, which is encoded by the neuronal voltage dependent calcium channel gamma 
2 (Cacng2) gene, or Stargazin, has been shown to regulate the trafficking and channel gating of 
AMPARs at the neuronal post synapses by mechanisms not entirely understood (17, 19-22). The 
relevance of this relationship is evident in the dysregulation of AMPARs as a consequence of 
Stargazin mutations, which lead to the phenotype of severe epilepsy and ataxia in mice (23). 
Stargazin encodes the brain-specific Stargazin protein that is enriched in the synaptic plasma 
membrane (23). Through the interaction of its cytoplasmic tails with other synaptic PDZ proteins 
domain, such as PSD95, Stargazin is able to recruit intracellular AMPARs and to regulate their 
activity by delivering them to the synapse (17, 24, 25). Thereafter, through the regulation of 
AMPARs, Stargazin is directly involved in driving the ability of neurons to communicate at the 
synapse, a process that supports the brain plasticity required for experience-dependent responses.  
Although these studies were mostly focused at the level of protein-protein interactions, 
investigations have indicated the prevalence of conserved correlation between levels of mRNA 
transcription and abundance of the proteins they encode (26-34). This further sustains the relevance 
of Stargazin and Gria genes expression in synaptic plasticity, as well as in memory and learning 
associated research. Within neurological and behavioural investigations, Stargazin expression has 
further been implicated not only in epilepsy but also in Schizophrenia, Bipolar and depressive 
disorders (23, 35, 36). Interestingly, Stargazin modulation has equally been noted in mammalian 
spinal neurons associated to chronic pain and inflammatory responses (37, 38). 
No investigation has yet characterized Stargazin modulation in relation to non-coding 
transcriptional activity. This study examined the modulation of a conserved and annotated antisense 
lncRNA to Stargazin, which was differentially expressed upon behavioural training of mice. This 
antisense lncRNA was shown to influence the expression of Stargazin mRNA as well as the 
expression of Gria2 and Gria4 genes. The results of the present chapter may suggest that lncRNAs 
could have an important role at the centre of the synaptic plasticity circuitry in the mammalian 
brain.  
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4. Results 
4.1 Modulation of Stargazin and its antisense lncRNA.  
Whole-genome RNA-Seq of samples from fear-conditioned mice detected an important number of 
reads mapping to both the Stargazin coding transcript and its antisense lncRNA locus. Both genes 
were up-regulated in the Ctx animals compared with the naïve group (39). The non-coding 
transcript was already annotated with the RNA accession number AK043153.1. The UCSC mouse 
genomic database had identified this two-exon transcript on the positive strand as an lncRNA  (Fig. 
4.1). This is also consistent with the findings of the GENCODE project, predicting that lncRNAs 
show a bias for containing only two exons within their sequences (40). 
No functions have yet been shown for this 2126 bp antisense lncRNA, which for the purpose of this 
thesis is designated “Anti-Star lncRNA”. As for many other lncRNAs, this transcript also showed a 
small-predicted open reading frame, which could theoretically allow for the translation of functional 
peptides (Fig. 4.1). Thereafter, a predictive approach to interrogate the coding potential of 
AK043153.1 was taken by running the FASTA sequence through a publicly available coding 
potential calculator software (41). The results of this test, in concordance with the UCSC 
classification, indicated that AK043153.1 is a non-coding transcript.   
 
Figure 4.1: Stargazin (Cacng2) vs Anti-Star lncRNA (AK043153) genomic annotation. Adapted from the 
UCSC database. Verification of the coding potential levels confirmed that Anti-Star lncRNA is an ncRNA in 
addition to having an open reading frame of 270 nt. 
Validation by qPCR of mPFC Stargazin and Anti-Star lncRNA gene expression confirmed the up-
regulation trend in Ctx mice (Fig. 4.2, A, B). Although not statistically significant, an up-regulation 
was also detected for Stargazin in fear-conditioned animals, but this tendency was not observed in 
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the antisense lncRNA modulation (Fig. 4.2, A, B). These results suggest the possible molecular co-
activation between these genes within the mouse cortical region that may be specifically driven by 
contextual novelty and not by fear learning stimuli.  
           
Figure 4.2: Nuclear enriched mPFC in vivo dynamics of Stargazin mRNA and Anti-Star lncRNA. (A) 
Stargazin showed a trend towards up-regulation upon stimulation, which was significant in the comparison 
between naïve and Ctx animals (naïve vs Ctx **p < .01, Kruskal–Wallis test statistics = 10.22). (B) The non-
coding antisense transcript mirrored the mRNA modulation, which suggests the presence of co-activation 
processes (naïve vs Ctx, *p < .05, ANOVA, F (2, 21) = 5.604).  
Stargazin expression has been shown to be a modulator of inflammatory and pain responses (37, 38, 
42-44). Considering these reports a potential link to the shock-related pain sensitivity response was 
further interrogated. The in vivo dynamics of both genes was compared in mice subjected to a foot-
shock only stimulus (3 US, 0.04 mA) accompanied by a mild fear conditioning protocol (3 CS–US, 
0.04 mA paired stimuli).  
The test induced highly significant levels of freezing in fear-conditioned mice (Fig. 4.3, A). By 
contrast, there were no significant changes in the levels of expression of Stargazin mRNA and Anti-
Star lncRNA. Both transcripts remained virtually unchanged under all the stimuli presented during 
the behavioural training (Fig. 4.3, B, C). The results indicated that these genes are not involved in 
the pain response under the mild parameters of the experimental assay used and confirmed an effect 
of context exposure on both genes within the mPFC.   
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Figure 4.3: In vivo pain-associated response within the Stargazin locus in nuclear-enriched mPFC 
samples. (A) Behavioural test with 3 CS–US unpaired stimuli produced significant levels of fear acquisition 
in the trained animals (t test, *** p <.001, t = 4.975, df = 10). (B,C) Paired 3 CS–UC fear-conditioning 
treatment and shock-only stimulus produced no significant effect (p > .05, df = 10) on Stargazin and Anti-
Star lncRNA levels of nuclear-enriched RNA within the mPFC.  
As mentioned, there is an important protein–protein interaction between Stargazin and the 
regulation of AMPARs within the hippocampus, which is most relevant in synaptic plastic 
processes (19, 45) and correlation between levels of mRNA transcription and abundance of the 
proteins they encode is also predicted (26-34). Therefore, Stargazin mRNA levels of nuclear 
enriched expression, together with the Anti-Star lncRNA transcript, were examined within the 
hippocampal brain region of trained mice.  
Unlike the co-expression pattern observed in the cortex tissue from the same animals (Fig. 4.2, A, 
B), there was a significant inverse trend between the expression of both genes in fear-conditioned 
mice (Fig. 4.4, A, B). Stargazin was down-regulated only in fear-trained mice, whereas Anti-Star 
lncRNA expression was increased in these animals compared with both Ctx and naïve mice (Fig. 
4.4, A, B). Because these genes do not overlap but share the promoter region, this result is 
consistent with the hypothesis of an independent transcriptional event for both transcripts that is 
specific to the fear-induced response. 
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Figure 4.4: In vivo dynamics of Stargazin mRNA and Anti-Star lncRNA in the nuclear-enriched 
hippocampus. (A) Stargazin showed trend towards down-regulation upon stimulation that was significant 
for the comparison between naïve and fear-conditioned (FC) animals, and between Ctx and FC mice (naïve 
vs FC, naïve vs Ctx **p < .01, ANOVA, F (2, 21) = 6.703). (B) The non-coding antisense transcript showed 
the opposite trend to the mRNA modulation and was significant only for the comparison between Ctx and 
FC mice (Ctx vs FC **p < .01, Kruskal–Wallis test statistics 11.26). 
Overall, the in vivo dynamic expression of Stargazin and Anti-Star lncRNA observes a tissue 
specific modulation in behaviour. While in the mPFC a co-expression of both transcripts can be 
seen in response to novelty in context exposed mice; within the hippocampus brain region this 
response becomes inverse and specific to fear conditioning. 
4.2 In vitro characterization of Anti-Star lncRNA. 
Given that no previous investigations have reported on the expression of Ani-Star lncRNA, its level 
of stability, cell compartment localization and responsiveness to neural stimulation were next 
characterised.  
4.2.1 Stability of Anti-Star lncRNA may imply functionality. 
Identifying the level of RNA stability is becoming increasingly more important to understanding the 
principles governing eukaryote gene expression and functionality. Although the mRNAs associated 
with cellular functions, as for example housekeeping genes, show higher indices of stability, 
transcription-related and activity dependent-regulated genes are generally less stable (33, 46-48). 
Transcripts that display a prompt reaction to an external stimulus, such as early response genes, 
have been shown to have the fastest decay rate; i.e., RNA degradation occurs in <2 hours (46). 
Among the early response genes, Egr1 has been shown to peak in expression within 30 min and to 
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maintain this level up to 75 min post stimulation. Consistent with this response to stimulation, its 
decay rate has been determined at 30 min (48). Recent investigations of lncRNA stability have 
shown a rapid degradation, at just over 30 min, of the brain-enriched and activity dependent-
responsive lncRNA Neat1 (49). This shows the power of stability assays to uncover activity-
dependent responses of genes in a non-traditional way, as for example membrane depolarization by 
KCl induction.  
To investigate the stability of Stargazin and Anti-Star lncRNA, actinomycin-D was used to halt 
their transcription and to examine their rate of degradation in neuronal cultures. Egr1 was used as a 
marker of early RNA decay in highly responsive genes, as opposed to a stable housekeeping gene 
such as Ppia, and Neat1 was used as an additional referent associated with non-coding transcription 
stability. The results of this study were consistent with those of previous studies and validate the 
assay described in this chapter (Fig. 4.5, A–C) and chapters 4 and 7. Thereafter, the assay was used 
to investigate level of Stargazin and Anti-Star lncRNA stability to determine their potential activity-
dependent molecular function in neuronal cultures. 
                
Figure 4.5: Stability measurements relative to the basal state and validation of the decay rates of 
known genes. (A) Ppia housekeeping gene showed a high level of stability throughout the 6 h test. (B) The 
early response gene Egr1 exhibited a highly significant degradation 30 min after actinomycin D application 
and a virtually absolute decay after the 3 h mark. (C) LncRNA Neat1 exhibited a significant decay rate after 
30 min, and both transcripts remained at low levels until the 6 h time point. (*) p < .05; (**) p < .005; (***) 
p < .0005 and (****) p < .00005, t test, n = 4 per group. 
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Consistent with its proposed regulatory role in the brain, Stargazin has a short lifetime and was 
significantly degraded 1 h post drug infusion, whereas its stability levels remained around 30% 6 h 
after treatment (Fig. 4.6, A). More interestingly, Anti-Star lncRNA showed a lower half-life and its 
levels of stability decreased significantly from 15 min (Fig. 4.6, B). This showed a decay rate for 
the lncRNA that it is even faster than that described for the early response gene Egr1.   
   
 
Figure 4.6: Stability measurements relative to the basal state for Stargazin mRNA and its antisense 
lncRNA. (A) Stargazin gene exhibited a highly significant degradation 1 h after actinomycin D application 
and a virtually absolute decay at the 6 h mark. (B) Anti-Star lncRNA exhibited a higher decay rate, which 
was significant 15 min after actinomycin D application and showed the same level of degradation as 
Stargazin at the 6 h mark. (*) p < .05; (**) p < .005; (***) p <.0005 and (****) p < .00005, t test, n = 4 per 
group. 
The rates of decay, which are faster and markedly lower in the case of the non-coding transcript, 
showed similar levels of potential molecular function for both genes in neuronal cultures. 
Interestingly, the different patterns of stability within the initial hour after treatment (Fig. 4.6, A, B) 
support the notion of independent transcription associated with this novel lncRNA and potentially 
different decay mechanisms. 
4.2.2 Cell compartment stimulus-dependent expression of Anti-Star lncRNA.  
Given that the dynamic expression of Stargazin and Anti-Star lncRNA, which were initially 
detected using the RNA-Seq approach, was enriched for nuclear RNA extraction, the possibility of 
subcellular specific expression of the lncRNA upon neural induction was also examined. To do this, 
the expression level of Anti-Star lncRNA in the nuclear and cytosolic fractions of KCl stimulated 
neurons were scrutinised separately.  
Ba
sa
l
15
m
30
m 1h 2h 3h 4h 6h
0
50
100
150
Stargazin mRNA stability
Act-D
St
ab
ilit
y 
le
ve
l  
(%
)
** *
***
*
***
Ba
sa
l
15
m
30
m 1h 2h 3h 4h 6h
0
50
100
150
Act-D
St
ab
ilit
y 
le
ve
l  
(%
)
Anti-Star lncRNA stability
* *
** **
****
*
***
A B
 
 98 
The up-regulation of Anti-Star lncRNA (Fig. 4.7, A, B) was verified by qPCR analysis. This up-
regulation was consistent with the in vivo expression pattern detected in hippocampi of fear-
conditioned mice and the cortex of Ctx mice. Further, nuclear Anti-Star lncRNA expression was 
increased at 1 h post stimulation alone, and the cytosolic fraction expresses was up-regulation at 3 h 
post stimulation (Fig. 4.7, A, B). These results suggest that the levels of Anti-Star lncRNA 
expression following neural stimulation are specific to the cell compartment. 
       
Figure 4.7: Anti-Star lncRNA expression patterns within the cell. (A) Anti-Star lncRNA showed a 
significant up-regulation upon stimuli at 1 h post KCl neuronal induction in the nuclear fraction and a 
decrease from 1 h to 3 h post stimulation (Basal vs 1h, and 1h vs 3h, *p < .01, ANOVA, F (2, 5)=13.72). (B) 
The non-coding antisense transcript confirmed the significant up-regulation upon stimulation at 3 h post KCl 
neuronal stimulation within the cytosolic fraction (Basal vs 3 h, and 1 h vs 3 h, **p < .01, ANOVA, F (2, 6) 
= 14.17). 
Such patterns of transcription implicate a potential time-stimuli-dependent shuttling of Anti-Star 
lncRNA, between the nucleus and the cytoplasm, which in turn may lead to a function that is 
specific to the cell compartments. 
4.3 In vitro regulatory activity of Anti-Star lncRNA. 
A specific shRNA was used to investigate the likely regulatory role of Anti-Star lncRNA in relation 
to Stargazin. An in vitro knockdown assay of this lncRNA was performed under KCl stimulation. 
Subsequently, the differential expression of Anti-Star lncRNA in the hippocampus and cortex was 
investigated further using a specific in vitro knockdown assay to identify a possible regulatory role 
in relation to Stargazin mRNA and whether this is tissue specific. 
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4.3.1 Anti-Star lncRNA modulates Stargazin mRNA. 
Anti-Star lncRNA knockdown was significant at both the basal and stimulated levels (Fig. 4.8, A) 
in cortex-derived neurons. More importantly, this effect was accompanied by significant down-
regulation of the coding gene counterpart in KCl-induced neurons (Fig. 4.8, B). In addition, no 
activation was observed in the levels of transcription of Anti-Star lncRNA or Stargazin in cortical 
neurons (Fig. 4.8, A, B). 
Figure 4.8: Anti-Star lncRNA knockdown (KD) in cortical neurons and the response of Stargazin. (A) 
Effective Anti-Star lncRNA knockdown was achieved consistently both in the basal state and under neuronal 
KCl stimulation (Control vs KD in the basal state, *p < .05, t = 4.443 df = 4; Control vs KD after 1 h KCl 
stimulation, *p <.05, t = 3.651 df = 4 and Control vs KD after 3 h KCl stimulation, **p <.01, t = 5.091 df = 
4). (B) Stargazin coding gene was dysregulated in Anti-Star lncRNA KD cells in a similar fashion (Control 
vs KD after 1 h KCl stimulation, *p < .05, t = 3.786 df = 4 and Control vs KD after 3 h KCl stimulation, **p 
< .01, t = 5.175 df = 4).  
Significant up-regulation of the non-coding and coding genes was observed upon KCl induction in 
hippocampal neurons and a significant knockdown of Anti-Star lncRNA was verified, but these 
were not followed by a significant change in the Stargazin mRNA level (Fig. 4.9, A, B).  
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Figure 4.9: Anti-Star lncRNA knockdown in hippocampal neurons and the Stargazin response. (A) 
Effective Anti-Star lncRNA knockdown (KD) was achieved consistently both in the basal state and under 
neuronal KCl stimulation (Control vs KD in the basal state, **p < .01, t =  6.018 df =  4; Control vs KD after 
1 h KCl stimulation, *p < .05, t =  4.193 df =  4 and Control vs KD after 3 h KCl stimulation, *p < .05, t =  
4.547 df = 4). (B) Stargazin coding gene was unresponsive to the KD of its antisense ncRNA within 
hippocampal cultures although a marked decrease was observed at 3 h post KCl induction.  
Although Anti-Star lncRNA was responsive to neural stimulation in the hippocampus, its targeted 
dysregulation had a significant effect only on the regulation of the Stargazin coding gene within the 
cortical fraction (Fig. 4.8, B). 
4.3.2 Anti-Star lncRNA modulates AMPAR-encoding genes. 
A central dogma of molecular biology is the fundamental principle that DNA transcription 
correlates with RNA translation into proteins, which assumes an association between mRNA 
expression and protein turnover. Research has proven the relationship between protein interactions 
and their respective levels of mRNA transcription, by which the expression of two genes correlates 
with the interaction of the proteins they encode and can alter the molecular pathways under their 
control (26-34). Following this basic principle of molecular biology, the level of AMPAR-encoding 
genes shown to be associated with Stargazin was further investigated. 
Stargazin protein has an important role in regulating AMPAR subunits at the post-synapse and has 
been found to modulate GluR1 (50, 51), GluR2 and GluR4 (52). At the level of mRNA 
transcription, Gria genes encode the four subunits of AMPARs. It was next investigated whether 
the dysregulation of Anti-Star lncRNA, which affects Stargazin expression in cortical neurons, has 
an underlying influence on Gria gene expression. Significant down-regulation of Gria2 was 
detected after knockdown of Anti-Star lncRNA at 3 h post KCl induction (Fig. 4.10, A), and 
significant down-regulation of Gria4 was detected at 1 h following KCl treatment (Fig. 4.10, B). 
The level of transcription of Gria1 remained unaltered (not shown).  
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Figure 4.10: Anti-Star lncRNA knockdown (KD) in cortical neurons and AMPAR response. (A) Gria2 
dysregulation was consistent with the Anti-Star lncRNA KD 3 h post KCl stimulation (Control vs KD after 3 
h of KCl induction, *p <.05, t = 3.272 df = 4). (B) Gria4 dysregulation also followed the Anti-Star lncRNA 
KD at 1 h post KCl stimulation (Control vs KD at 1 h KCl, **p < .01, t = 4.684 df = 4). 
 
Effective in vitro Anti-Star lncRNA knockdown therefore affected both the regulatory transcription 
of the Stargazin coding gene and the expression of selective AMPAR-encoding genes in the cortical 
fraction. Given that proteomic activity may correlate with the relative levels of gene expression, this 
result suggests that Anti-Star lncRNA is a likely candidate for use in deciphering the molecular 
pathways involved in synaptic plasticity.  
This lncRNA seems to shuttle between the nuclear compartment and the cytoplasm 1 h post 
stimulation, but it remains to be elucidated whether Anti-Star lncRNA performs different functions 
specific to its cellular enrichment. In such a scenario, it may be anticipated that the regulatory effect 
of the non-coding transcript over both GluR encoding genes may respond to different molecular 
pathways. 
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Chapter Conclusion and Perspectives 
This investigation has identified the tissue-specific differential regulation of an annotated but 
functionally unidentified lncRNA that is antisense to Stargazin. Anti-Star lncRNA exhibited a 
selective up-regulation upon fear training only within the adult hippocampus, a finding that was 
consistent with the observation in hippocampal stimulated neuronal cultures. Within the mPFC, this 
lncRNA was responsive in only context-exposed animals compared with the naïve animals. Anti-
Star lncRNA was unresponsive in cortical neuronal KCl stimulation, suggesting that it might have 
similar expression responses in mouse hippocampus at different developmental stages; whereas 
within the cortex, it may be developmentally regulated, as is the case for AMPAR units (53-56). 
mRNAs have a shorter half-life and are naturally less abundant than proteins (33). However, 
investigations have confirmed that there is a significant correlation between the patterns of gene 
expression and the associated rate of protein turnover, which affects protein–protein interactions 
and the relevant molecular pathways they coordinate (26-32). This justifies the relevance of 
investigating the underlying gene expression networks of interacting proteins, as is the case for 
Stargazin and AMPAR units. This section discusses the evidence that Anti-Star lncRNA may have 
a specific regulatory effect over both the Stargazin synaptic gene and the AMPAR-encoding genes 
Gria2 and 4. Such an effect was found only in stimulated cortical neurons, which suggests a 
potential role for Anti-Star lncRNA in regulating the expression of core genes involved in the 
molecular pathways associated with synaptic plasticity in the mouse. 
The evolution of gene expression within the human brain, particularly in the cortex region, has been 
suggested to contribute to our cognitive and behavioural diversification from the last common 
ancestor with chimpanzees (57, 58). However, identification of potential non-coding transcripts 
responsible for the rewiring of neural connections and plasticity in the non-primate brain remains to 
be proven. Thus far, Malat1 lncRNA is the only lncRNA that has been shown to cause reduction of 
synaptic density in the mouse hippocampus, by driving the expression of genes that code for post-
synaptic proteins, such as Neuroligin 1 and the Synaptic Cell Adhesion molecule 1 (59). 
This research has produced evidence of a role of a tissue-specific response of Anti-Star lncRNA in 
mammalian behaviour. The relevance of such finding is given by the added in cis influence of Anti-
Star lncRNA in a major synaptic plasticity-associated gene, Stargazin. Moreover, this research has 
also shown that Anti-Star lncRNA affects the genes coding for GluR 2 and 4. It remains to be 
confirmed whether the potential Anti-Star lncRNA in cis regulatory function over Stargazin 
interferes at the protein–protein level in the interaction between Stargazin and the AMPAR subunits 
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or whether there is an independent mechanism by which this lncRNA may exert direct control over 
the AMPAR subunit-encoding genes. 
Although Gria4 is widely distributed throughout the CNS, it is restricted in the hippocampus to the 
first week of postnatal development and is highly expressed in layers III and IV of the adult cerebral 
cortex (53, 54). Importantly, a recent investigation using Gria4-knockout mice has indicated its role 
in the acquisition of spatial reference memory and spatial working memory (60). Mutations induced 
by a retrotransposable element in Gria4 have been shown to be responsible for the absence seizures 
in particular mouse strains (61, 62). Because retrotransposable elements have no coding capability 
(63), this supports the relevance of Gria4 in cognitive and neurological disorders and provides 
evidence of its potential to associate with non-coding fractions of the genome. Gria2 expression 
reduces calcium influx at the post-synapse through the AMPAR channel complex, whereas its 
deletion has been shown to facilitate LTP in mice (64-66). This may indicate an important role for 
Anti-Star lncRNA in the regulation of such processes within the mouse brain. 
The results of the present investigation contribute to broaden the understanding of regulatory 
lncRNAs in the brain and their potential function in neural plasticity associated with complex 
mammalian behavioural responses. The effects of developmental stage, cell compartment and 
stimulus-specific response of this Anti-Star lncRNA suggest that further in vivo investigations are 
needed to determine the extent of its regulatory functions. 
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CHAPTER    5   
“The fact that introns and ncRNAs carry out the majority of the transcription of the genomes of 
humans and other complex organisms suggest that a second tier of genetic output and a network of 
parallel RNA-mediated interactions has evolved in these organisms, which may enable the 
integration and coordination of sophisticated suits of gene expression” 
John Mattick, 2003 
Parts of this chapter are included in the work published in Biological Psychiatry (1).  
5. In Vivo Characterization of Gomafu LncRNA and its Role 
in Adaptive Behaviour 
Introduction 
The role of lncRNA-directed epigenetic regulation in behavioural responses is still largely 
unexplored. In vivo manipulation of lncRNAs to interrogate phenotypic variations linked to 
molecular pathways in the mammalian brain is also lacking. However, recent investigations in 
model organisms, such as Drosophila, have shown the relevance of non-coding transcription in 
locomotion and sleep-associated behaviours (2, 3). For example, loss of the neural-specific 
cytoplasmic lncRNA YAR has been shown to interrupt sleep regulation and has been suggested as a 
factor that directs the molecular brain circuitry driving sleep behaviour in flies (2). Additionally, 
CRG lncRNA, which is antisense to Cask (Ca2+ calmodulin-dependent protein kinase) mRNA, 
positively regulates this coding gene in directing the locomotor activity and climbing ability of flies 
(3). These results provide significant new insights into the role of lncRNAs in neurological 
afflictions associated with movement and sleep deprivation disorders but, more importantly, they 
represent the first evidence of the influence of lncRNA on behaviour. 
In mice, loss of BC1 ncRNA has been linked to reduced exploration and increased anxiety in 
association with modulation of appetite behaviour (4). Although considered to be an lncRNA, the 
91-nucleotides long BC1 ncRNA actually falls within the arbitrary size category of sncRNAs. 
However, this is the only putative lncRNA that has been associated with alterations in behavioural 
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responses in the mouse. Further research has indicated that BC1 ncRNA may be a regulator of 
translational processes in dopamine 2 receptor protein (5) and a modulator of the involvement of 
GluRs in neuronal excitability and synaptic plasticity (6). 
Genome-wide screening has also uncovered non-coding transcription involved in human 
behavioural conditions. RNA-Seq and DNA methylation analysis of post mortem dorsolateral PFC 
brain tissue of people who have died by violent suicidal have indicated that the expression pattern 
of Marcks is dependent on in its antisense lncRNA, which has been identified as LOC285758 (7). 
This lncRNA was strongly linked to the manner of death and, although methylation in CpG islands 
present in the locus failed to correlate with Marcks gene expression, it was significantly associated 
with LOC285758 lncRNA transcription (7).      
Similarly, analysis of blood and saliva samples in genome-wide studies of women suffering PTSD 
identified novel non-protein-coding markers related to this condition (8). The researchers reported a 
novel LincRNA, AC068718, which contains a retrotransposable element and predicted its putative 
regulatory function in the stress-related conditions (8). The relationship between lncRNAs and their 
inserted repetitive elements in the brain has been confirmed, as in the case of a SINE element 
within a nuclear lncRNA antisense to the ubiquitin carboxyl-terminal hydrolase L1 (Uchl1) gene 
(9). Targeted deletion of the embedded SINE element within the antisense lncRNA indicated its 
functionality in governing Uchl1 protein translation (9), which is important in normal brain function 
and neurodegenerative disease (10). It is therefore possible that similar mechanisms may be 
involved in behavioural disorders related to the AC068718 retroelement containing lncRNA. 
Investigations of Affymetrix U133 array analysis of the nucleus accumbens from heroin abuse 
patients uncovered a set of lncRNAs, Malat1, Neat1, Meg3, Emx2os and Gomafu, that were 
significantly up-regulated (11). Malat1 lncRNA has been suggested to regulate synapse formation 
by regulating the coding genes involved in these neural processes (12). The recent suggestion that 
Gomafu lncRNA may be involved in the alternative splicing of Erbb4, the gene associated with 
LTP, suggests that Gomafu may also play a role in synaptic plasticity (13).  
Consistent with the literature, the RNA-Seq analysis following fear conditioning in mice detected 
the altered expression of major lncRNAs, between which Gomafu lncRNA was dysregulated in 
mice fear-specific response (chapter 3). Collectively, these studies and the results of the present 
investigation suggest a potential role for non-coding transcription in influencing behavioural 
responses in higher organisms. 
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5. Results 
5.1 Activity-dependent regulation of Gomafu lncRNA. 
The RNA-Seq and RNA-Capture assessments detected down-regulation of Gomafu lncRNA in the 
fear-conditioned compared with naïve mice (Fig. 5.1). 
Gomafu is a nuclear restricted non-coding transcript that shows specific expression within the 
nervous system during neurogenesis and differentiation of retinal developing cells and is associated 
with the pluripotency of stem cells (14-17). Recent findings have shown that Gomafu is down-
regulated in post mortem cortical tissue of schizophrenia patients and in primary cortical neurons 
after KCl stimulation (18). 
   
Figure 5.1: Nuclear RNA-Capture. Probes targeting the Gomafu locus produced significant reads in the 
fear-conditioned animals (FC) (naïve vs FC *p < .05, ANOVA, F(2,21) = 3.992).  
Transcriptome screening results were confirmed by in vivo qPCR analysis in which Gomafu was 
consistently down-regulated in fear-conditioned animals (Fig. 5.2, A). Gomafu expression was also 
investigated within the hippocampus of the same animals, but no significant modulation was found 
in this brain region (Fig. 5.2, B).  
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Figure 5.2: Tissue-specific expression of Gomafu. (A) Down-regulation of Gomafu lncRNA in trained 
animals (ANOVA, **p < .01, F (2, 20) = 5.953 naïve vs FC and Ctx vs FC) was detected within the mPFC. 
(B) There was no significant modulation of Gomafu within the hippocampal brain region.  
Considering that the animals trained under a fear-conditioning paradigm in this investigation were 
subjected to repetitive pairings of 6 CS–US with a high level of shock intensity (0.7 mA), it was 
questioned whether the Gomafu response resulted from pain sensitivity alone. The Gomafu in vivo 
dynamic was examined in an additional assay using the shock-only stimulus accompanied by a mild 
fear conditioning protocol (3 CS–US, 0.4 mA). This test produced no significant changes in 
Gomafu expression (Fig. 5.3), which suggested that the Gomafu response was related to fear 
conditioning because the shock-only treatment caused no change. This also suggested that a 
threshold level of aversive stimulation is needed to trigger Gomafu lncRNA modulation given that 
the expression did not differ under the 3 CS–US mild fear-conditioning paradigm (US of only 0.4 
mA) (Fig. 5.3).  
    
Figure 5.3: Responses to shock only and mild fear conditioning in mice. A milder paired 3 CS–UC fear-
conditioning treatment and foot-shock only stimulus (0.4 mA) had no significant effect on Gomafu 
expression (p > .05, n = 6 per group).  
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To investigate further the Gomafu lncRNA activity-dependent patterns of expression in the brain, 
membrane-induced depolarization was induced by KCl treatment of cortical neurons. Gomafu 
lncRNA was up-regulated within the first 30 min post stimulation and was followed by a significant 
decrease in expression from 1.5 h onwards (Fig. 5.4, A). This pattern was consistent with a previous 
finding indicating dysregulation of Gomafu upon neural stimulation (18).  
Although, traditionally, neural stimulation through membrane depolarization is accepted as a 
method for examining activity-dependent response of genes, the latest understanding of RNA 
stability suggests its potential use in determining a transcript’s levels of functionality. As described 
in chapter 4, the rate at which RNA is degraded and replenished through transcription is related to 
its function; RNAs with a shorter half-life are processed more rapidly and are therefore more 
responsive to environmental stimuli (19, 20). mRNAs associated with structural cellular functions, 
for example housekeeping genes, have greater stability, whereas activity-dependent mRNAs are 
naturally unstable (21-24). Consequently, transcripts that show a rapid reaction to external stimuli, 
such as early response genes, exhibit the fastest decay rate, usually <2 h (21).  
The stability of Gomafu lncRNA in neuronal culture, which may indicate its degree of regulation 
and function in the mouse brain, was examined. Cortical neurons were treated with actinomycin D 
to halt transcription at consecutive time points. This approach revealed a significant reduction in 
Gomafu expression 30 min post drug administration (Fig. 5.4, B), which indicated its fast decay rate 
with a half-life of 30 min.  
 
Figure 5.4: In vitro analysis of Gomafu functionality in neuronal cultures. (A) KCl treatment of cortical 
neurons followed by qPCR analysis showed increased Gomafu lncRNA within the initial 30 minutes (m) 
post KCl stimulus. Gomafu was then become significantly down-regulated from 1.5 h onwards (basal vs 3 h 
*p < .05, t = 3.203 df  = 4; 0.5h vs 1.5 h  *p < .05, t = 3.842 df = 4; .5 vs 3h **p < .01, t = 5.008 df = 4; 0.5 h 
vs 7h **p < .01, t = 4.693 df = 4 and basal vs 7 h *p < .05, t = 3.024 df = 4) (B) RNA Stability measurements 
of Gomafu demonstrated a significant decay rate after 30 min, which remained low until 6 h. (*) p < .05; 
(**) p < .005 and (***) p < .0005, t test, n = 4 per treatment. 
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Given the results of the in vivo and in vitro verification assays, it can be expected that a brain-
specific functional expression of Gomafu lncRNA occurs during behavioural stimulation. 
5.2 In vivo effect of Gomafu lncRNA knockdown in fear 
acquisition. 
To explore the role of Gomafu in behaviour, an ASO-mediated knockdown approach was 
implemented. Gomafu knockdown was initially optimized in vitro in cortical neurons using specific 
chimeric ASOs targeting the non-coding transcript.  
First, the efficiency of a specific ASO targeting Gomafu was tested by electroporation of the ASOs 
into cultured cortical neurons (Fig. 5.5, A). qPCR analysis showed significant down-regulation of 
Gomafu at 3 h post electroporation, but this effect was not verified at 6 h (Fig. 5.5, B, C). Gomafu 
ASO-induced knockdown of about 50% was achieved at a concentration of 1 µM 3 h post-
administration, while a lower dose of 200 nM did not produce significant knockdown (Fig. 5.5, D). 
                 
Figure 5.5: Gomafu knockdown in vitro. (A) Nuclear-specific transfection through electroporation of 
ASOs in cortical neurons with an estimated 50% efficiency. (B-C) Knockdown (KD) of Gomafu lncRNA 
was effective at 3 h post ASO electroporation (at 1 µM concentration) in vitro in cortical neuronal cultures, (t 
test, *p <.05, t = 3.461, df = 6); although the down-regulation of this lncRNA persisted, at 6 h it was not 
significant. For the in vitro assay, an empty vector (FG12) was electroporated as the control (Cntl) 
parameter. (D) KD by Gomafu ASO was assessed in cortical neurons at 1 µM concentration 3 h post 
transfection (***p <.001, t = 11.59 df = 4) relative to Cntl. 
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Infusing ASO within the mPFC using both a scrambled and a saline control assessed the level of 
Gomafu lncRNA knockdown in vivo. The down-regulation of Gomafu lncRNA was significant in 
both assays, although the scrambled test indicated a potential enhancement of this effect and it was 
therefore discarded for down-stream investigations (Fig. 5.6, A, B).  
 
Figure 5.6: Gomafu knockdown in vivo. (A,B) Knockdown (KD) of Gomafu lncRNA was significantly 
achieved at 3 h post ASO infusion in vivo within the mPFC compared with the saline control group (t test, *p 
< .05, t = 2.298, df = 11). Scrambled oligo administration enhanced the significant down-regulation of this 
lncRNA in vivo (t test, **p < .01, t = 3.669, df = 10). 
To test the relevance of knocking down Gomafu on fear learning, ASOs were infused in vivo into 
the mouse mPFC region (Fig. 5.7, A). Three hours post infusion; the mice were subjected to the 
mild fear conditioning protocol (3 CS–US; 0.4 mA US) to assess the effect of knocking down 
Gomafu on fear learning and memory. A control group was also infused at the same time with 
saline only. During training with the mild delay fear-conditioning protocol, the knockdown group 
appeared to show a higher tendency for freezing behaviour (Fig. 5.7, B). However, repeat of the 
fear recall test 24 h later showed no differences in the freezing responses associated with Gomafu 
ASO-induced knockdown treatment compared with the control (Fig. 5.7, C).  
The recall test results suggested that the acquisition in Gomafu knockdown mice was not associated 
with learning processes since the treated animals had no significant memory of the previous 
conditioning episode. Psychological stress supports recall event failure, which provides evidence 
that the stress-induced anxiety response underlies the increase in fear acquisition (25-28). Previous 
investigations strongly indicate that stress increases fear acquisition but interferes with conditioning 
and extinction recall (27, 29-31). Parallel research in humans has shown that lack of memory or 
impaired verbal recall of previous exposure to fear and trauma cannot exclude the effects of the 
initial experience and that they are associated with posttraumatic stress disorders and anxiety (32). 
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Figure 5.7: Knockdown of Gomafu lncRNA in the PLPFC increased freezing behaviour during 
acquisition but showed no effect on long-term fear memory. (A) Coronal section image of mouse infused 
with 6-Fam fluorescein-labelled Gomafu ASO (600 nM) co-stained with DAPI (blue). (B) Fear acquisition 
profile of animals trained with 3 CS–US, 3 h post infusion (CS3: *p < .03, t = 2.672, df = 12). (C) Fear 
memory recall assessed 24 h later showed similar freezing levels between control and Gomafu KD animals. 
These results prompted us to investigate whether manipulation of Gomafu in vivo influenced the 
stress response more than did fear learning memory.  
5.3 In vivo effect of Gomafu lncRNA knockdown on anxiety. 
The potential involvement of Gomafu in anxiety-related behaviour was investigated with a second 
in vivo knockdown experiment using the same ASO treatment. In this experiment, mice were 
exposed to repetitive mild stressors associated with novel environments by being placed in an 
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activity monitor (AM) chamber, an Elevated Plus Maze (EPM), and again into the AM for 10 min 
each, with interval rest of 30 min. The repetition of tasks was expected to increase the stress level in 
mice.  
The EPM trial induced no significant differences in the activity in Gomafu ASO-induced 
knockdown mice. By contrast, the second placement in the AM showed a strong preference for 
Gomafu ASO-induced knockdown mice to remain in the periphery of the chamber and to avoid the 
central area (Fig. 5.8, A, B).  
       
Figure 5.8: Activity monitor task representative profile of Gomafu knockdown. Compared with control 
animals (A), Gomafu KD mice (B) avoided the centre in the activity monitor task.  
The AM records showed that Gomafu ASO-induced knockdown mice spent significantly less time 
in the centre of the chamber (Fig. 5.9, A). They were also significantly more active and travelled 
longer distances along the edges and spent more time in self-grooming compared with the control 
animals (Fig. 5.9, B, C and D). Such characteristics correlate strongly with the development of an 
anxiety state in mice (33).  
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Figure 5.9: Gomafu lncRNA knockdown induces anxiety-like behaviour. (A) The mild anxiety test in 
Gomafu KD animals in the activity monitoring chamber showing significantly less time spent in the centre of 
the platform (**p < .01, t = 3.922, df = 16). (B, C, D) Gomafu KD mice also exhibited a significant tendency 
to travel longer distances outside the centre and increased ambulatory and stereotypic time compared with 
control animals (*p < .01, t = 2.523, df = 16; *p < .01, t = 2.158, df = 16 and *p < .01, Mann–Witney U 16, 
respectively). 
These behavioural outcomes suggested that there is a requirement for a precise level of Gomafu 
lncRNA transcription to halt anxiety under stressful conditions in mice.  
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Chapter Conclusion and Perspectives 
Gomafu lncRNA (also known as Miat and Rncr2) is a brain-enriched lncRNA located in nuclear 
neural bodies within the cell (14, 15). This lncRNA is involved in neurogenesis and oligodendrocyte 
linage specification (34) and can interact with transcription factors such as Oct4 in controlling 
pluripotency (35) and with splicing agents linked to neuropsychiatric disorders (18, 36). Gomafu 
displays high levels of sequence conservation and was first identified in relation to myocardial 
infarction and retinal cell fate specification (16, 17, 37). Recent investigations have also placed 
Gomafu as a regulator of microvascular dysfunction and as a modulator of migration and survival of 
endothelial cells (38). Although this is one of the most frequently investigated lncRNAs in 
association with cell fate regulation and brain function, its role in behaviour remained unexplored. 
Using Pavlovian fear conditioning and anxiety tests, this investigation has established the relevance 
of non-coding transcription in mammalian anxiety that may derive from traumatic events. This 
research demonstrated that in vivo Gomafu knockdown within the mPFC induces fear conditioning 
and anxiety in mammals. Given that anxiety disorders are key factors in the development of 
schizophrenia (39-41), the results of this research are consistent with previous research showing 
Gomafu lncRNA dysregulation in post mortem PFC from schizophrenia patients (18).  
The observation in the present investigation that mice subjected to shock-only testing showed no 
significant changes in Gomafu expression suggests that this lncRNA has no involvement in the 
sensory pain system response. Mice trained with a mild fear conditioning protocol also showed no 
change in Gomafu level, which suggests that a threshold threat intensity is needed to induce this 
lncRNA modulation. 
Fear is an evolutionarily programed response required for self-preservation and survival, but it can 
also induce pathological behaviours that are fuelled by the persistent memory of adverse events (42). 
The PFC is a major site that mediates stress-associated disorders and can elicit an anxiety response 
in the fear-conditioning paradigm (43-45). Fear conditioning has been demonstrated to induce 
greater anxiety-like behaviours in high fear learning mouse lines, which establishes a direct genetic 
link between fear conditioning and anxiety (46). The PFC is also vulnerable to dendritic spine loss 
as a result of stress and as a pre-stage for the development of schizophrenia (47) and has been 
implicated as a neurological site for stress and anxiety behavioural responses following fear-related 
learning (44, 45, 48). Predictability, uncontrollability and uncertainty are crucial in the development 
of fear and anxiety. Although there is a wide range of afflictions related to anxiety, there is a 
tendency for anxious individuals to overestimate a threat outcome, and stimuli such as fear 
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conditioning can be perceived as a threat (49). It has also been shown that delay fear conditioning 
requires a learning process input with no conscious awareness and does not involve declarative 
memory mechanisms (50, 51). The results presented here are consistent with the idea of placing 
Gomafu lncRNA as a new target in investigations related to the development of anxiety afflictions 
that is possibly related to PTSD and the neurobiology of non-declarative memory circuitries.  
Gomafu has been linked to eye movement abnormalities of schizophrenia patients and its 
dysregulation in the splicing modulation of genes related to this condition (18, 52). Concordantly, 
Gomafu resides in a conserved locus that has been shown repeatedly to be related to schizophrenia 
and generalized anxiety disorders (52-55).  
Previous research (18) and the present investigation indicate that down-regulation of Gomafu 
lncRNA may relieve the molecular mechanisms that have a role in proper brain function. 
Consequently, precise levels of Gomafu lncRNA transcription may be needed to retain the neural 
circuitries involved in the development of anxiety disorders.  
The results of this chapter show a potential role for non-coding transcription in anxiety-associated 
mice response, while further investigations are needed to define the extent of lncRNA regulatory 
function in other behaviours related to neurological disorders.  
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CHAPTER 6 
“It will take years, perhaps decades, to construct a detailed theory that explains how DNA, RNA 
and the epigenetic machinery all fit into an interlocking, self-regulating system. But there is no 
longer any doubt that a new theory is needed to replace the central dogma that has been the 
foundation of molecular genetics and biotechnology since the 1950s” 
Gibbs, 2003 
Parts of this chapter are included in the work published in Biological Psychiatry (1). 
6. In cis Regulation of Gomafu LncRNA in Anxiety-like 
Behaviour 
Introduction 
Research indicates that eukaryote genomic expression can be overridden by transgenerational 
epigenetic mechanisms of chromatin modifiers such as the Polycomb group proteins (PcGs) and 
trithorax group (TrxG) of proteins (2). Acting on histone tails, these highly conserved proteins are 
responsible for repression and activation of gene expression (3, 4). Although their regulatory 
mechanisms have not been studied extensively, it is becoming more evident that these protein 
complexes may be closely associated with ncRNAs (5, 6). While the search for models of their 
interactions with ncRNAs continues, a recent investigation has shown that PcGs bind RNA 
molecules in vitro, and that the PcGs are able to bind canonical and non-canonical RNA targets (7). 
However, the work of these researchers could not prove an RNA binding specificity for the PcGs 
complexes in vivo (7).  
There are two PcGs: Polycomb group protein repressive complex 2 (PRC2) and Polycomb group 
protein repressive complex 1 (PRC1). PRC2 comprises histone methyltransferase machinery 
conferred by several proteins, among which Ezh2, assisted by Eed and Suz12, performs the 
catalytic activity of the complex (8). This group silences target genes by placing a di- or 
trimethylation mark on histone 3 lysine 27, which renders a closed chromatin state that is unable to 
be transcribed (9). The ability of long ncRNAs to functionally interact with and direct the PRC2 has 
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been suggested (10-14) and identified in cancer and developmental studies (15, 16). Research has 
also shown that the activity of PRC2 is tightly regulated to control the genes involved in 
development and the cell cycle (17-19). Within the brain, PRC2 plays prominent roles in 
glioblastoma growth and heterogeneity (20, 21), and progenitor cell differentiation (22-24). Recent 
investigations have shown that PRC2 interacts with an lncRNA that is antisense to Bdnf and suggest 
a coordinated function in regulating Bdnf transcription (25). Given the tissue-specific expression 
patterns of lncRNAs, the relevance of this finding are debatable because the experimental evidence 
has been shown in the human embryonic kidney (HEK293) cell line.  
Although a relationship between PRC1 and non-coding transcripts has also been proposed (26), 
virtually nothing is known about these interactions in the brain. Bmi1 and Ring1b are the E3 ligase 
catalytic units of the PRC1 complex and work together in driving the monoubiquitination of lysine 
119 of histone protein H2A to induce the silencing of targeted genes (27-30). Over-expression of 
Bmi1 has been shown to maintain pluripotency and to enhance the self-renewal of neural stem cells 
through regulation of cell cycle inhibitors (31-33). The scientific literature has shown that Bmi1 is 
the driver of the so-called “guardian of the genome, p53” and is a regulator of the brain response to 
oxidative stress (34-37). Bmi1 expression in cortical neurons results in suppression of reactive 
oxygen species (ROS) and consequent prevention of cell death induced by DNA damage (34). 
Recent investigations have proven that heterozygous Bmi1-knockout mice exhibit an aging 
phenotype within the adult brain (38). Its antioxidant protective attributes place Bmi1 and PRC1 
activity at the centre of aging processes in the brain and the development of neurodegenerative 
diseases. 
Gomafu lncRNA shows affinity for the UACUAAC sequence of Sf1, which is involved in 
regulating the kinetics of alternative splicing (39). Barry et al. (2013) have demonstrated that, by 
interacting with Qki and Srsf1, Gomafu plays an in trans role by driving the alternative splicing of 
Disc1 and Erb4, which are schizophrenia-associated genes. Moreover, the latest investigation has 
suggested that Gomafu can sequester splicing factors, such as Celf3 protein, into nuclear 
compartments, but this finding was limited to an in vitro neuroblastoma (N2A) system (40). 
Gomafu can also interact with other transcription factors such as Oct4 in controlling pluripotency 
(41) and has been shown to be an epigenetic driver of microvascular dysfunction by working as a 
decoy for miRNAs involved in this condition (42).  
These investigations confirm the relevance of Gomafu lncRNA in eukaryote transcriptional events. 
However, its in cis regulatory pathways have not been disclosed. The present chapter uncovered a 
potential interaction between Gomafu lncRNA and PRC1 complex, through Bmi1 binding. 
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Additionally, the combined activity of these molecules was shown to modulate the expression of 
genes associated with the development of anxiety-related behaviours. 
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6. Results  
6.1 Identification of potential target genes. 
Following the studies of the in vivo function of Gomafu lncRNA in the development of anxiety in 
mice described in the earlier chapters, we examined the potential molecular mechanisms involved 
in the phenotype. 
The nuclear-enriched RNA-Seq analysis detected genes located in chromosome 5 and adjacent to 
Gomafu (1). To identify the coding genes that may be targeted by Gomafu in cis, the expression 
levels of its neighbouring transcripts were analysed in Gomafu ASO induced-knockdown. No other 
genes, except for Crybb1 showed expression changes as a consequence of the in vitro Gomafu 
knockdown (Fig. 6.1).  
The genes encoding the crystallin family of proteins are contiguous to Gomafu, with Crybb1 
mRNA transcribed from the opposite strand to Gomafu lncRNA. Crybb1 has recently been 
associated with risk of neurodevelopmental psychiatric disorders such as schizophrenia and autism 
(43) and, together with Gomafu, resides in the conserved locus that is strongly linked to 
schizophrenia and anxiety disorders (44-48). 
          
Figure 6.1: In vitro Crybb1 up-regulation upon Gomafu knockdown. qPCR analysis of genes adjacent to 
the Gomafu locus on chromosome 5 in neurons exposed to a 200 nM concentration of Gomafu ASO. 
Consequently, a non-significant Crybb1 up-regulation was detected.   
The nuclear RNA-Seq screening indicated a similar pattern of Crybb1 up-regulation in the mPFC of 
fear-conditioned mice as opposed to the decreased expression of Gomafu (1). qPCR analysis 
showed that fear-conditioned animals consistently exhibited a significant up-regulation of Crybb1 
(Fig. 6.2, A). A dose-dependent effect of Gomafu knockdown on Crybb1 using a higher ASO 
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concentration (1 µM) was further confirmed (Fig. 6.2, B). These results indicated an inverse 
relationship between down-regulation of Gomafu and consequent up-regulation of Crybb1.   
 
Figure 6.2: Levels of Crybb1 expression. (A) In vivo qPCR analysis of Crybb1 in fear-conditioned (FC) and 
context (Ctx) mice showed a significant up-regulation upon fear stimulation relative to naïve animals 
(ANOVA *p < .05, Kruskal–Wallis statistic = 6.455, n = 8 per group). (B) Replication of the Gomafu 
knockdown assay at a higher oligo concentration of 1 µM in cortical neurons confirmed a dose-dependent 
effect on Crybb1 expression (***p < -.001, t = 11.59, df = 4).   
6.2 PRC1 interaction with Gomafu lncRNA regulates the Crybb1 
promoter. 
The potential antisense regulation of Gomafu lncRNA over Crybb1 in an activity-dependent 
manner provides further evidence of the molecular methods to explore the mechanisms used by 
Gomafu in driving adaptive responses to stress.  
As discussed, many lncRNAs have been shown to interact with PcGs (11, 12, 25). Considering its 
role in oxidative stress within the brain and its association with neurodegenerative disorders (33, 36, 
49, 50), Bmi1 represented an interesting candidate among the various proteins integrating the PcGs. 
Independent research has predicted a Bmi1-binding motif sequence (51, 52). This binding motif 
was present in both Gomafu and Crybb1 transcripts (Fig. 6.3). A moderate interaction between 
Gomafu and Bmi1 was also reported in the supplemental material of a recent scientific publication 
(47). 
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Figure 6.3: Putative Bmi1-binding sites in both Gomafu lncRNA and Crybb1 promoter. (A) Schematic 
representation of Gomafu putative interacting regions 1 and 2 with Bmi1. (B) Previously identified binding 
motif for this protein (51) present in the Crybb1 promoter. 
ChIP and RIP techniques were implemented to identify a potential common interactor between 
Crybb1 and Gomafu. These were used to investigate RNA- and DNA-binding proteins in the PRC 
complexes such as Suz12, Ring1b and Bmi1 (53-55).  
RIP analysis using Bmi1 antibody revealed an enriched interaction between Gomafu lncRNA in the 
naive mouse mPFC but not with U6 small nuclear RNA (Fig. 6.4, A). By contrast, experiments 
using Ring1b and Suz12 antibodies did not result in a significant enrichment of Gomafu ncRNA, 
suggesting a degree of specificity towards Bmi1 (Fig. 6.4, B). The hypothesis that PRC1 proteins 
also interact with the Crybb1 promoter in an activity-dependent manner was then investigated. An 
in vitro ChIP assay showed activity-dependent binding of Bmi1 and Ring1b followed by the 
ubiquitin histone 2A k119 repressive mark within the Crybb1 promoter, which were released upon 
KCl stimulation (Fig. 6.4, C).  
Both Bmi1 and Ring1b are the E3 ligase catalytic units of the PRC1 complex that represses the 
expression of targeted genes (27-29). Although binding of Suz12, a member of PRC2, was 
observed, this interaction was unresponsive to stimulation (Fig. 6.4, C), which confirmed the 
specific activity-dependent recruitment of PRC1 to the Crybb1 promoter. Studies have shown that 
Bmi1 is a neuroprotective gene in the aging brain, where it promotes DNA repair and regulates the 
p53 oxidative pathway (34, 36, 37). Additionally, dysregulation of Bmi1 and Bmi1 in knockout 
mice has been shown to induce brain oxidative stress, which is considered a molecular pre-stage of 
many psychiatric disorders (36, 38, 56). These precedents justified the investigation of a potential 
connection between Bmi1 and Gomafu lncRNA regulatory function in neural activity.  
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A ChIP analysis followed by in vitro knockdown of Gomafu in cortical neurons was performed to 
test whether Gomafu is required for Bmi1 interaction with Crybb1. A specific decrease in Bmi1 
protein binding to the Crybb1 promoter was detected at about 3 h after knockdown of Gomafu, 
whereas this was not observed in the negative control region containing the Suz12-binding site (Fig. 
6.4, D).  
 
Figure 6.4: Interaction of Gomafu with PRC1 in the Crybb1 promoter region, which led to 
transcriptional repression. (A) In vivo RIP assay in mPFC tissue revealed a significant binding of Bmi1 to 
Gomafu lncRNA relative to IgG in exonic region 2 (Reg 2, *p <.05, t = 2.916, df = 4, n = 3 per group) and 
marked binding in the consecutive primer for exonic region 1 (Reg 1, p =.07, t = 2.434 df = 4, n = 3 per 
group), as opposed to the negative locus on U6 RNA. (B) RIP analysis of the same regions containing 
Ring1b- and Suz12-binding sites showed no significant enrichment compared with the negative control, U6 
(n = 3 per group). (C) In vitro ChIP analysis under the basal condition and KCl stimulation showed 
significant dysregulation of Bmi1 at the Crybb1 promoter region, about 1.76 kb from the TSS (region 1) in 
KCl-treated cells (***p < .001, t = 6.369, df = 6, n = 4 per group) which was followed by down-regulation of 
the Ring1b and Ubh2ak119 repressive marks (**p < .01, t =  3.511, df = 4, n = 3 per group and *p < .05, t = 
5.426, df = 4, n = 3 per group, respectively). No significant changes were seen in the same region for Suz12. 
(D) In vitro ChIP analysis revealed a significant decrease in Bmi1 binding at 1.76 kb from the Crybb1 TSS 
within region 1 only, using two consecutive primers, Reg1 and Reg2, following ASO-mediated Gomafu KD 
in cortical neurons (*p < .05, t = 4.427 df = 4, n = 3 per group and at 1.35 kb from the TSS p = 0.118, t = 
1.986 df = 4, n = 3 per group), whereas no changes were observed in the negative control containing the 
Suz12-binding site.  
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It was then hypothesized that Bmi1 regulates the Crybb1 promoter through Gomafu and that this 
protein–DNA–RNA interaction is modulated in the fear-associated stress-induced condition. ChIP 
analysis was used in mPFC obtained from mice subjected to the fear-conditioning paradigm. This 
assay showed a marked decrease in Bmi1 binding on the Crybb1 promoter of fear-conditioned 
animals relative to the naïve group (Fig. 6.5, A).  
The results were consistent with the expectation that Bmi1 functions as a repressor (27, 28, 57) of 
the Crybb1 promoter in the basal state, Bmi1 is then released upon stimulation and allows Crybb1 to 
increase transcription during fear acquisition (Fig. 5.2, A). Such interaction was found to be negative 
for a secondary region within the Crybb1 promoter, which was not predicted to bind to Bmi1 (Fig. 
6.5, B).  
 
Figure 6.5. In vivo interaction of Gomafu with the PRC1 complex in the Crybb1 promoter. (A) In vivo 
ChIP analysis of mPFC tissue from trained mice showed Bmi1 binding at about 1.76 kb from the Crybb1 
TSS and that this binding decreased markedly after fear conditioning (ANOVA, p = .116, F (2,6) = 3.143, n 
= 3 per group; t test between naïve and fear conditioned mice, p =.064). (B) ChIP analysis of a negative 
region about 1 kb from the Crybb1 TSS did not show similar regulation by Bmi1 of Crybb1 (ANOVA, p = 
.755, F (2, 6) = 0.2943, n = 3 per group). 
6.3 In vivo function of Crybb1 in anxiety-like behaviour. 
Crystallin clusters are molecular chaperone proteins belonging to the heat shock family of genes, 
which are known to play a major role in maintaining cellular homeostasis in response to stress (58-
60). The alpha crystallin group of small HSPs has been widely investigated and is linked to cellular 
stress in hippocampal neurons (61, 62), brain dysfunction (63-67) and neuronal differentiation (68). 
The closely related beta crystallin family, in the adult brain remains largely unexplored. Heat shock 
chaperon proteins have a general evolutionary adaptive function associated with the cellular stress 
response, also present in the brain (60, 61, 69-72). These molecular chaperons are essential in 
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protecting the genome from the aggregation of misfolded proteins, which have particular relevance 
in the development of neurodegenerative diseases, such as AD and HD (73-77).  
Although Crybb1 expression has been associated with the occurrence of cataracts in the eye (58, 78, 
79) and oligodendrocyte development (80), its specific function in the adult brain has not been 
determined. 
To test the hypothesis that fear-related anxiety in mice is linked to Crybb1 expression, the 
behavioural effect of in vivo Crybb1 knockdown (Crybb1) was investigated. 
First, the Crybb1 gene knockdown efficiency was tested in vitro using lentiviral packaged shRNAs 
in cortical neurons (Fig. 6.6, A, B). 
 
Figure 6.6: In vitro Crybb1 knockdown. (A) Experiments using different shRNAs targeting Crybb1 
mRNA, packaged in-house using a third-generation lentiviral packaging system produced a significant effect 
for shRNA number 4 (t test, shRNA4 relative to basal, *p < .05, t = 3.413, df = 4). (B) Bar graph 
representation of the Crybb1 shRNA effect compared with that in control (Cntl) neurons (t test, shRNA4 
relative to basal, *p < .05, t = 3.413, df = 4). 
Consistent with the trend of Crybb1 expression after Gomafu knockdown in vitro and Gomafu 
knockdown in vivo, which induced anxiety (chapter 5), knockdown of Crybb1 resulted in an 
opposite pattern: a decrease in mice anxiety-like behaviours. In this experiment, the Crybb1 
knockdown animals spent more time in the centre of the AM chamber, were less active, and 
travelled shorter distances through the duration of the test (Fig. 6.7, A-B).  
In the pre-training test used to induce stress in these mice, Crybb1 knockdown mice spent 
significantly more time in the open arms of the EPM, which also indicated that the decreased 
expression of Crybb1 led to a reduction in anxiety (Fig. 6.7, C).  
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Together with the up-regulation of Crybb1 in fear-conditioned mice, these results confirmed that 
Crybb1-directed knockdown within the mPFC has a role in fear-induced stress-associated behaviour 
in mice.  
 
 
Figure 6.7: Knockdown of Crybb1 mRNA expression decreases anxiety in mice. (A,B) The anxiety test 
demonstrated that Crybb1 knockdown (KD) animals (Crybb1-KD) spent significantly more time within the 
centre of the AM chamber (*p < .05, t =  2.559, df = 12, Cntl n = 6, Crybb1-KD n = 8) while travelling 
significantly shorter distances (**p < .01, t =  3.263 df = 12, Control (Cntl) n = 6, Crybb1-KD n = 8). (C) 
Crybb1 knockdown mice also spent significantly more time within the open arms of the EPM (*p < .05, t =  
2.269 df = 12, control (Cntl) n = 6, Crybb1-KD n = 8), an effect that was more pronounced within the first 5 
min of this trial (**p < .01, t =  3.634 df = 12, Cntl n = 6, Crybb1-KD n = 8).  
This investigation thereafter proposes that, in the basal state, Gomafu can interact with major 
chromatin modifiers, such as the PRC1 through Bmi1, to halt in cis transcription of heat shock 
chaperone proteins such as Crybb1. Upon stressful stimulation, dysregulation of Gomafu retrieves 
the Bmi1 ubiquitin repressive mark from Crybb1, allowing its further up-regulation (Fig. 6.8). 
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Figure 6.8: Working model depicting activity-dependent regulation of Gomafu lncRNA in the mouse 
prefrontal cortex. Under the basal condition, Gomafu lncRNA associates with the PRC1 (Bmi1) complex to 
mediate the in cis repression of Crybb1, potentially through the histone ubiquitination mark. Upon 
environmental stimulation, such as that triggered by the fear-conditioning paradigm, Gomafu lncRNA is 
significantly down-regulated, which rapidly releases Bmi1 from the Crybb1 promoter and allows its 
transcription, eventually resulting in the up-regulation of Crybb1.  
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Chapter Conclusion and Perspectives 
PgCs and lncRNAs represent two molecular mechanisms that may have evolved to ensure a rapid 
systemic response to external cues. lncRNAs have been proven to interact with the main regulators 
of chromatin remodelling such as PRC2 (11, 12, 81-83), PRC1 (26), p53 (84, 85) and Rest (52, 86). 
However, the function of these interactions within the adult brain has not been further explored.  
The ability of Gomafu to interact with transcription factors (41) and with splicing agents associated 
with neuropsychiatric disorders (47) shows the in trans gene regulatory function of Gomafu, 
whereas the potential mechanisms for its in cis function remain elusive. It is now accepted that 
lncRNAs may show both types of gene regulatory functions, as in the case of Malat1 lncRNA (87). 
Malat1 can function in trans by interacting with hPSF proteins (88) and serine/arginine splicing 
factors to regulate proto-oncogene transcription and cell cycle fate, respectively (89, 90). In 
addition, Malat1 knockdown also induces mRNA up-regulation of genes adjacent to this lncRNA 
(91).  
The results of this investigation suggest that Gomafu plays a significant role in driving the 
expression of proximal coding genes upon stressful stimulation through the recruitment of a PRC1 
component, Bmi1. Bmi1 has been shown to be a major regulator of the cellular stress response (50, 
92-94) and may be involved in actions to sustain stem cell self-renewal in both the peripheral and 
central nervous systems (31, 32, 49, 95, 96). Bmi1 also plays a key role in the defensive response to 
oxidative stress by supporting neuronal survival through repression of p53 (34, 36). In the basal 
state, Gomafu may tether the PRC complex to the transcription site of genes associated with the 
adaptive responses to fear and anxiety. Dysregulation of Gomafu, therefore, releases the histone 
repressive signature of PRC1, which allows the expression of coding genes and can induce neural 
activation and abnormal behaviour in mice. 
This research using Crybb1 knockdown also shows a newly described role of this gene in the mouse 
anxiety response. Crybb1 becomes up-regulated in vivo after fear conditioning at the time that 
Gomafu and its associated repressive activity becomes down-regulated. Crybb1 has already been 
identified in investigations associated with neurodevelopmental disorders such as schizophrenia and 
autism (43). Consistent with previous findings (47) and the present research, Gomafu and Crybb1 
are transcribed within the human locus 22q12.1, which is homologous to mouse chromosome 5 and 
which is linked to schizophrenia and generalized anxiety disorders (44-46, 48). Concordantly, 
Crybb1 belongs to the heat shock family, whose members are involved in stress tolerance pathways 
(69, 97). However, a sustained level of Crybb1 transcription may contribute to dysfunctional 
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behaviours. The regulatory mechanisms that modulate Gomafu expression rest unchartered. 
Nonetheless, previous research has indicated that decapping and degradation of lncRNAs by Dpc2 
influenced chromatin state and the regulation of proximal inducible genes (98). Further, recent 
investigations have detected significant levels of RNA methylation, including Gomafu, in fear 
conditioning associated assays of mice mPFC, which had a role in RNA stability of associated fear 
memory (99). 
Earlier investigations (47) and the results of this chapter indicate that a proper level of transcription 
of Gomafu lncRNA may be needed to maintaining the molecular mechanisms involved in the 
development of anxiety disorders and psychiatric illness.  
This suggests that Gomafu lncRNA is a possible epigenetic driver of complex behaviour and is 
associated with stress development processes. It also shows the need for further investigation into 
non-coding transcription such as the molecular links between environmental stimuli and 
development of psychiatric disorders. Given the predicted enrichment of genes linked to metabolic 
pathways, such as oxidative stress (chapter 3), it would be interesting to explore whether Gomafu 
has a more systemic role in the brain oxidative stress pathway through its interaction with Bmi1 and 
other chaperon proteins.  
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Long Noncoding RNA-Directed Epigenetic
Regulation of Gene Expression Is Associated
with Anxiety-like Behavior in Mice
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ABSTRACT
BACKGROUND: RNA-directed regulation of epigenetic processes has recently emerged as an important feature of
mammalian differentiation and development. Perturbation of this regulatory system in the brain may contribute to the
development of neuropsychiatric disorders.
METHODS: RNA sequencing was used to identify changes in the experience-dependent expression of long
noncoding RNAs (lncRNAs) within the medial prefrontal cortex of adult mice. Transcripts were validated by real-time
quantitative polymerase chain reaction and a candidate lncRNA, Gomafu, was selected for further investigation. The
functional role of this schizophrenia-related lncRNA was explored in vivo by antisense oligonucleotide-mediated
gene knockdown in the medial prefrontal cortex, followed by behavioral training and assessment of fear-related
anxiety. Long noncoding RNA-directed epigenetic regulation of gene expression was investigated by chromatin and
RNA immunoprecipitation assays.
RESULTS: RNA sequencing analysis revealed changes in the expression of a significant number of genes related to
neural plasticity and stress, as well as the dynamic regulation of lncRNAs. In particular, we detected a significant
downregulation of Gomafu lncRNA. Our results revealed that Gomafu plays a role in mediating anxiety-like behavior
and suggest that this may occur through an interaction with a key member of the polycomb repressive complex 1,
BMI1, which regulates the expression of the schizophrenia-related gene beta crystallin (Crybb1). We also
demonstrated a novel role for Crybb1 in mediating fear-induced anxiety-like behavior.
CONCLUSIONS: Experience-dependent expression of lncRNAs plays an important role in the epigenetic regulation
of adaptive behavior, and the perturbation of Gomafu may be related to anxiety and the development of
neuropsychiatric disorders.
Keywords: Anxiety, Behavior, Crybb1, Epigenetics, Gomafu, Noncoding RNA
http://dx.doi.org/10.1016/j.biopsych.2015.02.004
Once considered vestiges of our evolutionary history associ-
ated with junk DNA, noncoding RNAs (ncRNAs) have emerged
as important regulators of epigenetic processes, transcrip-
tional activation, and posttranscriptional gene silencing (1–5).
Advances in RNA sequencing (RNA-seq) technology have
resulted in the discovery of a large number of long ncRNAs
(lncRNAs) (6–11), many of which show features of functionality
(12–14). There are at least 50,000 genes specifying lncRNAs
scattered throughout the human genome, with many
expressed in a highly cell type-specific and developmental
stage-specific manner (15–20). Moreover, a significant number
of brain-enriched or brain-specific lncRNAs are found adjacent
to genes encoding transcriptional regulators and key drivers of
neural development (21), including those involved in the
regulation of stem cell pluripotency, neuronal differentiation,
and synaptogenesis (16,18,22–24).
In agreement with these findings, lncRNAs have been
implicated in neurodevelopmental disorders such as Rett
syndrome (25), autism (26,27), schizophrenia (SZ) (28,29),
and Fragile X syndrome (30). Screening of lncRNA activity
has also shown links between lncRNA expression and drug
abuse (31,32), suicidal behavior (33), and potentially anxiety
disorders. For instance, it has been reported that experimental
knockdown (KD) BC1 leads to increased anxiety-like behavior
in mice (34,35).
Recent evidence indicates that the expression of lncRNAs
can be altered in an activity-dependent manner (29,36). Long
ncRNAs have been found to be co-expressed with activity-
dependent genes such as C-fos, Arc, Nr4a2, and Bdnf,
suggesting a coordinated network of coding and noncoding
gene expression associated with neuronal plasticity (29,36,37).
Despite these correlative links, little is known about the
expression and function of brain lncRNAs, nor the mecha-
nisms by which these transcripts influence protein-coding
gene expression within the context of neuropsychiatric dis-
ease. Here, we combined high-throughput RNA-seq with
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molecular and behavioral approaches to identify changes in
the expression of lncRNAs. We also determined whether these
changes contribute to the epigenetic regulation of gene
expression underlying the development of anxiety disorders.
METHODS AND MATERIALS
Animals
Naïve 9-week-old C57BL/6 male mice were housed individu-
ally in sections of divided cages, with free access to food and
water under a 12-hour light/dark cycle in a humidity- and
temperature-controlled vivarium. Behavioral tests were con-
ducted during the light cycle, and all procedures were
performed with approval from the Animal Ethics Committee
of The University of Queensland.
Fear Conditioning
For tissue collection and sequencing library preparation, three
groups of mice (n = 8 per group) were used: a naïve, age-
matched, home-cage control group; a fear-conditioned group
that received six pairings of a 2-minute 80 dB white noise
conditioned stimulus (CS) that co-terminated with a 1-second
foot-shock at .7 mA as the unconditioned stimulus (US) (intertrial
interval of 2 minutes); and a context only group that was
exposed to the CS but not the US. Animals were sacrificed 90
minutes posttraining, followed by medial prefrontal cortex
(mPFC) dissection and nuclear-enriched RNA extraction. To
determine the effect of Gomafu knockdown on fear conditioning,
animals were infused with 600 nmol/L of a Gomafu antisense
oligonucleotide (ASO), directly into the mPFC, whereas the
control group received an infusion of a scrambled control. Three
hours after infusion, mice were trained using a mild fear
acquisition protocol to avoid a nonspecific response (three
CS-US pairing with foot-shocks of .4 mA), followed by a two-
CS test for memory recall in the same context 24 hours later.
Measures of Anxiety
Anxiety tests for the knockdown and control groups were
performed 3 hours after ASO infusion and 2 weeks after lentiviral
infusion, respectively, and involved the use of mild stressors
(38). This included a 10-minute exposure to a 27 3 27 3 20.3
cm open field chamber with 200 lux of light intensity, which was
followed by an interval of 30 minutes. Mice were then introduced
for 10 minutes into an elevated plus maze (under bright light at
900 lux in the open arms and 200 lux in the closed arms), and
the time spent in the open arms was recorded. Following a
second interval of 10 minutes, mice were once more placed in
the open field for 10 minutes, at which point time spent in the
center was automatically determined in seconds, while ambu-
latory time, distance travelled, and self-grooming time were
calculated as a ratio between zone results.
Stereotaxic Surgery and Cannula Implantation
Mice were anesthetized with ketamine (100 mg/kg) and xylazine
(10 mg/kg). Surgeries were performed under stereotaxic guidance
and cannulas were implanted bilaterally within the prelimbic region
of the PFC (PLPFC) at 11.8 mm anterioposterior and 22 mm
dorsoventral to bregma. Mice were allowed to recover for a
minimum of 7 days before experiments. Animals were trans-
cardially perfused posttraining with cold phosphate buffered saline
(Lonza, Walkersville, Maryland), followed by 4% paraformaldehyde
in phosphate buffered saline. Brains were dissected out, sec-
tioned, and the localization of the ASO and short hairpin RNA
infusion was determined by fluorescence microscopy.
Nuclear Enrichment, RNA Extraction, and Reverse
Transcription
Medial PFC derived from fear-conditioned mice was homo-
genized in nuclear buffer (detailed in Supplement 1) followed
by RNA extraction using the RNAeasy Mini kit (Qiagen, Hilden,
Germany). Reverse transcription and complementary DNA
synthesis was performed following the Quantitech Reverse
Transcription kit protocol (Qiagen), with the exception of RNA
eluted from RNA immunoprecipitation assays, which was
reverse transcribed using Super Script III First Strand Syn-
thesis (Invitrogen, Carslbad, California). The assay was vali-
dated both in vitro and in vivo (Figure S6A,B in Supplement 1).
RNA Sequencing
Nuclear-enriched RNA (1 μg), with a minimum RNA Integrity value
of 8, from six samples per treatment was used to build a total RNA
library using the Illumina TruSeq RNASample Preparation v2
protocol (Illumina Inc., San Diego, California). Each animal was
individually indexed, representing a single library per mouse, which
was further multiplexed in two pools of nine animals before loading
into the Illumina flow cell. Samples with low read alignment were
excluded, resulting in five animals for naïve and context groups
and four mice for fear conditioning. The quality of the RNA library
was verified on an Agilent DNA 1000 chip (Agilent Technologies,
Santa Clara, California) and run on the Bioanalyzer (Agilent
Technologies), while quantification was determined by quantitative
real-time polymerase chain reaction, after which the samples were
sequenced using the Illumina HiSeq v3 platform (Illumina Inc.).
Bioinformatic Analysis
Mapping of reads to the mouse genome (mm10) was performed
using the Bowtie2 and TopHat 2.0.6 programs (Johns Hopkins
University, Baltimore, Maryland) (39). Cufflinks 2.0.2 (BETA) algo-
rithms (Cole Trapnell Lab, University of Washington, Seattle,
Washington) were then implemented for assembly of RNA
sequencing reads into transcripts and analysis of differential levels
of transcript expression among treatment groups as previously
described (40,41). For the purpose of this investigation, we used a
cutoff of p , .03.
Gene Knockdown
ASOs targeting Gomafu lncRNA were designed using the IDT
Antisense design software (Integrated DNA Technologies Inc.,
Commercial Park, Coralville, Iowa) targeting the splicing
regulatory regions known as exonic splicing enhancers, as
well as sequences with higher G and C content and low
potential for RNA secondary structure formation. Primer
sequences are detailed in Table S4 in Supplement 1. Short
hairpin RNAs (GeneCopoeia Inc., Rockville, Maryland) target-
ing Crybb1 messenger RNA (mRNA) were packaged in-house
using a third generation lentiviral packaging system.
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Primary Neurons Cell Culture and Electroporation
Cortical neuronal cells were dissociated from C57BL/6 mouse
embryos at embryonic day 16 and plated onto poly-L-ornithine
hydrochloride-coated plates. Cultures were grown in Neuro-
basal medium (GIBCO Life Technologies, Grand Island, New
York) containing 5% fetal bovine serum, 1% penicillin/strep-
tomycin, 1% GlutaMAX, and 2% B27 supplement (GIBCO Life
Technologies) and were maintained at 371C with 5% carbon
dioxide. Electroporation of ASOs was performed using the
Nucleofector transfection system (Lonza, Basel, Switzerland)
according to the manufacturer’s instructions. Potassium chlor-
ide treatments were performed at 50 mmol/L concentration.
Technical Validation of RNA Sequencing Gene
Target Selection
Gene expression was measured using the SYBR Green
quantitative reverse-transcription polymerase chain reaction
detection method on a RotorGene 3000 (Qiagen). The 22λλCt
method was applied to estimate differential levels of gene
expression. Analysis of variance and Holm-Sidak multiple
comparison tests were applied to establish gene expression
differences among groups. Validation was performed with the
original RNA used for RNA-seq.
Chromatin Immunoprecipitation
Dissociated cortical neurons were subjected to electroporation
with 200 nmol/L ASO for Gomafu knockdown followed by
BMI1 pull-downs 3 hours posttransfection. For in vivo studies,
tissues were dissected out and homogenized 1.5 hours after
training. Tissue and cells were processed as previously
described (42). Chromatin was immunoprecipitated using 4
μg chromatin immunoprecipitation (ChIP)-grade antibodies
specific to BMI1 (1T21, Abcam, Cambridge, England, United
Kingdom), SUZ12 (ab12073, Abcam), RING1B (D22F2, Cell
Signaling, Danvers, Massachusetts), H2AK119 (D2764, Cell
Signaling), mouse immunoglobulin G (103533, Active Motif,
Carlsbad, California), and rabbit immunoglobulin G (2295402,
Millipore, Billerica, Massachusetts). DNA-protein interactions
were analyzed by quantitative reverse-transcription polymer-
ase chain reaction using primers specific to the binding motifs
of the proteins being investigated.
RNA Immunoprecipitation
Naïve tissues were dissected out and homogenized followed
by fixation and cross-linking. Immunoprecipitation with 4 μg of
the antibody of interest was performed as previously
described (22), and RNA was extracted using the Trizol
method (Ambion, Carlsbad, California), followed by DNase
treatment using the TURBO DNA-free Ambion kit (Ambion).
RESULTS
Long Noncoding RNAs Are Dynamically Expressed in
the mPFC in Response to Behavioral Experience
Fear-conditioned mice exhibited a robust increase in fear-
related behavior at the end of training compared with context-
only exposed mice (Figure S1A in Supplement 1). Nuclear RNA
was extracted from the mPFC of mice sacrificed 90 minutes
after behavioral training, and transcriptome-wide profiles were
obtained by RNA-seq. In total, we detected more than 400 loci
that exhibited differential expression of protein-coding and
noncoding RNAs (Figure 1A). A complete list of differentially
expressed transcripts identified by RNA-seq is provided in
Table S1 in Supplement 1.
Intergenic lncRNAs from 53 loci were identified as being
significantly altered in either context-exposed or fear-
conditioned mice, with the majority of these transcripts being
found within 100 kilobase (kb) of the nearest protein-coding
gene, consistent with a potential cis-regulatory function
(21,43) (Figure 1B–E; Table S2 in Supplement 1). RNA-seq
analysis also revealed a cluster of modulated protein-coding
genes, some of which have been implicated in behavioral
regulation, in mediating the stress response, and in neuro-
psychiatric disorders (Table S3 in Supplement 1).
Experience-Dependent Alterations in lncRNA
Expression Within the mPFC
To validate the RNA-seq findings, candidates were selected
for downstream analyses. We first examined the expression of
two protein-coding genes, Bdnf (exon IV) and Homer1, which
are involved in neural plasticity and memory (Figure 2A,B;
Table S3 in Supplement 1). Bdnf has been reviewed as the
master regulator of neuronal circuitries driving learning and
synaptic plasticity (44). This gene has a complex structure that
allows its differential epigenetic response to stimuli (45,46);
however, Bdnf exon IV has particularly been shown to
participate in memory processes within the mammalian PFC
(47). There was a significant increase in Bdnf exon IV and
Homer1 mRNA expression in context-exposed mice, confirm-
ing previous studies demonstrating the activity-dependent
nature of these genes in models of experience-dependent
plasticity.
We further observed a significant decrease in the expres-
sion of the activity-dependent immediate early gene Npas4
(Figure 2C). Although Npas4 expression is related to fear
learning, a downregulation of this gene is correlated with both
exposure to stress and impairments in the formation of fear
memory (48–51). Indeed, stressors can also lead to fear
incubation or enhanced fear-potentiated startle, which may
be related to anxiety rather than learning per se (52–54). In the
experiments described here, we used a strong fear condition-
ing protocol (six CS-US pairings of a .7 mA foot-shock), which
we expected could lead to an increase in stress reactivity and
anxiety. In this paradigm, fear-conditioned mice showed high
levels of freezing, not only during CS onset but also during the
intertrial interval (Figure S1A,B in Supplement 1).
Concordantly, we also observed an increase in the expres-
sion of the stress- and anxiety-related gene, Hsp901b, follow-
ing fear conditioning (Figure 2D). Although there was no effect
of fear conditioning on the expression of the synaptogenesis-
related lncRNA Malat1 (Figure 2E), two intergenic lncRNAs of
unknown function exhibited a significant, but nonspecific,
decrease in expression following behavioral training
(Figure 2F,G). The first of these, Gm21781, is upstream of a
gene that encodes a DNA binding protein known as zinc finger
and BTB domain containing 2 (Zbtb2), which has been shown
to be a potent epigenetic regulator (55), and the second,
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Figure 2. Quantitative reverse-transcription polymerase chain reaction validation of plasticity-related genes and noncoding RNA transcripts. (A-D) Analyses
of protein coding genes confirm upregulation of Bdnf exon IV messenger RNA (naïve vs. context exposure [Ctx], ***p , .001, Kruskal-Wallis test statistics
16.58), upregulation of Homer1 (naïve vs. Ctx, *p , .05, analysis of variance [ANOVA], F2,20 5 5.119), downregulation of Npas4 (naïve vs. fear conditioning
[FC], *p , .05, ANOVA, F2,20 5 5.5), and upregulation of Hsp901b (naïve vs. FC, **p , .01, Kruskal-Wallis test statistics 9.459). (E-G) Analyses of long
noncoding RNAs (lncRNAs) demonstrate a nonsignificant slight upregulation of Malat1, while Gm21781 lncRNA and Gm11762 lncRNA were downregulated
following fear conditioning relative to naïve mice (ANOVA, **p , .01, F2,20 5 7.308 and ANOVA, **p , .01, F2,20 5 5.892, respectively). (H) Specific
downregulation of Gomafu lncRNA in fear-conditioned mice (ANOVA, **p , .01, F2,20 5 5.953 naïve vs. FC and Ctx vs. FC). n 5 8 per group.
Figure 1. Transcriptome-wide analysis of nuclear RNA expression in the mouse prefrontal cortex reveals dynamic regulation of coding genes as well as
long noncoding RNAs (lncRNAs). (A) BioVenn graphic of loci detected by nuclear-enriched RNA-sequencing with p , .03 corresponding to each pairwise
comparison for naïve, context exposure (Ctx), and fear conditioning (FC) groups. (B) Distribution analysis of lncRNA loci revealing close proximity to coding
genes. (C–E) Volcano plot showing log2 fold change magnitude of lncRNAs with p , .03 in each pairwise analysis. Upregulation of genes in context (D, E) and
in naïve (F) animals is shown to the right side of the 0 in each figure.
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Gm11762, is antisense to neuronal pentraxin 1 (Nptx1), which
has been reported to enhance synaptogenesis and glutamate
signaling through clustering of alpha-amino-3-hydroxy-5-
methyl-4-isoxazole propionic acid receptors (56). Finally, we
observed a significant downregulation of the neuropsychiatric
disease-related lncRNA Gomafu in the mPFC, which occurred
following fear conditioning but not after context exposure
(Figure 2H). Importantly, the downregulation of Gomafu in fear-
conditioned animals was also observed in a targeted RNA-seq
experiment performed in these mice (Figure S2A in
Supplement 1) using a recently developed highly sensitive
RNA capture protocol (57), thereby confirming the previously
reported activity-dependent nature of the expression of this
lncRNA (29). Together, these data suggest that experience-
induced regulation of lncRNAs may play a role in regulating
neuronal plasticity and cognitive processes in the adult brain.
ASO-Mediated Knockdown of Gomafu Within the
mPFC Induces Anxiety-like Behavior
To determine whether Gomafu regulates adaptive behavior,
we employed an ASO-mediated knockdown approach.
The efficacy of an ASO designed to specifically target
Gomafu (Gomafu KD) was first tested in cultured primary
cortical neurons at different time points (Figure S3A,B in
Supplement 1). The preliminary screening indicated an app-
roximately 50% knockdown at a concentration of 1 μmol/L,
when measured 3 hours postadministration (Figure 3A), which
decreased further by 6 hours postinfusion (Figure S3A,B in
Supplement 1).
ASO-mediated Gomafu KD also produced a high rate of
neuronal transfection when infused directly into the PLPFC
in vivo (Figure 3B) before fear conditioning and was prelimi-
narily verified by gene expression assay compared with a
saline and a scrambled control group (Figure S4A,B in
Supplement 1). Following a mild fear-conditioning protocol,
mice infused with ASO-mediated Gomafu KD exhibited a
moderate but significant enhancement in freezing behavior
(Figure 3C). However, 24 hours later, these mice did not
demonstrate a difference in fear recall of the previous con-
ditioning episode when compared with the control group,
indicating there was no effect of Gomafu on long-term
memory per se (Figure 3D).
Given that stress-induced anxiety has been shown to
enhance fear responding and interfere with memory retrieval
events (58–61), we also examined the effect of Gomafu KD on
anxiety-like behavior in an independent cohort of mice.
Infusion of ASO-mediated Gomafu KD into the PLPFC led to
a decrease in the amount of time spent in the center of an
open field (Figure 4A,E), which was accompanied by a
significant increase in distance traveled (Figure 4B), ambula-
tory time (Figure 4C), and stereotypic grooming behavior
(Figure 4D), all of which are characteristic features of increased
anxiety in mice (62). These data suggest that a reduction in the
expression of the lncRNA Gomafu in the mPFC promotes
behaviors that have been implicated in the development of
anxiety disorders.
A Dual Role for the Neuropsychiatric-Disease
Related lncRNA Gomafu
Long ncRNAs have been shown to exert dual control over
gene expression through both cis- and trans-mediated mech-
anisms (63–65). As indicated above, the majority of lncRNAs
that were differentially expressed in an experience-dependent
manner were encoded within 100 kb of the nearest protein-
coding gene, suggesting that these experience-dependent
lncRNAs may control gene expression via a cis-mediated
mechanism. Given that the activity-dependent lncRNA
Gomafu was downregulated in the mPFC following behavioral
Figure 3. Knockdown (KD) of
Gomafu long noncoding RNAs (ncRNA)
in the prelimbic region of the prefrontal
cortex enhances fear response during
behavioral training. (A) Knockdown
level by Gomafu antisense oligonucleo-
tide (ASO) was assessed in cortical
neurons 3 hours posttransfection (***p
, .001, t 5 11.59, df 5 4, n 5 3 per
group) relative to control (cntl). (B)
Coronal section of mouse brain infused
with 6-Fam fluorescein-labeled
Gomafu ASO (600 nmol/L) and co-
stained with DAPI (blue). (C) Fear
acquisition profile of animals trained
at three conditioned stimulus (CS)-
unconditioned stimulus, 3 hours post-
infusion (CS3: *p , .05, t 5 2.672,
df 5 12, n 5 6 in cntl and n 5 8 in
ASO-induced Gomafu KD). (D) Recall
test performed in mice 24 hours after
the initial fear conditioning.
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training and that it has previously been shown to regulate
alternative splicing associated with neuropsychiatric disease
through a trans-mediated mechanism (29), we examined
whether this lncRNA also regulates gene expression associ-
ated with fear-induced anxiety.
Crystallin clusters are molecular chaperone proteins
belonging to the heat shock family of genes and are known
to play a major role in maintaining cellular homeostasis in
response to stress (66–68). While the alpha-beta cluster has
been associated with neurodegenerative diseases (69,70), a
beta family member, Crybb1, has been reported to exert a
major effect over these crystallin clusters by acting as an
intermolecular chaperone that regulates their correct folding
and misfolding (71). Furthermore, Crybb1 has previously been
associated with SZ and stress (72–75). In contrast to Gomafu,
fear conditioning led to a significant and specific increase in
the level of Crybb1 mRNA (Figure 5A), with no change being
observed with its close homolog, Cryba4, which is located on
the same strand as Gomafu (Figure S2 in Supplement 1).
To test the hypothesis that Gomafu exerts its influence on
proximal gene expression via a cis-mediated mechanism, we
employed a model of primary cortical neurons in vitro. As
expected, infusion of ASO-mediated Gomafu KD in primary
cortical neurons led to a significant increase in Crybb1 mRNA
expression (Figure 5B). Next, considering that members of the
polycomb repressive complex (PRC) have been shown to
interact with lncRNAs to affect gene expression (22,76–80), we
explored the relationship between Gomafu and major compo-
nents of PRC1 and PRC2, namely BMI1 and RING1B and
SUZ12, respectively. The binding motifs for these molecules
have been identified (81,82) and were present within 2 kb of
the transcription start site of Crybb1 and within the gene body
of Gomafu (Figure 5C). RNA immunoprecipitation using an
antibody specific to BMI1 revealed an interaction with Gomafu
Figure 4. Knockdown (KD) of
Gomafu long noncoding RNAs
induces anxiety-like behavior. (A,E)
A mild anxiety test performed on
Gomafu knockdown animals in an
activity monitoring chamber demon-
strated that significantly less time was
spent in the center of the field (**p ,
.01, t 5 3.922, df 5 16, n 5 9 per
group). (B–D) Gomafu knockdown
mice also exhibited a significant ten-
dency to travel longer distances out-
side the center of the field, as well as
having an increased ambulatory and
stereotypic grooming time compared
with control animals (*p , .05, t 5
2.523, df 5 16, n 5 9 per group; *p ,
.05, t 5 2.158, df 5 16, n 5 9 per
group; and *p , .05, Mann-Whitney
U score 5 16, n 5 9 per group,
respectively).
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Figure 5. Interaction of Gomafu with the
polycomb repressive complex (PRC)1 complex
in the Crybb1 promoter region leads to tran-
scriptional repression. (A). In vivo quantitative
reverse-transcription polymerase chain reaction
analysis of Crybb1 in fear conditioned (FC) and
context (Ctx) mice showed a significant upre-
gulation in response to the fear stimulus relative
to naïve animals (analysis of variance [ANOVA]
*p , .05, Kruskal-Wallis statistic 6.455, n 5 8
per group). (B) Significant in vitro upregulation
of Crybb1 resulted from antisense oligonucleo-
tide-mediated Gomafu knockdown (KD) at
1 μmol/L concentration in cortical neurons (***p
, .001, t 5 12.89, df 5 4, n 5 3 per group). (C)
Schematic diagram showing Gomafu long non-
coding RNA and Crybb1 genomic structure and
loci on chromosome 5, including the promoter
region of Crybb1 containing the BMI1 consen-
sus sequence. (D) In vivo RNA immunoprecipi-
tation assay from medial prefrontal cortex tissue
revealed a significant binding of BMI1 on
Gomafu long noncoding RNA relative to immu-
noglobulin G (IgG) in exonic region 2 (Reg2, *p ,
.05, t 5 2.916, df 5 4, n 5 3 per group) and a
marked binding in the consecutive primer for
exonic region 1 (Reg1, p 5 .07, t 5 2.434, df 5
4, n 5 3 per group), as opposed to the negative
locus on U6 RNA. (E) RNA immunoprecipitation
analysis for the same regions containing
RING1B and SUZ12 binding sites showed no
significant enrichment compared with the nega-
tive control, U6 (n 5 3 per group). (F) In vitro
chromatin immunoprecipitation (ChIP) analysis
under basal conditions and potassium chloride
(KCl) stimulation exposed a significant dysregu-
lation of BMI1 at the Crybb1 promoter region,
approximately 1.76 kilobase (kb) from transcrip-
tion start site (TSS) (region 1) in KCl-treated cells
(***p , .001, t 5 6.369, df 5 6, n 5 4 per group),
which was followed by downregulation of the
RING1B and UBH2Ak119 repressive marks (p
, .05, t 5 3.511, df 5 4, n 5 3 per group and **p
, .01, t 5 5.426, df 5 4, n 5 3 per group,
respectively). No significant changes were seen
in the same region for SUZ12. (G) In vitro ChIP
analysis revealed a significant decrease in BMI1
binding at 1.76 kb from the Crybb1 TSS, using
two consecutive primers, Reg1 and Reg2, fol-
lowing antisense oligonucleotide-mediated
Gomafu KD in cortical neurons (*p , .05, t 5
4.427, df 5 4, n 5 3 per group and at 1.35 kb
from TSS p 5 .118, t 5 1.986, df 5 4, n 5 3 per
group), whereas no changes were observed in a
negative control containing the SUZ12 binding
site. (H) In vivo ChIP analysis from medial
prefrontal cortex tissue of trained mice showed
BMI1 binding at approximately 1.76 kb from the
Crybb1 TSS, which markedly decreased after
fear conditioning (ANOVA, p 5 .116, F2,6 5
3.143, n 5 3 per group; t test between naïve
and fear conditioned mice, p 5 .064, n 5 3 per
group). (I) ChIP analysis in a negative region
about 1 kb from the Crybb1 TSS did not show similar regulation of BMI1 on Crybb1 (ANOVA, p 5 .755, F2,6 5 .2943, n 5 3 per group). mRNA,
messenger RNA.
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lncRNA (Figure 5D). In contrast, there was no significant
interaction between Gomafu and the PRC2 components
SUZ12 and RING1B (Figure 5E). In addition, no interaction
was observed between a U6 negative control and these
proteins (Figure 5E), further supporting the presence of a
specific interaction between Gomafu and BMI1.
We further verified through in vitro ChIP assay an activity-
dependent binding of the PRC1 proteins BMI1 and RING1B
accompanied by the ubiquitin histone 2A lysine 119 repressive
mark within the Crybb1 promoter, which was released upon
potassium chloride-induced depolarization (Figure 5F).
Although binding of the PRC2 component SUZ12 was
observed, the interaction was unresponsive to stimulation
(Figure 5F), confirming the specific activity-dependent recruit-
ment of PRC1 to the Crybb1 promoter.
To test whether Gomafu is required for the interaction
between BMI1 and Crybb1, we performed a Gomafu knock-
down experiment in cortical neurons, followed by ChIP
analysis. After transfection with an ASO targeting Gomafu
KD, there was a significant decrease in BMI1 occupancy at the
Crybb1 promoter (Figure 5G). However, importantly, there was
no effect of the knockdown on SUZ12 occupancy (Figure 5G).
This finding is consistent with the idea that, under basal
conditions, BMI1 is maintained at the Crybb1 promoter
through a direct interaction with Gomafu, which serves to
repress the transcriptional activity of Crybb1.
To investigate the interaction between BMI1 and Crybb1
in vivo, similar ChIP analyses were performed that revealed
BMI1 occupancy at the proximal promoter of Crybb1 in mPFC
tissue obtained from naïve animals. Although not significant, a
marked decrease was observed in fear-conditioned compared
with naïve animals (Figure 5H). Relative to input, there was little
evidence of BMI1 occupancy in a region of the Crybb1 promoter
distal to the BMI1 binding motif (Figure 5I). These results suggest
that, upon neuronal stimulation or behavioral training, a decrease
in Gomafu releases PRC1 from the Crybb1 promoter, leading to
an activity-dependent increase in Crybb1 mRNA expression.
A Novel Function for Crybb1 in the Adult Brain
To test the hypothesis that fear-related anxiety in mice is
linked to Crybb1 expression, we examined the behavioral
effect of Crybb1 knockdown (Figure S5 in Supplement 1).
Consistent with our Gomafu findings, knockdown of Crybb1
decreased anxiety-like behavior in the activity-monitoring
chamber (Figure 6A,B). Interestingly, in the pretraining test
used to induce stress in these subjects, mice treated with
Crybb1 knockdown spent significantly more time in the open
arms, also supporting the idea that decreased Crybb1 led to a
decrease in anxiety (Figure 6C). We therefore show that
Crybb1 directed knockdown within the mPFC has a role in
stress-associated responses in mice.
DISCUSSION
The present findings reveal widespread experience-dependent
activation of lncRNAs in the mPFC, including differential
expression of a significant number of nonoverlapping inter-
genic lncRNAs. In particular, the expression of the SZ-
associated lncRNA, Gomafu, was decreased in the mPFC
following fear conditioning, and ASO-mediated knockdown of
this lncRNA promoted stress reactivity and anxiety-like behav-
ior with no effect on long-term memory.
Fear is an evolutionary programmed response for self-
preservation and survival, but it can also induce pathological
behaviors fueled by the persistent memory of adverse events
(83). The PFC is a major site mediating stress-associated
disorders and can elicit an anxiety response in the fear-
conditioning paradigm (84–86). Fear conditioning has further
been demonstrated to induce greater anxiety-like behaviors in
high fear learning mouse lines, establishing a direct genetic
link between fear conditioning and anxiety (87). Concordantly,
the PFC is also vulnerable to stress inducing SZ (88) and has
been implicated as a likely neurological site for stress and
anxiety behavioral responses following fear-related learning
(85,86,89).
Consistent with our findings, Gomafu has been reported to
show evidence of dysregulation in postmortem cortical tissue
of patients who had suffered SZ (29), which is commonly
associated with anxiety disorders (90–96). Gomafu is
expressed in specific neurons, localized in subnuclear
speckle-like structures (97), and has been found to be
associated with the splicing factors SRSF1 and QK1 (29),
the latter of which has been linked with SZ (98–100). Moreover,
Figure 6. Knockdown (KD) of Crybb1 messenger RNA expression decreases anxiety in mice. (A, B) An anxiety test demonstrated that Crybb1 knockdown
animals (Crybb1-KD) spent significantly more time within the center of the activity-monitoring chamber (*p , .05, t 5 2.559, df 5 12, Control [Cntl] n 5 6,
Crybb1-KD n 5 8), while travelling significantly shorter distances (**p , .01, t 5 3.263, df 5 12, Cntl n 5 6, Crybb1-KD n 5 8). (C) Crybb1 knockdown mice
also spent significantly more time within the open arms of the elevated plus maze (*p , 0.05, t 5 2.269, df 5 12, Cntl n 5 6, Crybb1-KD n 5 8), an effect that
was more pronounced within the first 5 minutes of this trial (**p , .01, t 5 3.634, df 5 12, Cntl n 5 6, Crybb1-KD n 5 8).
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Gomafu knockdown and overexpression affects expression
and alternative splicing of genes associated with SZ, such as
Erbb4 and Disc1 (29).
Here, we have identified a potential pathway of Gomafu
regulatory function through recruitment of the PRC1 complex
to the site of gene transcription. This suggests a dual function
of Gomafu on distal and local genes that guide epigenetic
modulators in abnormal behaviors. It is well established that
splicing is regulated by epigenetic factors (101,102), possibly
via the four-dimensional organization of transcription-splicing
complexes (103), which may themselves be built on RNA
scaffolds (104). Although the mechanistic basis of the inter-
action of Gomafu with epigenetic processes has yet to be
resolved, these results add to the emerging evidence that
epigenetic function of lncRNAs may play a role in behavior and
neurological diseases (105,106).
We also showed that the expression of the Crybb1 gene
was increased in the mPFC following fear conditioning and
after Gomafu knockdown. Dysregulation of Crybb1 has been
associated with SZ and autism (72) and both Gomafu and
Crybb1 reside in the conserved human locus 22q12.1 (29),
which has been related to SZ and generalized anxiety dis-
orders (73–75,107). Although it has been linked to the develop-
ment of cataracts (68,108,109), the specific function of Crybb1
in the adult brain has not been determined. Here, in con-
junction with lncRNA activity, we have discovered a novel role
for Crybb1 in mediating fear and stress-associated responses,
with its repression appearing to reduce anxiety-like behavior
in mice.
We suggest that Gomafu, in addition to its role in regulating
alternative splicing in trans (29), acts in cis to direct the
epigenetic regulation of Crybb1. Under basal conditions,
Gomafu maintains the PRC1 at the promoter of Crybb1, which
serves to repress its expression. In response to neuronal
activation or fear conditioning, the activity-dependent down-
regulation of Gomafu, and its subsequent dissociation from
BMI1, relieves its repressive control over the Crybb1 promoter,
leading to increased Crybb1 gene expression (Figure 7). Bmi1
has been reported to act as a major regulator of the cell stress
response (110–113) and to sustain stem cell self-renewal in
both the peripheral and central nervous systems (114–118). It
also plays a key role in the defensive response to oxidative
stress by affecting neuronal survival through repression of p53
(119,120).
These results imply a complex relationship between lncRNA
activity and transcriptional regulation in the adult brain. The
dual function of Gomafu is reminiscent of previous work
demonstrating that the lncRNA Malat1 can both function in
trans, by interacting with hPSF protein (121) and serine/
arginine splicing factors to regulate gene expression and cell
cycle fate, respectively (63,64), and in cis to regulate the
expression of adjacent genes (65).
In summary, we have shown that the downregulation of
Gomafu lncRNA drives anxiety-like behavior. We further
propose a novel role for lncRNAs within the mPFC in directing
the epigenetic regulation of gene expression associated with
adaptive behavior. Together with its role in governing SZ-
related alternative splicing (29), in trans, Gomafu also may
function in cis to control gene expression and complex
behavior. These findings suggest that further investigation
into lncRNAs as molecular links between epigenetic mecha-
nisms and the development of neuropsychiatric disorders is
warranted.
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CHAPTER 7 
“I am still turning over stones, hoping to find something new” 
Craig Mello,  
Nobel Prize siRNA discovery 
7. Expression of SncRNA in Fear Conditioning  
Introduction 
Non-Coding RNAs may represent a regulatory epigenetic layer of gene expression within the 
eukaryotic genome (1-9). They are enriched in the brain and recent evidence suggests that many 
ncRNAs are induced by experience (10-13). Among sncRNAs, miRNAs are at the forefront of 
research into the role of sncRNAs in cognitive processes (14, 15). However, a second class of small 
RNAs, the snoRNAs, which are members of the mRNA splicing machinery, have also been shown 
to be expressed within the CNS (16-19). Despite these observations, no further studies have 
investigated the functional relevance of snoRNAs in the adult brain. This may relate to the 
difficulties associated with proper annotation and validation of their expression because of the 
highly repetitive nature of snoRNAs across the genome (20).  
Although snoRNAs are commonly accepted as guide RNAs for post-transcriptional modification, 
mounting scientific evidence suggests that they may have a role in cell function and disease 
development (21-27). The nucleus contains a large population of snoRNAs (28, 29), which are 
categorised according to their ability to recognise specific conserved motifs and to bind different 
ribonucleotide complexes (30). The C/D box and the H/ACA box are two classes of snoRNAs in 
charge of inducing post-transcriptional modifications on rRNAs. These types of snoRNAs present 
specific conserved motif sequences for base pairing of rRNAs close to the 5" and 3" ends, 
respectively (31). Such structures also allow snoRNAs to perform their housekeeping function of 
processing snRNAs, tRNAs and rRNAs by 2"O-ribose-methylation and pseudouridylation (32-34). 
This enables snRNAs to assembly into the spliceosome, which is essential for the splicing activity 
of this molecular complex in protein synthesis.  
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Studies of the role of snoRNAs in cell function have indicated that snoRNAs can be processed into 
smaller RNAs, which are transported to the cytoplasm by unknown mechanisms and that function 
as miRNAs in gene silencing of target mRNAs (35). Supporting a non-canonical biological role for 
snoRNAs, independent studies have reported that transcriptional modulation of these sncRNAs has 
a role in cancer development (21-24, 36-38). More interestingly, recent studies have indicated that 
snoRNAs can activate protein kinase R, a protein that is sensitive to stress and that promotes cell 
death playing a role in the metabolic stress pathway (39). 
Further research has detected a particular type of snoRNAs with no sequence that is complementary 
to specific snRNAs or rRNAs (18) and which is called “orphan snoRNA” (40, 41). These orphan 
snoRNAs are enriched in the brain and appear to be expressed in specific cell populations within 
the CNS (19, 34, 42), which contrasts with the ubiquitous nature of canonical snoRNAs (43). It is 
becoming evident that snoRNAs may also be involved in the epigenetic regulation of gene 
expression in a tissue-specific fashion (44, 45). Concordantly, the brain-specific SNORD115 has 
been shown to induce RNA editing of 5htr2c in mouse models of Prader–Willis syndrome (PWS), 
which suggests a role for snoRNAs in regulating serotonergic circuitry in the adult brain (46).  
Although most snoRNAs are transcribed from intronic regions of coding genes, they can also be 
processed from lncRNA sequences (29, 47). This supports the idea that non-coding sequences, such 
as introns, can enable functional transcription (30, 48, 49). Furthermore, snoRNAs found adjacent 
to non-coding regions appear to participate in the biogenesis of their proximal lncRNAs (50). While 
a relationship between sncRNAs and lncRNAs has been suggested (51-53), it is not known whether 
this relationship also exists in the adult mammalian brain.  
A general connection between non-coding transcription and genomic imprinting seems to take place 
in particular loci where clusters of sncRNAs are associated with lncRNA niches (54-56). Parent-
specific allele expression is imprinted during gametogenesis through epigenetic mechanisms 
involving DNA methylation (57-59). Imprinted chromosomal regions have been shown to contain 
antisense lncRNAs harbouring sncRNAs, which show distinctive expression pattern compared with 
their neighbouring coding genes and contribute to maintenance of the imprinted signal (55, 56, 60-
62). Latest research has shown a species-specific class of lncRNAs in association with the 
imprinted PWS locus, called sno-lncRNAs, which are produced by alternative splicing events and 
are flanked by snoRNAs (51). Early studies showed that IPW lncRNA, a paternally expressed sno-
lncRNA transcribed within this region and flanked by SNORD115 and SNROD116, is deleted in 
about 70% of PWS patients (63, 64). PWS is a neurodevelopmental disorder involving mild 
intellectual disability, early onset of severe obesity and hyperphagia among other symptoms, and 
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recent investigations have narrowed the disease to a key non-coding region involving IPW lncRNA 
and snord116 (65-67). Additionally, IPW lncRNA has been shown to direct gene regulation of a 
maternally imprinted gene cluster in trans, which leads to chromatin modification in PWS stem cell 
models (68). This example shows the potential links between imprinting, lncRNAs and snoRNAs in 
the epigenetic regulation of transcriptional events. 
The present chapter provides evidence for the activity-dependent transcription of sncRNAs in the 
mouse brain. It highlights the detection of experience-induced snoRNAs that are transcribed from 
paternally imprinted genomic regions and schizophrenia-associated miRNAs originating from 
maternally imprinted loci. The data suggest that there might be multiple layers of sncRNA-
mediated regulation of gene expression, which may be directly influenced by maternal and paternal 
imprinting in association with lncRNA loci.  
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7. Results 
7.1 Experience-dependent regulation of sncRNAs.  
Transcriptome-wide sequencing of small RNAs from mice hippocampi revealed a transcriptional 
activity derived from various classes of sncRNAs (Fig. 7.1, A). Among these transcripts, there was 
a marked overrepresentation of a cluster of snoRNAs produced from chromosome 7 (Fig. 7.1, B).  
 
Figure 7.1: Predicted small RNA-seq transcripts: naïve, context (Ctx) and fear conditioning (FC). A) 
About 30% of the predicted RNAs (n = 8 per group) were snoRNAs, and a high percentage, ~60%, were 
unidentified (Other) or newly described transcripts. B) Chromosome 7 snoRNA clusters represented >50% 
of the total snoRNA population detected in these groups. 
Comparison of the sncRNA profiles between the different training groups showed the modulation 
of miRNAs that were previously indicated as markers associated with schizophrenia, cognition and 
epigenetic pathways. For example, the brain-specific miR-184-3p (69) was significantly up-
regulated following context-exposed animals and significantly down-regulated in fear-conditioned 
animals (Table 7.1). miR-182 was significantly down-regulated in fear-conditioned mice relative to 
context-only-treated mice (Table 7.1). Previous investigations have detected a disruption in memory 
formation following overexpression of miR-182 in the lateral amygdala of rats, indicating its 
relevance in cognitive processes (70). The sequencing results also revealed a significant up-
regulation of miR-153 in fear-conditioned mice relative to context-only-treated mice and a 
significant down-regulation in context-exposed compared with naïve mice (Table 7.1). Previous 
research has indicated that dysregulation of miR-153 is associated with increased expression of 
amyloid precursor protein and amyloid precursor-like protein 2 in AD (71, 72). 
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Table 7.1: Small RNA-seq detection of miRNAs associated with cognitive processes. 
Gene logFC logCPM P Value FDR 
mmu-miR-184-3p (ctx vs FC) 12.07802208 3.985865408 2.11E-67 2.30E-65 
mmu-miR-184-3p (naïve vs ctx) -12.09945729 3.959361878 2.74E-71 7.44E-69 
mmu-miR-182-5p 14.22629759 6.126051508 1.24E-66 9.61E-65 
mmu-miR-153-5p -9.502090528 5.317164107 4.96E-79 1.35E-76 
The sequencing data also showed a large number of transcripts arising from parentally imprinted 
regions, which included miRNAs produced from a maternally imprinted region in mouse 
chromosome 12. This locus has been linked to schizophrenia and is also present in the human 
conserved region of chromosome 14 (73, 74). Further subsets of miRNAs across several 
chromosomes that have been identified as a potential miRNA signature for schizophrenia were also 
detected by the Small RNA-Seq approach (Table 7.2) (73, 75). 
Table 7.2: Small RNA-Seq of miRNAs. Detail of miRNAs detected by RNA-Seq, which were 
previously accounted for as biomarkers for schizophrenia and associated with lncRNAs (73, 74). 
 
 
MiRNA Trend p - value Schizophrenia signature 
mmu-miR-184-3p Up in Ctx vs Naïve 2.74E-71 chr9 
mmu-miR-184-3p Down in FC vs Ctx 2.11E-67 chr9 
mmu-miR-574-3p Down in FC vs Ctx 9.74E-71 chr5 
mmu-miR-181a-2-3p Down in Ctx vs Naïve and Up in FC vs Ctx 4.66E-55 chr1 
mmu-miR-679-5p Down in Ctx vs Naïve and Up in FC vs Ctx 2.81E-51 chr12 
mmu-miR-382-3p Down in Ctx vs Naïve and Up in FC vs Ctx 1.64E-37 chr12 
mmu-miR-370-5p Down in Ctx vs Naïve and Up in FC vs Ctx 2.04E-19 chr12-Rian lncRNA 
mmu-miR-540-3p Down in Ctx vs Naïve and Up in FC vs Ctx 1.61E-17 chr12 
mmu-miR-341-5p Down in Ctx vs Naïve and Up in FC vs Ctx 3.13E-17 chr12-Rian lncRNA 
mmu-miR-30e-5p Down in Ctx vs Naïve and Up in FC vs Ctx 5.08E-16 chr4 
mmu-miR-377-3p Down in Ctx vs Naïve and Up in FC vs Ctx 3.55E-12 chr12-Mirg lncRNA 
mmu-miR-758-3p Down in Ctx vs Naïve and Up in FC vs Ctx 1.00E-06 chr12 
mmu-miR-146b-5p Down in Ctx vs Naïve 7.59E-05 ch19 
mmu-miR-99a-3p Down in Ctx vs Naïve and Up in FC vs Ctx 0.000241444 chr16 
mmu-miR-323-5p Up in Ctx vs Naïve 0.000803934 chr12 
mmu-miR-412-3p Down in Ctx vs Naïve and Up in FC vs Ctx 0.001588245 chr12-Mirg lncRNA 
mmu-miR-493-3p Up in Ctx vs Naïve 0.001842902 chr12 
mmu-miR-877-5p Down in Ctx vs Naïve and Up in FC vs Ctx 0.002612149 chr17 
mmu-miR-494-3p Up in Ctx vs Naïve 0.00272441 chr12 
mmu-miR-505-3p Down in Ctx vs Naïve and Up in FC vs Ctx 0.00475518 chrx 
mmu-miR-485-3p Down in Ctx vs Naïve and Up in FC vs Ctx 0.008681561 chr12-Mirg lncRNA 
mmu-miR-431-3p Down in Ctx vs Naïve and Up in FC vs Ctx 0.012622747 chr12 
mmu-miR-323-3p Up in Ctx vs Naïve 0.01593103 chr12 
mmu-miR-667-3p Up in Ctx vs Naïve 0.017990795 chr12 
mmu-miR-136-5p Down in Ctx vs Naïve 0.022533873 chr12 
mmu-miR-341-3p Down in Ctx vs Naïve and Up in FC vs Ctx 0.024357064 chr12-Rian lncRNA 
mmu-miR-128-3p Down in Ctx vs Naïve 0.026393615 chr1 
mmu-miR-3072-3p Up in Ctx vs Naïve 0.027583583 chr12-Mirg lncRNA 
mmu-miR-539-3p Down in Ctx vs Naïve 0.028261916 chr12 
mmu-miR-300-5p Down in Ctx vs Naïve and Up in FC vs Ctx 0.032182161 chr12 
mmu-miR-409-5p Up in Ctx vs Naïve 0.034999465 chr12-Mirg lncRNA 
mmu-miR-544-3p Down in FC vs Ctx 0.001517743 chr15 
mmu-miR-3072-3p Down in FC vs Ctx 0.006596431 chr12-Mirg lncRNA 
 
 147 
The transcriptome profile also uncovered a range of snoRNA expression within the hippocampus. 
These included a snoRNA cluster transcribed from chromosome 7 (Figure 7.1, B; Table 7.3). This 
locus has been shown to be associated with paternal imprinting-related disorders such as PWS and 
Angleman syndrome (AS) (76). Interestingly, both imprinted miRNAs and snoRNAs were derived 
or associated with lncRNAs, such as Mirg, Rian and Ipw, which are transcribed within these loci. A 
recent investigation has revealed a molecular interaction between these imprinted non-coding 
regions, which results in chromatin modifications in PWS models (77). 
Table 7.3: Small RNA Sequencing of snoRNAs. Detail of snoRNA clusters detected by RNA-Seq within 
chromosome 7, a region involved in the neurogenetic disorder PWS (65, 77, 78). 
 
snoRNA Trend p-value PWA
Gm23660 Down in FC vs Ctx 0.001820068 chr7
Gm22863 Down in Ctx vs Naïve 0.000812581 chr7
Gm23313 Down in Ctx vs Naïve and Up in FC vs Ctx 0.001636904 chr7
Gm23682 Up in Ctx vs Naïve and Down in FC vs Ctx 0.003827143 chr7
Gm22629 Up in Ctx vs Naïve 0.004707996 chr7
Gm25017 Up in Ctx vs Naïve 0.006064265 chr7
Gm24528 Up in Ctx vs Naïve 0.006103007 chr7
Gm24983 Up in Ctx vs Naïve 0.00878312 chr7
Gm26097 Down in Ctx vs Naïve 0.010018893 chr7
Gm26337 Up in Ctx vs Naïve and Down in FC vs Ctx 0.010261801 chr7
Gm24866 Up in Ctx vs Naïve 0.010406241 chr7
Gm24759 Up in Ctx vs Naïve 0.010701034 chr7
Gm23560 Up in Ctx vs Naïve and Down in FC vs Ctx 0.010834471 chr7
Gm26136 Down in Ctx vs Naïve and Up in FC vs Ctx 0.01160506 chr7
Gm24702 Up in Ctx vs Naïve and Down in FC vs Ctx 0.01196045 chr7
Gm26434 Up in Ctx vs Naïve 0.013860767 chr7
Gm25230 Up in Ctx vs Naïve 0.014131163 chr7
Gm25209 Up in Ctx vs Naïve 0.014849132 chr7
Gm25710 Up in Ctx vs Naïve 0.01665747 chr7
Gm25461 Up in Ctx vs Naïve and Down in FC vs Ctx 0.01769894 chr7
Gm26334 Up in Ctx vs Naïve 0.019157015 chr7
Gm23359 Down in Ctx vs Naïve and Up in FC vs Ctx 0.019974855 chr7
Gm25474 Down in Ctx vs Naïve and Up in FC vs Ctx 0.020093541 chr7
Gm25741 Up in Ctx vs Naïve and Down in FC vs Ctx 0.021195325 chr7
Gm24206 Up in Ctx vs Naïve 0.021331289 chr7
Gm23944 Up in Ctx vs Naïve 0.022227841 chr7
Snord35a Down in Ctx vs Naïve 0.022900286 chr7
Gm22584 Down in Ctx vs Naïve 0.023205303 chr7
Snord34 Down in Ctx vs Naïve 0.024420434 chr7
Snord116l2 Down in Ctx vs Naïve 0.025401959 chr7
Gm24585 Up in Ctx vs Naïve 0.025765918 chr7
Gm24862 Up in Ctx vs Naïve and Down in FC vs Ctx 0.027838064 chr7
Gm25098 Up in Ctx vs Naïve 0.030707801 chr7
Gm22630 Up in Ctx vs Naïve 0.031679001 chr7
Gm25156 Up in Ctx vs Naïve 0.032520067 chr7
Gm24657 Up in Ctx vs Naïve 0.033170746 chr7
Gm26502 Down in Ctx vs Naïve 0.037209997 chr7
Gm25146 Up in Ctx vs Naïve 0.038396251 chr7
Gm25314 Up in Ctx vs Naïve and Down in FC vs Ctx 0.044598585 chr7
Gm25874 Up in Ctx vs Naïve 0.044717231 chr7
Gm24799 Down in Ctx vs Naïve 0.046286726 chr7
Gm22912 Up in Ctx vs Naïve 0.047026761 chr7
Gm24153 Down in Ctx vs Naïve 0.048992131 chr7
Gm25646 Up in Ctx vs Naïve 0.050017536 chr7
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Many differentially regulated snoRNAs detected by RNA-Seq were also transcribed from other 
sparse lncRNAs hosts, such as Snhg1, Snhg7, Snhg12, Gas5, and Taf1d. Finally, in fear-
conditioned relative to context-only-treated animals, there was a marked up-regulation of the well-
known brain-specific snoRNA35 (also known as HBI-36), which is transcribed from an intronic 
region of 5htr2c (19).   
Further supporting a potential molecular function, the sequencing data identified the experience-
dependent modulation of Snord42a, which was down-regulated in fear-conditioned mice, and 
Snord34, which was down-regulated in context-exposed animals. Both Snord42a and Snord42b, are 
transcribed from an intronic region of the ribosomal protein L23a (Rpl23a) and have no reported 
function other than the canonical activity of guiding 2"-O-methylation of rRNAs (79). Its down-
regulation has nonetheless been shown to be responsive to teratogen exposure during development 
(80). Similarly, Snord34 is encoded by Rpl13 (51), and its modulation has been identified after 
hypoxic ischaemic insult associated with encephalopathy (81) and in the vitamin D signalling 
pathways in murine islets  (82).  
These results suggest that there is a wide range of sncRNAs that respond to behavioural stimulation, 
including many examples of snoRNAs, which were previously understood to be housekeeping 
genes. 
7.2 Analysis of sncRNA expression.  
The human Snord116 (HBII-85) is located downstream of the paternally imprinted region PWS 
15q11-q13 and is associated with the dysregulation of the neighbouring genes Snurf and Snrpn (78, 
83). Although its housekeeping functions involve canonical modifications of snRNAs, it is possible 
that this snoRNA may also be an epigenetic driver of gene expression through unknown 
mechanisms. Snord116 lacks complementarity with rRNAs, and its deletion has been suggested to 
contribute to PWS (65, 78, 83) and to growth retardation (76). The transcriptome analysis showed 
marked down-regulation of Snord116-12 in context-exposed mice compared with the fear-
conditioned mice. Because Snord116 is represented by a cluster of transcripts, copies identified as 
GM23313 and GM26502it also showed significant up-regulation in the fear-conditioned mice 
relative to the context-exposed mice. qPCR confirmed this trend, although it was not statistically 
significant, and this result suggests a possible experience-dependent role of Snord116 that remains 
to be verified (Fig. 7.2, A). The repetitive nature of snoRNA sequences, which means that >100 
 
 149 
copies may show a different expression response, makes the in vivo validation of snoRNAs 
sequencing results very complex. 
 
Figure 7.2: q-PCR analysis of experience-dependent snoRNAs. (A) Snord116 copy variants were up-
regulated in fear-conditioned (FC) mice relative to context (Ctx) and Naïve mice (Kruskal–Wallis test p > 
.05, Kruskal–Wallis statistics = 5.290, n = 8 per group) (B) Snord115 copy GM25017 was up-regulated in 
Ctx compared with naïve mice and was down-regulated in Ctx compared with FC mice, which were 
consistent with the sequencing results (Kruskal–Wallis test ** p <.01, Kruskal–Wallis statistics = 13.14, n = 
8 per group). 
Changes in the expression of several copies of Snord115 were similarly detected. Further validation 
of one of these transcripts showed significant down-regulation following fear conditioning (Fig. 7.2, 
B). The orphan Snord115 (HBII-52), also represented by multiple copies, is found upstream from 
the Ube3a maternal deletion associated with AS and down-stream from the paternally imprinted 
region for PWA (84). Snord115 exhibits phylogenetically conserved antisense base complementary 
to the 3"-untranslated region of 5htr2c (19, 34) and has been reported to be involved in both pre-
mRNA splicing and editing of 5htr2c in PWS models (44, 46, 85). Snord115 is thought to alter the 
5htr2c receptor modulation in the reward pathway and in mice exposed to cocaine (86). Consistent 
with these results, a Snord115-engineered duplication has been shown to induce abnormal 
behaviour in a mouse model of autism (87). This may be the most well-known snoRNA in brain-
associated function, yet its gene regulatory mechanisms remain unknown. Interestingly, although 
Snord115 nuclear localisation and interaction with ribonucleotide protein complexes has been 
shown (44), recent investigations have shown its association with non-canonical ribonucleoproteins 
that may facilitate its epigenetic regulation of 5htr2c expression (88).  
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7.3 snoRNA stability and implications for gene expression. 
In this investigation, the snoRNAs screened were not significantly responsive to neural stimulation 
by KCl induction (not shown), and it was hypothesised that these kinds of ncRNAs may require 
more specific stimulation to elicit transcription. Identifying levels of RNA stability is becoming 
increasingly more important to understanding the principles governing eukaryote gene expression 
and functionality. Whereas mRNAs associated with cellular functions, such as housekeeping genes, 
show higher levels of stability, activity-dependent regulated coding genes are naturally less stable 
(89-92). Actinomycin D was used to determine the half-life of snoRNAs and to study individually 
their potential association with activity-dependent functional responses.  
The snoRNAs screened through this assay showed a marked decay by 3 h, which suggested the 
presence of activity-dependent regulation. snoRNAs transcribed from coding loci such as U6, 
Snord34, and a copy from Snord116, exhibited a trend towards higher levels of stability (Fig. 7.3, 
A–C) compared with the Snord115 copy (Fig. 7.3, D). Interestingly, U6 snoRNA has traditionally 
been used as a housekeeping gene in sncRNA expression assays and, although here it showed a 
significant level of decay, this was the only interrogated snoRNA that seemed to return to its initial 
index of stability. These results together with the response of U6 to membrane depolarisation 
(chapter 2, Fig 2.3) suggest that U6 may also be regulated by external stimuli. 
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Figure 7.3: Half-life measurement of snoRNAs. A) After an approximate 50% reduction during the first 30 
min, which remained significant compared with the basal levels, intronic Snord34 showed a stable trend 
through the 6 h assay. B) Snordd116 copy showed a gradual decay with a reduction of only 25% within the 
first 1 h. C,D) Snord115 copy showed the highest and fastest decay rates among the snoRNAs screened with 
a constant decrease from 30 min to <25% by 4 h after actinomycin D addition. (*) p < 0.05; (**) p < 0.005; 
(***) p < 0.0005 and (****) p < 0.00005, t test. 
These results are consistent with the prospective activity-dependent regulatory expression of orphan 
snoRNAs, which may not apply to all transcripts of this category.  
7.4 snoRNAs potential gene targets. 
Identifying the target mRNAs of orphan snoRNAs is important for understanding the broad 
functions of snoRNAs in the brain, in addition to those involved in rRNAs processing. At the time 
of this investigation, human target mRNAs were identified for Snord116 copies, while deletions in 
this cluster and ablation of its host lncRNA have been linked to dysregulation of circadian genes 
(40, 93). Concordantly, snord115 has been shown to target the splicing and editing of 5htr2c (40, 
44, 46, 85).  
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The application of publicly available predictive tools (94) to infer the potential targets of the 
snoRNA cluster in chromosome 7 (Table 7.3) and other relevant snoRNAs detected within the 
transcriptome screening, predicted that these transcripts can target non-coding genes and coding 
genes involved mainly in catalytic function (Table 7.4). Consistent with the orphan definition, many 
copies of Snord115 and Snord116 are transcribed from intergenic regions and have no sequence 
complementary to rRNAs. For example, Snord115 copy GM25314, which has no rRNA 
complementarity, is predicted to target Plch1, a gene linked to regulatory pathways involved in 
neurogenesis and synaptic plasticity, and copy GM25017, which targets Atxn1, has been previously 
associated with AD and autism (95).  
Additionally, intronic Snord34 was predicted to target Tet2, a gene that codes for one of a family of 
proteins involved in epigenetic function associated with cognition (96-98). Snord34 may also target 
a regulator of acetylation and transcription activation linked to fear learning, such as Ep300 (99-
101). Snord42a was predicted to target the synaptic plasticity-related gene Myo V. Myo V proteins 
are highly abundant in the brain and are involved in the exocytosis of secretory vesicles and neuron-
active substances from the cell, thereby playing an important role in recycling AMPA receptors at 
hippocampal synapses (102). Consistent with a potential role in epigenetic pathways, Snord42 was 
also predicted to target Xist lncRNA, a major regulator of gene dosage compensation and epigenetic 
gene silencing (103, 104). 
Next, gene ontology (GO) for molecular functions of the predicted mRNA targets was further 
investigated with the application of Panther software (105). Nearly 80% of all gene targets for this 
cluster included association with catalytic activity, DNA binding transcription factors and receptor 
activity-related proteins (GO:0003824, GO:0005488, GO:0004872) (Table 7.4).  
Table 7.4: Gene ontology (GO) of detected snoRNA targets. GO of molecular function associated with 
predicted target genes of snoRNA clusters derived from chromosome 7. 
GO Molecular function Genes Percentage 
Catalytic Activity (GO:0003824) 79 33.90% 
Binding (GO:0005488) 69 29.60% 
Receptor Activity (GO:0004872) 35 15.00% 
Transporter Activity (GO:0005215) 23 9.90% 
Enzyme Regulator Activity (GO:0030234) 18 7.70% 
Nucleic Acid Binding Transcription Factor Activity (GO:0001071) 18 7.70% 
Structural Molecule Activity (GO:0005198) 16 6.90% 
Translation Regulator Activity (GO:0045182) 2 0.90% 
Protein Binding Transcription Factor Activity (GO:0000988) 1 0.40% 
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Overall, these results suggest a potential role for snoRNAs in transcriptional processes beyond their 
housekeeping functions that warrants further investigation. 
7.5 LncRNAs flanked by experience-dependent expression of 
sncRNAs. 
It has been suggested that there might be a co-regulation mechanism between parentally imprinted 
sncRNAs and lncRNAs (51, 52, 106). Recent investigations have suggested that sno-lncRNA, 
related to PWS may be undetectable in mice, which hinders research using rodent models to study 
this disorder (51). Here, the levels of expression of such sno-lncRNAs, like Ipw lncRNA and Mirg 
lncRNA, were investigated because of their association with the snoRNA cluster in chromosome 7 
and miRNAs in chromosome 12, respectively.  
Firstly, this study confirmed the in vitro and in vivo expression of Ipw lncRNA in mice, which was 
previously reported as undetectable. Hippocampal neuronal stimulation revealed a significant up-
regulation of both Ipw and Mirg lncRNAs (Fig. 7.4, A, B). However, neither lncRNA showed a 
significant modulation in vivo within the hippocampus of fear-conditioned mice (Fig. 7.4, C, D). 
This may suggest a locus-associated response in fear conditioning that is driven by sncRNAs 
derived from these long non-coding transcripts alone. Interestingly, the RNA-Seq results described 
in chapter 3 also revealed a down-regulation of Mirg lncRNA within the mPFC of conditioned 
animals, which may indicate that the tissue-specific regulation of this lncRNA is linked to 
behavioural training. 
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Figure 7.4: lncRNAs harbouring sncRNAs. A,B) Both Mirg and IPW lncRNAs showed a significant up-
regulation at 1 h that continued to increase at 3 h post stimulation (ANOVA *** p < .001, F(2,6) = 
33.64(2,6) and **** p <.0001, F(2,6) = 402.4, respectively). C,D) Behavioural training elicited no 
significant differences in gene expression in Mirg and IPW lncRNAs (ANOVA p > .05) between the fear 
conditioning (FC), context exposure (Ctx) and naïve animals. 
Together these data suggest that tissue-specific non-coding activity occurred as a result of fear 
conditioning in mice, although this investigation found no indication of a possible co-transcriptional 
event between sncRNAs and lncRNAs, which was previously termed as sno-lncRNAs. Instead, this 
seems to imply an alternative transcriptional response between small and long non-coding 
associated sequences triggered by external cues, which may be linked to imprinted chromosomal 
regions. 
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Chapter Conclusion and Perspectives 
Through a combination of behavioural training and high-throughput sequencing of the small RNA 
transcriptome, this chapter identified sncRNAs that were previously linked to psychiatric illnesses, 
such as schizophrenia, and neurogenetic disorders, such as PWS. Many sncRNAs were also found 
within regions enriched for lncRNA transcription. Interestingly, these loci are associated with 
chromosomal imprinting. 
Although snoRNAs are likely to be the last evolutionary link between Archaea and Eukarya (108) 
and are possibly the first ncRNAs to have been functionally transcribed, their regulatory activity of 
gene expression remains uncharted. Validation of a snoRNA candidate, Snord115, and prediction of 
potential snoRNA targets with important genes linked to brain function suggests that these 
transcripts may have a regulatory activity in response to experience. In support of this hypothesis, 
Snord115 showed high levels of decay in neuronal cultures, a trend that is strongly associated with 
functionality in mammalian genomes (89, 90, 92). Both Snords 115 and 116 are absent in the cortex 
of patients with PWS, whereas Snord115 targeting 5htr2c has been linked to autism (87), reward 
pathways of cocaine consumption (86), and contextual fear conditioning (107). Beyond their 
potential use as biomarkers for PWS, experimental evidence for the molecular pathways and 
functional relevance of these snoRNAs in the brain has not been explored.  
The identification of schizophrenia-associated miRNAs in the hippocampus within the context of 
fear conditioning sheds new light on the potential role of these transcripts in cognitive function. It is 
interesting that many snoRNAs are associated with lncRNAs, although the functional relationship is 
not well understood. An enrichment of miRNAs and snoRNAs from the imprinted regions 
associated with lncRNAs, such as Mirg and Ipw, might also suggest cross-talk between small and 
long non-coding transcripts that is linked to parentally imprinted gene expression in the adult brain. 
Although modulation of both miRNAs and snoRNAs derived from lncRNA sequences were 
detected, the main sno-lncRNAs Mirg and Ipw were not significantly responsive to behavioural 
training. This may reflect a specific layer of ncRNA activation in which lncRNAs have the 
versatility to respond themselves or to serve as transcriptional reservoirs for functional sncRNAs.    
By comparing the imprinted region patterns of expression, it became clear that there is potential 
involvement of hierarchical layers of non-coding transcription in which lncRNAs shared the loci 
with the sncRNAs related to neurogenetic and psychiatric disorders (Fig 7.5). Although this 
investigation did not explore this hypothesis, the results presented here indicate that these sncRNAs 
respond to behavioural stimuli and thereafter may have a role in cognitive processes within the 
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mouse brain. It remains to be determined whether the specific mechanism by which the suggested 
interaction between these small and long ncRNAs (51, 52, 106) could take place in fear-learning 
associated events. 
            
Figure 7.5: Layers of non-coding transcription potentially involved in fear conditioning. Illustration of 
a hypothetical pathway of lncRNAs derived sncRNAs, which have been associated with mental afflictions, 
exposing their possible relevance in cognitive processes. 
Some ncRNAs are specifically transcribed in clusters from imprinted loci (54). Many brain-
enriched snoRNAs are found within paternally imprinted regions (42, 50), a pattern that is similar to 
miRNA transcription originating from maternally imprinted non-coding regions (73, 74). Notably, 
recent research has revealed an interconnection between these imprinted loci and ncRNAs arising 
from within (77).  
In summary, together with previous investigations the results of this chapter demonstrate the 
relevance of snoRNAs derived from imprinted loci to neurological circuitries. The results of this 
investigation add to the understanding of the role of snoRNAs in activity-dependent gene 
expression within the adult brain, whose dysregulation may be related to cognitive impairment 
associated with neurological disorders. 
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CHAPTER 8 
“For in sciences, the authority of thousands of opinions is not worth as much as one tiny spark of 
reason of one individual” 
Galileo Galilei, 1612 
Discussion and Further Perspectives 
It was once said, “Nothing in biology makes sense except in the light of evolution” (1). Our highly 
developed PFC may be the brain region that define us (2). In humans, it represents the site for 
intersection of cognition with emotions, to the extent of being the distinguishing feature of our 
species (3). The vast majority of the newly evolved sequences in this region are identified as non-
coding ncRNAs (4). Among these transcripts, lncRNAs appear to be the most versatile in 
controlling molecular regulatory pathways because of their ability to interact with chromatin-
modifying complexes (5-7). Despite the many advances in understanding the molecular 
mechanisms of lncRNAs in vitro, their functional role in the adult brain has remained elusive. This 
thesis has uncovered the transcriptome-wide participation of major lncRNAs and newly described 
lncRNAs in fear acquisition, which indicate their activity-dependent responses in vivo (chapter 3). 
Detection of lncRNA enrichment in proximity to coding genes suggests an in cis regulatory role of 
lncRNAs over these neighbouring transcripts, a finding that was consistent with the results achieved 
for Anti-Star and Gomafu lncRNAs (chapters 4 and 5). By identifying the role of Gomafu lncRNA 
in anxiety, this research has provided further evidence of the potential involvement of lncRNAs in 
behaviour (chapter 5). Additionally, this investigation has uncovered that Gomafu may exert an in 
cis control through PRC1 epigenetic regulation of Crybb1, a small HSP whose novel role in anxiety 
was also discovered here (chapter 6). Finally, this thesis postulates the existence of major imprinted 
regions of sncRNA-containing-lncRNAs in the transcriptome landscape of fear conditioning 
(chapter 7). Overall, these findings advance the understanding of non-coding epigenetic regulatory 
function in mammalian behavioural responses. 
There is a now general consent in the literature that lncRNAs are key components of the epigenetic 
machinery in eukaryote systems (6, 8-10). This is based on the observations that lncRNAs are 
nuclear enriched and show levels of conservation at the promoter and exonic regions as well as in 
stretches of sequences serving as binding motifs for regulatory factors (11-13). The GENCODE 
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project has proven that lncRNA exonic regions are significantly more conserved than are neutrally 
evolving sequences, whereas RNA secondary structures conserved through evolution are associated 
with possibly functional ncRNAs (11). Although lncRNAs have been detected across all phyla, 
more than one-third is actually primate specific (11). In the human brain, they respond to external 
cues by activating a network of transcription associated with sense and antisense coding genes (14), 
which seems to be a phenomena (15) that is not entirely reproducible in mouse model systems (16).  
The recent observation that novel protein coding genes derive from lncRNA sequences (17) may 
indicate that lncRNAs are still ‘evolving sequences towards becoming coding genes’, which have 
turned into functional units in the process. It is interesting that such a preeminent transcription of 
non-coding RNAs has taken place in a prime brain area related to sophisticated molecular 
processing and complex behavioural responses, the human cortex. The human brain is highly 
developed and is the largest among primates, yet the differences in cognitive functions seem to 
relate to both size and the neural reorganization and processing that took place within the frontal 
cortex at the time of divergence from the last common ancestor with chimpanzees (18-20). 
Although primates evolved lateral prefrontal regions within the cortex, only humans fully 
developed a functional bilateralism and lateral frontal pole cortical regions that are associated with 
the ability for verbal communication and higher reasoning (21, 22). Research has shown that 
changes in functional connectivity in the human lateral PFC are engaged distinctively when 
cognitive flexibility and decision-making are required (23, 24). Additionally, the development of 
the PFC region is thought to be the centre for decision-making and adaptive behaviour applied to 
humans and mouse models (25-29).  
This investigation anticipated that non-coding gene dysregulation in the PFC could lead to 
modifications of complex behaviour of mammals.  
Although the response to fear is one basic ancestral mechanism involved in survival and adaptation, 
the anxiety state it generates, which is intrinsically related to exposure to a fearful event, may 
become pathological and interfere with the adaptive response (30). Generalization of the threat 
stimuli during conditioning has been implicated in the development and persistence of stress-related 
disorders such as anxiety and PTSD (31-34). Pavlovian fear conditioning is widely accepted as a 
framework for understanding the pathogenesis of anxiety-associated disorders (33, 35, 36). This 
investigation has confirmed a close genetic link between fear and anxiety while showing the 
involvement of Gomafu lncRNA in the articulation of both behaviours. Although this investigation 
confirmed the significant effect of Gomafu in fear conditioning, the lack of memory of the aversive 
event in Gomafu-knockdown animals and their anxious response to training shows that this lncRNA 
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influences anxiety and not learning and memory (chapter 5). Anxiety is a psychological and 
disabling emotional burden that has an impact on the quality of life in people with the disorder (37). 
The underlying biological reasons for anxiety are yet to be discovered, although oxidative stress is 
implicated as a causative agent in the development of pathological anxiety (38).  
Interestingly, the sequencing results predicted a stress response and the presence of several genes 
associated with oxidative stress (39) (chapter 3). Bmi1, a member of PRC1, is a main regulator of 
cell apoptotic pathways through the direction of oxidative stress processes (40-42). Dysregulation 
of the oxidative pathway in turn liberates the genomic machinery underlying the production of free 
radicals in the brain (43, 44). Additionally, HPSs such as Crybb1 are the frontline of the genome 
protection against stress-induced free radicals (45, 46). This study identified an interaction between 
Gomafu lncRNA and Bmi1 that may regulates the epigenetic expression of Crybb1 (chapter 6).  
It is also relevant to question whether Gomafu may have a more general role in driving the 
oxidative stress pathway underlying the stress-associated behavioural responses that are involved. 
This would place Gomafu in the control of a pre-stage in the development of neurodegenerative 
diseases, and further research is warranted to answer this question. The evidence presented in this 
thesis suggests that there is a feedback loop initiated by a fearful event as an environmental insult 
that may prompt an oxidative stress response, which is translated into a state anxiety as a coping 
mechanism. Potential failure of this system may establish the pathway of a defective adaptive 
response under the governance of Gomafu lncRNA.  
Although in trans activity of lncRNAs (47, 48) and a role of both in trans and in cis functions (49-
52) have been shown, many lncRNAs have a tendency to exert control over neighbouring genes 
(11, 15, 53, 54). It is possible that lncRNAs might interfere with both locus and inter-locus gene 
modulation. The key may rest within the conserved secondary structures that allow the 
interconnection with binding factors involved in transcriptional regulation. The relevance of 
lncRNAs may be dictated by their interaction with regulatory proteins, which suggests an extended 
hypothesis that lncRNAs might be guided by a function more so than a chromosomal location.  
The potential of lncRNAs for in cis modulate gene expression of proximal coding genes, was 
shown in this research through the examples of Gomafu and Anti-Star lncRNA. Further, this 
activity can interfere in the canonical pathways associated with these genes, which were shown here 
in the resulting modification of AMPAR-encoding genes after Anti-Star lncRNA knockdown. 
Considering the role of Stargazin protein and the close relationship between proteomic function and 
RNA transcription control (55-63), it would be interesting in the future to confirm the in vivo 
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relevance of Anti-Star ncRNA in driving Stargazin and AMPAR-encoding genes in synaptic 
plasticity and behaviour.  
These results are consistent with the literature showing the potential regulatory role of lncRNAs in 
transcriptional modification and gene expression via in cis molecular mechanisms. It is possible that 
Gomafu lncRNA acts as a scaffold that allows the interaction of repressive proteins, such as Bmi1, 
with DNA segments of the target genes. Although the mechanism underlying the change in Gomafu 
lncRNA functional activity upon stimulation remains unknown, unpublished investigations on m6A 
RNA methylation in our laboratory have shown a methylation mark in Gomafu lncRNA during fear 
conditioning training. Although the biological relevance of RNA methylation is in an early stage of 
understanding (64-66), this suggestion opens the doors for future research to determine whether 
RNA methylation can dictate Gomafu lncRNA activity associated with behavioural responses.  
It has been proposed that the close link between non-coding imprinting in the genome and in cis 
mechanisms can articulate epigenetic-guided transcriptional control of gene expression (53, 67-70). 
A small RNA sequencing approach used in this thesis has identified a distinctive percentage of 
sncRNAs read alignment in two imprinted regions (chapter 7) that are mainly associated with 
neurogenetic disorders and which are further enriched in lncRNA sequences (71-77). For example, 
it has been proposed that nuclear imprinted lncRNAs in chromosome 7 linked by snoRNAs, which 
are known as sno-lncRNAs, can sequester splicing factors within paraspeckle cell domains and then 
regulate the normal splicing of neighbouring coding genes (78, 79). Similarly, another cluster 
detected at chromosome 12, known as the Dlk1–Dio3-imprinted locus, hosts a set of lncRNAs, such 
as Mirg, Rian and Meg3 (80-85) (86), which are substrates for the transcription of sncRNAs 
associated with the development of psychiatric illness (74).  This locus was represented in both the 
RNA-Seq and the small RNA-Seq screening approaches. The RNA-Seq experiment showed that 
Mirg lncRNA was markedly up-regulated in fear-conditioned mice (39), a finding that was 
consistent with the observation of miRNA transcribed from this lncRNA that were detected through 
the Small RNA-Seq assay  (chapter 7).  
The bioinformatic approaches to uncover non-coding transcription in diverse model systems 
continue to be crucial for identifying the responsive nature of these sequences and their relevant 
molecular functions. Unlocking the mechanism underlying the actions of ncRNAs would aid in 
understanding their role in the human genome and would be valuable for furthering the progress of 
synthetic biology. Interference systems such as CRISPRi and siRNA are mostly RNA guided, and 
the combination of these methods with naturally functional RNAs could advance the field of 
genome editing and the associated therapeutics.  
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The mammalian brain is a complex organ of molecular interplay able to decode external stimuli, yet 
its workings remains largely unknown. This thesis has provided evidence that lncRNAs are 
transcribed in the mouse brain as a consequence of behavioural training, and that Gomafu lncRNA 
may participate in the articulation of complex adaptive responses. The present research also exposes 
the need for further investigations to confirm the relevance of non-coding transcription in the adult 
brain.  
  
  
 
 168 
References 
1. Ayala FJ (1977): "Nothing in biology makes sense except in the light of evolution": 
Theodosius Dobzhansky: 1900-1975. The Journal of Heredity. 68:3-10. 
2. Miller EK, Cohen JD (2001): An integrative theory of prefrontal cortex function. Annual 
Review of Neuroscience. 24:167-202. 
3. Semendeferi K, Armstrong E, Schleicher A, Zilles K, Van Hoesen GW (2001): Prefrontal 
cortex in humans and apes: a comparative study of area 10. American Journal of Physical 
Anthropology. 114:224-241. 
4. Pollard KS, Salama SR, Lambert N, Lambot MA, Coppens S, Pedersen JS, et al. (2006): An 
RNA gene expressed during cortical development evolved rapidly in humans. Nature. 443:167-172. 
5. Rinn JL, Chang HY (2012): Genome regulation by long noncoding RNAs. Annual Review 
of Biochemistry. 81:145-166. 
6. Holoch D, Moazed D (2015): RNA-mediated epigenetic regulation of gene expression. 
Nature Reviews Genetics. 16:71-84. 
7. Li JH, Liu S, Zheng LL, Wu J, Sun WJ, Wang ZL, et al. (2014): Discovery of Protein-
lncRNA Interactions by Integrating Large-Scale CLIP-Seq and RNA-Seq Datasets. Frontiers in 
Bioengineering and Biotechnology. 2:88. 
8. Morlando M, Ballarino M, Fatica A, Bozzoni I (2014): The Role of long noncoding RNAs 
in the epigenetic control of gene expression. ChemMedChem. 9:505-510. 
9. Nakagawa S, Kageyama Y (2014): Nuclear lncRNAs as epigenetic regulators-beyond 
skepticism. Biochimica et Biophysica Acta. 1839:215-222. 
10. Lee JT (2012): Epigenetic regulation by long noncoding RNAs. Science. 338:1435-1439. 
11. Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, et al. (2012): The 
GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, 
and expression. Genome Research. 22:1775-1789. 
12. Johnsson P, Lipovich L, Grander D, Morris KV (2014): Evolutionary conservation of long 
non-coding RNAs; sequence, structure, function. Biochimica et Biophysica Acta. 1840:1063-1071. 
13. Haerty W, Ponting CP (2015): Unexpected selection to retain high GC content and splicing 
enhancers within exons of multiexonic lncRNA loci. RNA. doi: 10.1261/rna.047324.114.    
14. Lipovich L, Dachet F, Cai J, Bagla S, Balan K, Jia H, et al. (2012): Activity-dependent 
human brain coding/noncoding gene regulatory networks. Genetics. 192:1133-1148. 
15. Villegas VE, Zaphiropoulos PG (2015): Neighboring Gene Regulation by Antisense Long 
Non-Coding RNAs. International Journal of Molecular Sciences. 16:3251-3266. 
16. Wood EJ, Chin-Inmanu K, Jia H, Lipovich L (2013): Sense-antisense gene pairs: sequence, 
transcription, and structure are not conserved between human and mouse. Frontiers in Genetics. 
4:183. 
17. Xie C, Zhang YE, Chen JY, Liu CJ, Zhou WZ, Li Y, et al. (2012): Hominoid-specific de 
novo protein-coding genes originating from long non-coding RNAs. PLoS genetics. 8:e1002942. 
18. Teffer K, Semendeferi K (2012): Human prefrontal cortex: evolution, development, and 
pathology. Progress in Brain Research. 195:191-218. 
19. Rilling JK (2014): Comparative primate neuroimaging: insights into human brain evolution. 
Trends in Cognitive Sciences. 18:46-55. 
20. Mattson MP (2014): Superior pattern processing is the essence of the evolved human brain. 
Frontiers in Neuroscience. 8. 
21. Uylings HB, Jacobsen AM, Zilles K, Amunts K (2006): Left-right asymmetry in volume 
and number of neurons in adult Broca's area. Cortex; A Journal Devoted to the Study of the Nervous 
System and Behavior. 42:652-658. 
22. Koechlin E (2011): Frontal pole function: what is specifically human? Trends in Cognitive 
Sciences. 15:241. 
 
 169 
23. Cole MW, Ito T, Braver TS (2015): The Behavioral Relevance of Task Information in 
Human Prefrontal Cortex. Cereb Cortex. doi: 10.1093/cercor/bhv072 
24. McGuire JT, Botvinick MM (2010): Prefrontal cortex, cognitive control, and the registration 
of decision costs. Proceedings of the National Academy of Sciences of the United States of America. 
107:7922-7926. 
25. Donoso M, Collins AGE, Koechlin E (2014): Foundations of human reasoning in the 
prefrontal cortex. Science. 344:1481-1486. 
26. Stokes MG, Kusunoki M, Sigala N, Nili H, Gaffan D, Duncan J (2013): Dynamic coding for 
cognitive control in prefrontal cortex. Neuron. 78:364-375. 
27. Narayanan NS, Cavanagh JF, Frank MJ, Laubach M (2013): Common medial frontal 
mechanisms of adaptive control in humans and rodents. Nature Neuroscience. 16:1888-1895. 
28. Koechlin E, Ody C, Kouneiher F (2003): The architecture of cognitive control in the human 
prefrontal cortex. Science. 302:1181-1185. 
29. Euston DR, Gruber AJ, McNaughton BL (2012): The role of medial prefrontal cortex in 
memory and decision making. Neuron. 76:1057-1070. 
30. Steimer T (2002): The biology of fear- and anxiety-related behaviors. Dialogues in Clinical 
Neuroscience. 4:231-249. 
31. Ehlers A, Clark DM (2000): A cognitive model of posttraumatic stress disorder. Behaviour 
Research and Therapy. 38:319-345. 
32. Ahmed O, Lovibond PF (2015): The impact of previously learned feature-relevance on 
generalisation of conditioned fear in humans. Journal of Behavior Therapy and Experimental 
Psychiatry. 46:59-65. 
33. Lissek S, Kaczkurkin AN, Rabin S, Geraci M, Pine DS, Grillon C (2014): Generalized 
anxiety disorder is associated with overgeneralization of classically conditioned fear. Biological 
Psychiatry. 75:909-915. 
34. Lang PJ, Davis M, Ohman A (2000): Fear and anxiety: animal models and human cognitive 
psychophysiology. Journal of Affective Disorders. 61:137-159. 
35. Lissek S, Powers AS, McClure EB, Phelps EA, Woldehawariat G, Grillon C, et al. (2005): 
Classical fear conditioning in the anxiety disorders: a meta-analysis. Behaviour Research and 
Therapy. 43:1391-1424. 
36. Bishop SJ (2007): Neurocognitive mechanisms of anxiety: an integrative account. Trends in 
Cognitive Sciences. 11:307-316. 
37. Mendlowicz MV, Stein MB (2000): Quality of life in individuals with anxiety disorders. 
The American journal of psychiatry. 157:669-682. 
38. Bouayed J, Rammal H, Soulimani R (2009): Oxidative stress and anxiety: relationship and 
cellular pathways. Oxidative medicine and cellular longevity. 2:63-67. 
39. Spadaro PA, Flavell CR, Widagdo J, Ratnu VS, Troup M, Ragan C, et al. (2015): Long 
Noncoding RNA-Directed Epigenetic Regulation of Gene Expression Is Associated with Anxiety-
like Behavior in Mice. Biological Psychiatry. doi:10.1016/j.biopsych.2015.02.004.  
40. Nakamura S, Oshima M, Yuan J, Saraya A, Miyagi S, Konuma T, et al. (2012): Bmi1 
confers resistance to oxidative stress on hematopoietic stem cells. PloS One. 7:e36209. 
41. Chatoo W, Abdouh M, David J, Champagne MP, Ferreira J, Rodier F, et al. (2009): The 
polycomb group gene Bmi1 regulates antioxidant defenses in neurons by repressing p53 pro-
oxidant activity. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience. 
29:529-542. 
42. Abdouh M, Chatoo W, El Hajjar J, David J, Ferreira J, Bernier G (2012): Bmi1 is down-
regulated in the aging brain and displays antioxidant and protective activities in neurons. PloS One. 
7:e31870. 
43. Gandhi S, Abramov AY (2012): Mechanism of oxidative stress in neurodegeneration. 
Oxidative Medicine and Cellular Longevity. 2012:428010. 
 
 170 
44. Kumar H, Lim HW, More SV, Kim BW, Koppula S, Kim IS, et al. (2012): The role of free 
radicals in the aging brain and Parkinson's disease: convergence and parallelism. International 
Journal of Molecular Sciences. 13:10478-10504. 
45. Franklin TB, Krueger-Naug AM, Clarke DB, Arrigo AP, Currie RW (2005): The role of 
heat shock proteins Hsp70 and Hsp27 in cellular protection of the central nervous system. 
International Journal of Hyperthermia: The Official Journal of European Society for Hyperthermic 
Oncology, North American Hyperthermia Group. 21:379-392. 
46. Beere HM, Green DR (2001): Stress management - heat shock protein-70 and the regulation 
of apoptosis. Trends in Cell Biology. 11:6-10. 
47. Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Brugmann SA, et al. (2007): Functional 
demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell. 
129:1311-1323. 
48. Rapicavoli NA, Poth EM, Zhu H, Blackshaw S (2011): The long noncoding RNA Six3OS 
acts in trans to regulate retinal development by modulating Six3 activity. Neural Development. 6. 
49. Feng J, Bi C, Clark BS, Mady R, Shah P, Kohtz JD (2006): The Evf-2 noncoding RNA is 
transcribed from the Dlx-5/6 ultraconserved region and functions as a Dlx-2 transcriptional 
coactivator. Genes & Development. 20:1470-1484. 
50. Tripathi V, Ellis JD, Shen Z, Song DY, Pan Q, Watt AT, et al. (2010): The nuclear-retained 
noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor 
phosphorylation. Molecular Cell. 39:925-938. 
51. Tripathi V, Shen Z, Chakraborty A, Giri S, Freier SM, Wu X, et al. (2013): Long noncoding 
RNA MALAT1 controls cell cycle progression by regulating the expression of oncogenic 
transcription factor B-MYB. PLoS Genetics. 9:e1003368. 
52. Zhang B, Arun G, Mao YS, Lazar Z, Hung G, Bhattacharjee G, et al. (2012): The lncRNA 
Malat1 is dispensable for mouse development but its transcription plays a cis-regulatory role in the 
adult. Cell Reports. 2:111-123. 
53. Lee JT, Bartolomei MS (2013): X-inactivation, imprinting, and long noncoding RNAs in 
health and disease. Cell. 152:1308-1323. 
54. Francescatto M, Vitezic M, Heutink P, Saxena A (2014): Brain-specific noncoding RNAs 
are likely to originate in repeats and may play a role in up-regulating genes in cis. International 
Journal of Biochemestry and Cell Biology. 54:331-337. 
55. Grigoriev A (2001): A relationship between gene expression and protein interactions on the 
proteome scale: analysis of the bacteriophage T7 and the yeast Saccharomyces cerevisiae. Nucleic 
Acids Research. 29:3513-3519. 
56. Jansen R, Greenbaum D, Gerstein M (2002): Relating whole-genome expression data with 
protein-protein interactions. Genome Research. 12:37-46. 
57. Greenbaum D, Colangelo C, Williams K, Gerstein M (2003): Comparing protein abundance 
and mRNA expression levels on a genomic scale. Genome Biology. 4:117. 
58. Bhardwaj N, Lu H (2005): Correlation between gene expression profiles and protein-protein 
interactions within and across genomes. Bioinformatics. 21:2730-2738. 
59. Clinton SM, Haroutunian V, Davis KL, Meador-Woodruff JH (2003): Altered transcript 
expression of NMDA receptor-associated postsynaptic proteins in the thalamus of subjects with 
schizophrenia. The American Journal of Psychiatry. 160:1100-1109. 
60. Maier T, Guell M, Serrano L (2009): Correlation of mRNA and protein in complex 
biological samples. FEBS Letters. 583:3966-3973. 
61. de Sousa Abreu R, Penalva LO, Marcotte EM, Vogel C (2009): Global signatures of protein 
and mRNA expression levels. Molecular bioSystems. 5:1512-1526. 
62. Schwanhausser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, et al. (2011): Global 
quantification of mammalian gene expression control. Nature. 473:337-342. 
63. Ning K, Fermin D, Nesvizhskii AI (2012): Comparative Analysis of Different Label-Free 
Mass Spectrometry Based Protein Abundance Estimates and Their Correlation with RNA-Seq Gene 
Expression Data. Journal of Proteome Research. 11:2261-2271. 
 
 171 
64. Fu Y, Dominissini D, Rechavi G, He C (2014): Gene expression regulation mediated 
through reversible m(6)A RNA methylation. Nature Reviews Genetics. 15:293-306. 
65. Chen T, Hao YJ, Zhang Y, Li MM, Wang M, Han WF, et al. (2015): m(6)A RNA 
Methylation Is Regulated by MicroRNAs and Promotes Reprogramming to Pluripotency. Cell Stem 
Cell. 16:289-301. 
66. Zhao BS, He C (2015): Fate by RNA methylation: m6A steers stem cell pluripotency. 
Genome Biology. 16:43. 
67. Sleutels F, Zwart R, Barlow DP (2002): The non-coding Air RNA is required for silencing 
autosomal imprinted genes. Nature. 415:810-813. 
68. Pauler FM, Koerner MV, Barlow DP (2007): Silencing by imprinted noncoding RNAs: is 
transcription the answer? Trends in Genetics. 23:284-292. 
69. Sun JN, Li W, Sun YP, Yu DH, Wen X, Wang H, et al. (2014): A novel antisense long 
noncoding RNA within the IGF1R gene locus is imprinted in hematopoietic malignancies. Nucleic 
Acids Research. 42:9588-9601. 
70. Zhang X, Li H, Burnett JC, Rossi JJ (2014): The role of antisense long noncoding RNA in 
small RNA-triggered gene activation. RNA. 20:1916-1928. 
71. Cavaille J, Seitz H, Paulsen M, Ferguson-Smith AC, Bachellerie JP (2002): Identification of 
tandemly-repeated C/D snoRNA genes at the imprinted human 14q32 domain reminiscent of those 
at the Prader-Willi/Angelman syndrome region. Human Molecular Genetics. 11:1527-1538. 
72. de los Santos T, Schweizer J, Rees CA, Francke U (2000): Small evolutionarily conserved 
RNA, resembling C/D box small nucleolar RNA, is transcribed from PWCR1, a novel imprinted 
gene in the Prader-Willi deletion region, which is highly expressed in brain. American Journal of 
Human Genetics. 67:1067-1082. 
73. Powell WT, Coulson RL, Crary FK, Wong SS, Ach RA, Tsang P, et al. (2013): A Prader-
Willi locus lncRNA cloud modulates diurnal genes and energy expenditure. Human Molecular 
Genetics. 22:4318-4328. 
74. Gardiner E, Beveridge NJ, Wu JQ, Carr V, Scott RJ, Tooney PA, et al. (2012): Imprinted 
DLK1-DIO3 region of 14q32 defines a schizophrenia-associated miRNA signature in peripheral 
blood mononuclear cells. Molecular Psychiatry. 17:827-840. 
75. Han ZB, He HJ, Zhang FW, Huang ZJ, Liu ZG, Jiang HJ, et al. (2012): Spatiotemporal 
expression pattern of Mirg, an imprinted non-coding gene, during mouse embryogenesis. Journal of 
Molecular Histology. 43:1-8. 
76. Lempiainen H, Couttet P, Bolognani F, Muller A, Dubost V, Luisier R, et al. (2013): 
Identification of Dlk1-Dio3 imprinted gene cluster noncoding RNAs as novel candidate biomarkers 
for liver tumor promotion. Toxicological Sciences: An Official Journal of the Society of Toxicology. 
131:375-386. 
77. Han ZB, Liu Q, Huang ZJ, Cui W, Tian YJ, Yan WL, et al. (2013): Expression and 
imprinting analysis of AK044800, a transcript from the Dlk1-Dio3 imprinted gene cluster during 
mouse embryogenesis. Molecules and Cells. 35:285-290. 
78. McCann KL, Baserga SJ (2012): Long Noncoding RNAs as Sinks in Prader-Willi 
Syndrome. Molecular Cell. 48:155-157. 
79. Yin QF, Yang L, Zhang Y, Xiang JF, Wu YW, Carmichael GG, et al. (2012): Long 
noncoding RNAs with snoRNA ends. Molecular Cell. 48:219-230. 
80. Seitz H, Royo H, Bortolin ML, Lin SP, Ferguson-Smith AC, Cavaille J (2004): A large 
imprinted microRNA gene cluster at the mouse Dlkl-Gtl2 domain. Genome Research. 14:1741-
1748. 
81. Seitz H, Youngson N, Lin SP, Dalbert S, Paulsen M, Bachellerie JP, et al. (2003): Imprinted 
microRNA genes transcribed antisense to a reciprocally imprinted retrotransposon-like gene. 
Nature Genetics. 34:261-262. 
82. Royo H, Bortolin ML, Seitz H, Cavaille J (2006): Small non-coding RNAs and genomic 
imprinting. Cytogenetic and Genome Research. 113:99-108. 
 
 172 
83. Lin SP, Youngson N, Takada S, Seitz H, Reik W, Paulsen M, et al. (2003): Asymmetric 
regulation of imprinting on the maternal and paternal chromosomes at the Dlk1-Gtl2 imprinted 
cluster on mouse chromosome 12. Nature Genetics. 35:97-102. 
84. Furuno M, Pang KC, Ninomiya N, Fukuda S, Frith MC, Bult C, et al. (2006): Clusters of 
internally primed transcripts reveal novel long noncoding RNAs. PLoS Genetics. 2:e37. 
85. Tierling S, Dalbert S, Schoppenhorst S, Tsai CE, Oliger S, Ferguson-Smith AC, et al. 
(2006): High-resolution map and imprinting analysis of the Gtl2-Dnchc1 domain on mouse 
chromosome 12. Genomics. 87:225-235. 
86. Da Rocha ST, Edwards CA, Ito M, Ogata T, Ferguson-Smith AC (2008): Genomic 
imprinting at the mammalian Dlk1-Dio3 domain. Trends in Genetics. 24:306-316. 
 
 
  
 
 173 
APPENDIX 
Table A.1: List of oligo primers used in this thesis 
Gene expression primers 
Gene 5’-’3 Sequence 
Bdnf ex IV 
Forward GCAGCTGCCTTGATGTTTAC 
Reverse CCGTGGACGTTTACTTCTTTC 
Bdnf-As lncRNA 
Forward ACATAAAGAACTATCCATCGAGG 
Reverse TTAAATTGACCTAGGTGAGAACCT 
Npas4 
Forward CAAGCAGACCTGAGCAAGGA 
Reverse AAGGGTTCATGGAGGCTGAA 
Anti-Star lncRNA 
Forward CACCCAAGATGAAAGGCAGA 
Reverse GGGATGTCACCACAGGAAGA 
Cacng2 (Stargazin) 
Forward AAACACCCGCATTCTTTTCC 
Reverse GGTCGCAGAGCCATTGAAC 
Homer1 
Forward GAGCGAAATGACCAGCGAAC 
Reverse GAGGCAACTCAACAAGGCAGA 
Crybb1 
Forward CTGATGGCAAGGGAAAAGG  
Reverse GAGGCAGGTCCCCTACTTTG  
Htra1 
Forward TTCTTGACAGAGTCCCACGA 
Reverse CCGTTGATGCTGATGATGAC 
Hsp90b1 
Forward AAAGTTCGCCTTCCAAGCTG 
Reverse TCCAGCGAGTGCATTTTCAT 
Dusp1 
Forward AGTACCCCTCTCTACGATCAGG 
Reverse CGAGAAGCGTGATAGGCACTG 
Crybb4 
Forward AAAGGCGAGCTGAACGATGA 
Reverse AGCCAGGAAACTGGGAACAA 
Galant9 
Forward CAAGCACCGTGTCCTAGCAG 
Reverse AGTGCCTAGCTGACCCTTGG 
Hspa1A 
Forward ATGGTGGTTGCACTGTAGGACT 
Reverse AAAATTGACCCGAGTTCAGGAT 
Hspa1b 
Forward TCCAGTAGCCTGGGAAGACATA 
Reverse CCACAAAACCTTAACATGGACAA 
Cdkn1a 
Forward CCTGGTGATGTCCGACCTG 
Reverse CCATGAGCGCATCGCAATC 
Cdk8 
Forward CGGGTCGAGGACCTGTTTG 
Reverse TGCCGACATAGAAATTCCAGTTC 
Fosl2 
Forward CCAGCAGAAGTTCCGGGTAG 
Reverse GTAGGGATGTGAGCGTGGATA 
Pomp 
Forward AGGTTCACCGTCTCCCGTT 
Reverse TCACCCATCAGTTCACTTTGTG 
Lfng 
Forward TGACTGCACCATTGGCTACAT 
Reverse CAAACATGCCATAGCTCAGGG 
Ppia 
Forward TGCTGCAGCCATGGTCAACCC 
Reverse CGTGTAAAGTCACCACCCTGGCAC 
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Gomafu 
Forward GCCAGGACGCAGAATAAGCA 
Reverse CTACAACCAGCAACGGAGCA 
Malat1 
Forward TGCGGGTGTTGTAGGTTTTT 
Reverse ACAGGAGTGAGGCTTGTGGT 
Gm21781 
Forward CCGGTGTATGGCTGCTTCTT 
Reverse TTGCCTTGGTCATGGTGTCT 
Gm11762 
Forward AAAGAGGAGTGAGGGGACCA  
Reverse CACAGCAACAGAAGGGTAACTATG  
ChIP and RIP primers 
Crybb1-Reg1 
Forward GGAAGGGACAGAGTCCACAGA 
Reverse TGAGACAGGGTCTCATGTAGCC 
Crybb1-Reg2 
Forward AGAGATGTGGGAAGGGACAGA 
Reverse CCAGGCAGCTCTTCAGATCA 
Crybb1 Neg.  
Forward TCCACTTGGGGTTCACACTG 
Reverse CGATAAACGGACAGGGAGGA 
Gomafu Reg1 
Forward GGGAGGTTCACAGGCAGAAC 
Reverse AAGAGGCGAAGAACGGACAG 
Gomafu Reg2 
Forward TCAGGGTTCCTCCACTCAGG 
Reverse GCATTCCACACCAGGACTCA 
U6 
Forward CTGCTTCGGCAGCACATATAC 
Reverse TTCACGAATTTGCGTGTCATCC 
Antisense oligo primer 
ASO-Gomafu mC*mU*mC*mU*mC*C*A*C*T*C*T*T*C*C*A*C*mC*mA*mC*mC*mU 
ShRNA oligo primer 
Crybb1-shRNA CATGGAGATCCAAGAGGAT 
Anti-Star -shRNA 
GATCCCCGAGAAACATACTGACTGGCTAAAGATTCAAGAGATCTTTAGCC
AGTCAGTATGTTTCTCTTTTTTC 
TCGAGAAAAAAGAGAAACATACTGACTGGCTAAAGATCTCTTGAATCTTT
AGCCAGTCAGTATGTTTCTCGGG 
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Table A.2: Intergenic lncRNAs detected through nuclear enriched RNA-Sequencing and 
flanking coding genes 
Group Chromosome Accession Id Proximal coding gene at each ' end 
N
A
ÏV
E
 V
S 
FC
 
chr6:3200766-3201599 EST CB271201  (multiple ESTs) // Samd9l 
chr17:6438459-6639830 BC049966.1; AK207024.1; AK178082.1 Tulp4 // Tmem181c-ps - Dynlt1f 
chr17:39842996-39848831 non-coding RNA, oocyte_piRNA3616 Esp15// Esp38  
chr15:97740035-97744685 no annotation multiple ESTs  Endou // Rapgef3 
chrY:90737360-90749420 mRNA EF685181/ EST BI988948 Similar to Sycp3 like Y-linked // Erdr1 
chr11:19720364-19721506 Glns-ps1 processed_pseudogene  Etaa1 // Spred2 
chr18:68692054-68692319 RNA: LSU-rRNA_Hsa  Mc2r // Tcf4 
chr2:163466261-163473003 oocyte_piRNA2342;  Gdap1 // Fitm2 
chr5:112213224-112229750 GOMAFU (MIAT) Mn1 // Cryba4 -  Crybb1 
chr15:102634976-
102635345 Rpl39-ps ANTISENSE Atf7 // Calcoco1 
chrX:20581022-20581345 Gm14539 (multiple ESTs) Rgn // Ndufb11 
chr11:58508822-58509365  Gm12254 (multiple ESTs) Olfr 331 // Olfr 330 
chr4:34485677-34486510 Gm12350 (multiple ESTs) Spaca1// Akirin2 
chr12:40203088-40229183 Gm7008, non-coding RNA Ifrd1 // Zfp277 
chr3:36515056-36532159 Gm11549, non-coding RNA  (mRNA AK077932)  Annexin A5 // Exosc9 
chr2:32271864-32272202 Gm13611  Uck1 // Swi5 
chrX:52772294-52772770 Gm14586 (multiple ESTs)  Gpc3 // Ccdc160  
chr6:127769297-127776730 AK076314.1 (multiple ESTs)  Prmt8 // BC049716 
C
T
X
 V
S 
FC
 
chr6:3200766-3201599 EST CB271201  (multiple ESTs)   // Samd9l 
chr17:39842996-39848831 non-coding RNA, oocyte_piRNA3616 Esp15// Esp38 
chr12:99645093-99645678 EST CF903167 (multiple ESTs)  Foxn3 // Efcab11 
chr17:70963665-70963895 Gm26561 lincRNA  Tgif1 // Myl12b 
chr6:49236443-49236622 mRNA AK045604  Igf2bp3 // Tra2a 
chr18:68692054-68692319 RNA: LSU-rRNA_Hsa  Mc2r // Tcf4 
chr3:5860332-5860778 RNA: LSU-rRNA_Hsa Pex2  // Pkia 
chr10:4388220-4396640 Gm21781  lincRNA  (multiple ESTs)  Zbtb2 // Rmnd1 
chr18:54699058-54699372 LSU-rRNA_Hsa Csnk1g3 // Zfp608 
chr16:35981504-35982022 AK144265.1 ncrna (Gm15564 antisense; Kpna1 retained_intron) Kpna1 // Parp9  
chr17:10202638-10319361 AK003349 // Qk 
chr15:102634976-
102635345 Rpl39-ps ANTISENSE Atf7 // Calcoco1 
chr9:78175314-78175625  Rn7SKm Ensembl Type: misc_RNA (331BP) Ick // Gsta4 
chr4:129969467-129984696  AK140473; EST CR515733 Ptp4a2 // Bai2 
chr5:112213224-112229750 GOMAFU (MIAT) Mn1 // Cryba4 -  Crybb1 
chr12:109730631-
109749457 
miRNA containing gene (Mirg), non-coding 
RNAEU616813.1 Rtl1 // Dio3 
chr17:6438459-6639830 BC049966.1; AK207024.1; AK178082.1  Tulp4 // Tmem181c-ps - Dynlt1f 
chr8:20587678-20589273 AK160987.1 non coding RNA 
Gm21092 Uncharacterized 
protein // Gm21119 
predicted gene 
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chr11:58508822-58509365  Gm12254 (multiple ESTs)  Olfr 331 // Olfr 330 
chr6:145266322-145266833 Rps25-ps1 Ensembl Type: processed_pseudogene (multiple ESTs) Kras // Ifltd1 
chr15:99663935-99667133  EST CF535018; EST BU843162 Racgap1// Ascic1 
chr11:61499102-61515481  AK036198.1; 3110043A19Rik  Mapk7 // B9d1 
C
T
X
 V
S 
N
A
ÏV
E
  
chr1:150264924-150266076 Gm15453 pseudogene Ptgs2 // Pdc 
chr6:3200766-3201599 EST CB271201  (multiple ESTs) // Samd9l 
chr7:107862993-107864037 Gm10156 processed_pseudogene; EST C88241  (multiple ESTs) Olfr 470// Olfr 472 
chr3:5860332-5860778 RNA: LSU-rRNA_Hsa Pex2  // Pkia 
chr17:70963665-70963895 Gm26561 lincRNA  Tgif1 // Myl12b 
chr9:27299161-27357545 Expressed sequence AI414108 (AI414108), non-coding RNA Igsf9b // Spata19 
chr10:92071040-92165178 RMST Tmpo // Nedd1  
chr16:35981504-35982022 AK144265.1 ncrna (Gm15564 antisense; Kpna1 retained_intron) Kpna1 // Parp9  
chr18:77262201-77264688 EST BE648773; EST AW122102 St8sia5 // Loxhd1 
chr11:119538578-
119569046 Gm11762, non-coding RNA, Nptx1 antisense Nptx1 // Rptor  
chr17:39842996-39848831 non-coding RNA, oocyte_piRNA3616 Esp15// Esp38 
chr2:163466261-163473003 oocyte_piRNA2342;  Gdap1 // Fitm2 
chrY:90737360-90749420 mRNA EF685181/ EST BI988948 Similar to Sycp3 like Y-linked//  Erdr1 
chr12:40203088-40229183 Gm7008, non-coding RNA Ifrd1 // Zfp277 
chr19:5842301-5845784 Neat1  // Frmd8 
chr3:36515056-36532159 Gm11549, non-coding RNA (also  mRNA AK077932) Annexin A5 // Exosc9 
chr4:129969467-129984696  AK140473; EST CR515733 Ptp4a2 // Bai2 
chr3:105721075-105724618  mRNA AK201659 6530418L21Rik // Rap1a 
chr9:44475789-44482237 AK078316.1; C030014I23Rik; EST BX516698  (multiple ESTs) Upk2 // Bcl91 
chr10:86690840-86705444 1810014B01Rik /Hsp901b 
chr2:31224422-31228376 mRNA AF240178  Gpr107 // Ncs1 
chr10:128550218-
128550871  mRNA AK193010  Rpl41 // Pa2g4  
chr10:71704286-71705801 EST EL608079  Ipmk // Zwint 
chrX:103162538-
103165182 Gm6206 Ensembl Type: processed_pseudogene  Dmrtc1a // Nap1l2 
chr6:83362373-83455244  B230319C09Rik, non-coding RNA Tet3 // Dguok 
chr17:48931628-49166035 1700008K24Rik, transcript variant 3, non-coding RNA (pirna associate) Lrfn2 // Mocs1 
 
 
 
 
 
